#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Decreased Thalamocortical Connectivity in Chronic Ketamine Users
#Text=Disintegration in thalamocortical integration suggests its role in the mechanistic ‘switch’ from recreational to dysregulated drug seeking/addiction.
1-1	0-9	Decreased	_
1-2	10-25	Thalamocortical	_
1-3	26-38	Connectivity	_
1-4	39-41	in	_
1-5	42-49	Chronic	http://maven.renci.org/NeuroBridge/neurobridge#HarmfulUseofKetamine[1]
1-6	50-58	Ketamine	http://maven.renci.org/NeuroBridge/neurobridge#HarmfulUseofKetamine[1]
1-7	59-64	Users	http://maven.renci.org/NeuroBridge/neurobridge#HarmfulUseofKetamine[1]
1-8	65-79	Disintegration	_
1-9	80-82	in	_
1-10	83-98	thalamocortical	_
1-11	99-110	integration	_
1-12	111-119	suggests	_
1-13	120-123	its	_
1-14	124-128	role	_
1-15	129-131	in	_
1-16	132-135	the	_
1-17	136-147	mechanistic	_
1-18	148-149	‘	_
1-19	149-155	switch	_
1-20	155-156	’	_
1-21	157-161	from	_
1-22	162-174	recreational	_
1-23	175-177	to	_
1-24	178-190	dysregulated	http://maven.renci.org/NeuroBridge/neurobridge#DrugDependence[2]
1-25	191-195	drug	http://maven.renci.org/NeuroBridge/neurobridge#DrugDependence[2]
1-26	196-203	seeking	http://maven.renci.org/NeuroBridge/neurobridge#DrugDependence[2]
1-27	203-204	/	http://maven.renci.org/NeuroBridge/neurobridge#DrugDependence[2]
1-28	204-213	addiction	http://maven.renci.org/NeuroBridge/neurobridge#DrugDependence[2]
1-29	213-214	.	_

#Text=In this study, we aimed to address whether thalamic nuclear groups show altered functional connectivity within the cerebral cortex in chronic ketamine users.
2-1	215-217	In	_
2-2	218-222	this	_
2-3	223-228	study	_
2-4	228-229	,	_
2-5	230-232	we	_
2-6	233-238	aimed	_
2-7	239-241	to	_
2-8	242-249	address	_
2-9	250-257	whether	_
2-10	258-266	thalamic	_
2-11	267-274	nuclear	_
2-12	275-281	groups	_
2-13	282-286	show	_
2-14	287-294	altered	_
2-15	295-305	functional	_
2-16	306-318	connectivity	_
2-17	319-325	within	_
2-18	326-329	the	_
2-19	330-338	cerebral	_
2-20	339-345	cortex	_
2-21	346-348	in	_
2-22	349-356	chronic	http://maven.renci.org/NeuroBridge/neurobridge#HarmfulUseofKetamine[3]
2-23	357-365	ketamine	http://maven.renci.org/NeuroBridge/neurobridge#HarmfulUseofKetamine[3]
2-24	366-371	users	http://maven.renci.org/NeuroBridge/neurobridge#HarmfulUseofKetamine[3]
2-25	371-372	.	_

#Text=One hundred and thirty subjects (41 ketamine users and 89 control subjects) underwent rsfMRI (resting-state functional Magnetic Resonance Imaging).
3-1	373-376	One	_
3-2	377-384	hundred	_
3-3	385-388	and	_
3-4	389-395	thirty	_
3-5	396-404	subjects	_
3-6	405-406	(	_
3-7	406-408	41	_
3-8	409-417	ketamine	http://maven.renci.org/NeuroBridge/neurobridge#HarmfulUseofKetamine[4]
3-9	418-423	users	http://maven.renci.org/NeuroBridge/neurobridge#HarmfulUseofKetamine[4]
3-10	424-427	and	_
3-11	428-430	89	_
3-12	431-438	control	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
3-13	439-447	subjects	_
3-14	447-448	)	_
3-15	449-458	underwent	_
3-16	459-465	rsfMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[5]
3-17	466-467	(	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[5]
3-18	467-480	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[5]
3-19	481-491	functional	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[5]
3-20	492-500	Magnetic	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[5]
3-21	501-510	Resonance	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[5]
3-22	511-518	Imaging	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[5]
3-23	518-519	)	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[5]
3-24	519-520	.	_

#Text=Based on partial correlation functional connectivity analysis we partitioned the thalamus into six nuclear groups that correspond well with human histology.
4-1	521-526	Based	_
4-2	527-529	on	_
4-3	530-537	partial	_
4-4	538-549	correlation	_
4-5	550-560	functional	_
4-6	561-573	connectivity	_
4-7	574-582	analysis	_
4-8	583-585	we	_
4-9	586-597	partitioned	_
4-10	598-601	the	_
4-11	602-610	thalamus	_
4-12	611-615	into	_
4-13	616-619	six	_
4-14	620-627	nuclear	_
4-15	628-634	groups	_
4-16	635-639	that	_
4-17	640-650	correspond	_
4-18	651-655	well	_
4-19	656-660	with	_
4-20	661-666	human	_
4-21	667-676	histology	_
4-22	676-677	.	_

#Text=Then, in the area of each nuclear group, the functional connectivity differences between the chronic ketamine user group and normal control group were investigated.
5-1	678-682	Then	_
5-2	682-683	,	_
5-3	684-686	in	_
5-4	687-690	the	_
5-5	691-695	area	_
5-6	696-698	of	_
5-7	699-703	each	_
5-8	704-711	nuclear	_
5-9	712-717	group	_
5-10	717-718	,	_
5-11	719-722	the	_
5-12	723-733	functional	_
5-13	734-746	connectivity	_
5-14	747-758	differences	_
5-15	759-766	between	_
5-16	767-770	the	_
5-17	771-778	chronic	http://maven.renci.org/NeuroBridge/neurobridge#HarmfulUseofKetamine[6]
5-18	779-787	ketamine	http://maven.renci.org/NeuroBridge/neurobridge#HarmfulUseofKetamine[6]
5-19	788-792	user	http://maven.renci.org/NeuroBridge/neurobridge#HarmfulUseofKetamine[6]
5-20	793-798	group	_
5-21	799-802	and	_
5-22	803-809	normal	_
5-23	810-817	control	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
5-24	818-823	group	_
5-25	824-828	were	_
5-26	829-841	investigated	_
5-27	841-842	.	_

#Text=We found that the ketamine user group showed significantly less connectivity between the thalamic nuclear groups and the cortical regions-of-interest, including the prefrontal cortex, the motor cortex /supplementary motor area, and the posterior parietal cortex.
6-1	843-845	We	_
6-2	846-851	found	_
6-3	852-856	that	_
6-4	857-860	the	_
6-5	861-869	ketamine	http://maven.renci.org/NeuroBridge/neurobridge#HarmfulUseofKetamine[7]
6-6	870-874	user	http://maven.renci.org/NeuroBridge/neurobridge#HarmfulUseofKetamine[7]
6-7	875-880	group	_
6-8	881-887	showed	_
6-9	888-901	significantly	_
6-10	902-906	less	_
6-11	907-919	connectivity	_
6-12	920-927	between	_
6-13	928-931	the	_
6-14	932-940	thalamic	_
6-15	941-948	nuclear	_
6-16	949-955	groups	_
6-17	956-959	and	_
6-18	960-963	the	_
6-19	964-972	cortical	_
6-20	973-992	regions-of-interest	_
6-21	992-993	,	_
6-22	994-1003	including	_
6-23	1004-1007	the	_
6-24	1008-1018	prefrontal	_
6-25	1019-1025	cortex	_
6-26	1025-1026	,	_
6-27	1027-1030	the	_
6-28	1031-1036	motor	_
6-29	1037-1043	cortex	_
6-30	1044-1045	/	_
6-31	1045-1058	supplementary	_
6-32	1059-1064	motor	_
6-33	1065-1069	area	_
6-34	1069-1070	,	_
6-35	1071-1074	and	_
6-36	1075-1078	the	_
6-37	1079-1088	posterior	_
6-38	1089-1097	parietal	_
6-39	1098-1104	cortex	_
6-40	1104-1105	.	_

#Text=However, no increased thalamic connectivity was observed for these regions as compared with controls.
7-1	1106-1113	However	_
7-2	1113-1114	,	_
7-3	1115-1117	no	_
7-4	1118-1127	increased	_
7-5	1128-1136	thalamic	_
7-6	1137-1149	connectivity	_
7-7	1150-1153	was	_
7-8	1154-1162	observed	_
7-9	1163-1166	for	_
7-10	1167-1172	these	_
7-11	1173-1180	regions	_
7-12	1181-1183	as	_
7-13	1184-1192	compared	_
7-14	1193-1197	with	_
7-15	1198-1206	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
7-16	1206-1207	.	_

#Text=This study provides the first evidence of abnormal thalamocortical connectivity of resting state brain activity in chronic ketamine users.
8-1	1208-1212	This	_
8-2	1213-1218	study	_
8-3	1219-1227	provides	_
8-4	1228-1231	the	_
8-5	1232-1237	first	_
8-6	1238-1246	evidence	_
8-7	1247-1249	of	_
8-8	1250-1258	abnormal	_
8-9	1259-1274	thalamocortical	_
8-10	1275-1287	connectivity	_
8-11	1288-1290	of	_
8-12	1291-1298	resting	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[8]
8-13	1299-1304	state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[8]
8-14	1305-1310	brain	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[8]
8-15	1311-1319	activity	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[8]
8-16	1320-1322	in	_
8-17	1323-1330	chronic	http://maven.renci.org/NeuroBridge/neurobridge#HarmfulUseofKetamine[9]
8-18	1331-1339	ketamine	http://maven.renci.org/NeuroBridge/neurobridge#HarmfulUseofKetamine[9]
8-19	1340-1345	users	http://maven.renci.org/NeuroBridge/neurobridge#HarmfulUseofKetamine[9]
8-20	1345-1346	.	_

#Text=Further understanding of pathophysiological mechanisms of the thalamus in addiction (ketamine addiction) may facilitate the evaluation of much-needed novel pharmacological agents for improved therapy of this complex disease.
9-1	1347-1354	Further	_
9-2	1355-1368	understanding	_
9-3	1369-1371	of	_
9-4	1372-1390	pathophysiological	_
9-5	1391-1401	mechanisms	_
9-6	1402-1404	of	_
9-7	1405-1408	the	_
9-8	1409-1417	thalamus	_
9-9	1418-1420	in	_
9-10	1421-1430	addiction	_
9-11	1431-1432	(	_
9-12	1432-1440	ketamine	http://maven.renci.org/NeuroBridge/neurobridge#HarmfulUseofKetamine[10]
9-13	1441-1450	addiction	http://maven.renci.org/NeuroBridge/neurobridge#HarmfulUseofKetamine[10]
9-14	1450-1451	)	http://maven.renci.org/NeuroBridge/neurobridge#HarmfulUseofKetamine[10]
9-15	1452-1455	may	_
9-16	1456-1466	facilitate	_
9-17	1467-1470	the	_
9-18	1471-1481	evaluation	_
9-19	1482-1484	of	_
9-20	1485-1496	much-needed	_
9-21	1497-1502	novel	_
9-22	1503-1518	pharmacological	_
9-23	1519-1525	agents	_
9-24	1526-1529	for	_
9-25	1530-1538	improved	_
9-26	1539-1546	therapy	_
9-27	1547-1549	of	_
9-28	1550-1554	this	_
9-29	1555-1562	complex	_
9-30	1563-1570	disease	_
9-31	1570-1571	.	_

#Text=Introduction
#Text=Ketamine is a “dissociative” anesthetic drug and a derivative of PCP (phencyclidine), but with a shorter duration of action and less toxicity.
10-1	1572-1584	Introduction	_
10-2	1585-1593	Ketamine	_
10-3	1594-1596	is	_
10-4	1597-1598	a	_
10-5	1599-1600	“	_
10-6	1600-1612	dissociative	_
10-7	1612-1613	”	_
10-8	1614-1624	anesthetic	_
10-9	1625-1629	drug	_
10-10	1630-1633	and	_
10-11	1634-1635	a	_
10-12	1636-1646	derivative	_
10-13	1647-1649	of	_
10-14	1650-1653	PCP	_
10-15	1654-1655	(	_
10-16	1655-1668	phencyclidine	_
10-17	1668-1669	)	_
10-18	1669-1670	,	_
10-19	1671-1674	but	_
10-20	1675-1679	with	_
10-21	1680-1681	a	_
10-22	1682-1689	shorter	_
10-23	1690-1698	duration	_
10-24	1699-1701	of	_
10-25	1702-1708	action	_
10-26	1709-1712	and	_
10-27	1713-1717	less	_
10-28	1718-1726	toxicity	_
10-29	1726-1727	.	_

#Text=Ketamine was first synthesized in 1962 by an American chemist Calvin Lee Stevens in the Parke-Davis Laboratories.
11-1	1728-1736	Ketamine	_
11-2	1737-1740	was	_
11-3	1741-1746	first	_
11-4	1747-1758	synthesized	_
11-5	1759-1761	in	_
11-6	1762-1766	1962	_
11-7	1767-1769	by	_
11-8	1770-1772	an	_
11-9	1773-1781	American	_
11-10	1782-1789	chemist	_
11-11	1790-1796	Calvin	_
11-12	1797-1800	Lee	_
11-13	1801-1808	Stevens	_
11-14	1809-1811	in	_
11-15	1812-1815	the	_
11-16	1816-1827	Parke-Davis	_
11-17	1828-1840	Laboratories	_
11-18	1840-1841	.	_

#Text=In 1970 the U.S.
12-1	1842-1844	In	_
12-2	1845-1849	1970	_
12-3	1850-1853	the	_
12-4	1854-1857	U.S	_
12-5	1857-1858	.	_

#Text=Food and Drug Administration (FDA) approved ketamine for human medical use as an anesthetic drug.
13-1	1859-1863	Food	_
13-2	1864-1867	and	_
13-3	1868-1872	Drug	_
13-4	1873-1887	Administration	_
13-5	1888-1889	(	_
13-6	1889-1892	FDA	_
13-7	1892-1893	)	_
13-8	1894-1902	approved	_
13-9	1903-1911	ketamine	_
13-10	1912-1915	for	_
13-11	1916-1921	human	_
13-12	1922-1929	medical	_
13-13	1930-1933	use	_
13-14	1934-1936	as	_
13-15	1937-1939	an	_
13-16	1940-1950	anesthetic	_
13-17	1951-1955	drug	_
13-18	1955-1956	.	_

#Text=However, it is also a psychedelic drug that can produce psychological dependence.
14-1	1957-1964	However	_
14-2	1964-1965	,	_
14-3	1966-1968	it	_
14-4	1969-1971	is	_
14-5	1972-1976	also	_
14-6	1977-1978	a	_
14-7	1979-1990	psychedelic	_
14-8	1991-1995	drug	_
14-9	1996-2000	that	_
14-10	2001-2004	can	_
14-11	2005-2012	produce	_
14-12	2013-2026	psychological	_
14-13	2027-2037	dependence	_
14-14	2037-2038	.	_

#Text=Recently, ketamine has been used as an illicit drug inside and outside of club and rave scenes in many parts of the world, such as China, Indonesia, Malaysia, and Australia.
15-1	2039-2047	Recently	_
15-2	2047-2048	,	_
15-3	2049-2057	ketamine	_
15-4	2058-2061	has	_
15-5	2062-2066	been	_
15-6	2067-2071	used	_
15-7	2072-2074	as	_
15-8	2075-2077	an	_
15-9	2078-2085	illicit	_
15-10	2086-2090	drug	_
15-11	2091-2097	inside	_
15-12	2098-2101	and	_
15-13	2102-2109	outside	_
15-14	2110-2112	of	_
15-15	2113-2117	club	_
15-16	2118-2121	and	_
15-17	2122-2126	rave	_
15-18	2127-2133	scenes	_
15-19	2134-2136	in	_
15-20	2137-2141	many	_
15-21	2142-2147	parts	_
15-22	2148-2150	of	_
15-23	2151-2154	the	_
15-24	2155-2160	world	_
15-25	2160-2161	,	_
15-26	2162-2166	such	_
15-27	2167-2169	as	_
15-28	2170-2175	China	_
15-29	2175-2176	,	_
15-30	2177-2186	Indonesia	_
15-31	2186-2187	,	_
15-32	2188-2196	Malaysia	_
15-33	2196-2197	,	_
15-34	2198-2201	and	_
15-35	2202-2211	Australia	_
15-36	2211-2212	.	_

#Text=There are multiple dangers associated with nonmedical use and abuse of ketamine, such as dependence and psychiatric morbidity, lower urinary tract dysfunction, brain structural and functional abnormality, and sexual impulsiveness or violence.
16-1	2213-2218	There	_
16-2	2219-2222	are	_
16-3	2223-2231	multiple	_
16-4	2232-2239	dangers	_
16-5	2240-2250	associated	_
16-6	2251-2255	with	_
16-7	2256-2266	nonmedical	_
16-8	2267-2270	use	_
16-9	2271-2274	and	_
16-10	2275-2280	abuse	_
16-11	2281-2283	of	_
16-12	2284-2292	ketamine	_
16-13	2292-2293	,	_
16-14	2294-2298	such	_
16-15	2299-2301	as	_
16-16	2302-2312	dependence	_
16-17	2313-2316	and	_
16-18	2317-2328	psychiatric	_
16-19	2329-2338	morbidity	_
16-20	2338-2339	,	_
16-21	2340-2345	lower	_
16-22	2346-2353	urinary	_
16-23	2354-2359	tract	_
16-24	2360-2371	dysfunction	_
16-25	2371-2372	,	_
16-26	2373-2378	brain	_
16-27	2379-2389	structural	_
16-28	2390-2393	and	_
16-29	2394-2404	functional	_
16-30	2405-2416	abnormality	_
16-31	2416-2417	,	_
16-32	2418-2421	and	_
16-33	2422-2428	sexual	_
16-34	2429-2442	impulsiveness	_
16-35	2443-2445	or	_
16-36	2446-2454	violence	_
16-37	2454-2455	.	_

#Text=Drug addiction (including ketamine) results in deficits in cognitive and emotional processes, which are involved in the thalamocortical network.
17-1	2456-2460	Drug	_
17-2	2461-2470	addiction	_
17-3	2471-2472	(	_
17-4	2472-2481	including	_
17-5	2482-2490	ketamine	_
17-6	2490-2491	)	_
17-7	2492-2499	results	_
17-8	2500-2502	in	_
17-9	2503-2511	deficits	_
17-10	2512-2514	in	_
17-11	2515-2524	cognitive	_
17-12	2525-2528	and	_
17-13	2529-2538	emotional	_
17-14	2539-2548	processes	_
17-15	2548-2549	,	_
17-16	2550-2555	which	_
17-17	2556-2559	are	_
17-18	2560-2568	involved	_
17-19	2569-2571	in	_
17-20	2572-2575	the	_
17-21	2576-2591	thalamocortical	_
17-22	2592-2599	network	_
17-23	2599-2600	.	_

#Text=The thalamus plays a central and dynamic role in information transmission and processing in the brain by controlling corticocortical information that is being passed through the thalamus from one cortical area to another.
18-1	2601-2604	The	_
18-2	2605-2613	thalamus	_
18-3	2614-2619	plays	_
18-4	2620-2621	a	_
18-5	2622-2629	central	_
18-6	2630-2633	and	_
18-7	2634-2641	dynamic	_
18-8	2642-2646	role	_
18-9	2647-2649	in	_
18-10	2650-2661	information	_
18-11	2662-2674	transmission	_
18-12	2675-2678	and	_
18-13	2679-2689	processing	_
18-14	2690-2692	in	_
18-15	2693-2696	the	_
18-16	2697-2702	brain	_
18-17	2703-2705	by	_
18-18	2706-2717	controlling	_
18-19	2718-2733	corticocortical	_
18-20	2734-2745	information	_
18-21	2746-2750	that	_
18-22	2751-2753	is	_
18-23	2754-2759	being	_
18-24	2760-2766	passed	_
18-25	2767-2774	through	_
18-26	2775-2778	the	_
18-27	2779-2787	thalamus	_
18-28	2788-2792	from	_
18-29	2793-2796	one	_
18-30	2797-2805	cortical	_
18-31	2806-2810	area	_
18-32	2811-2813	to	_
18-33	2814-2821	another	_
18-34	2821-2822	.	_

#Text=The thalamus is composed of a very complex circuitry between multiple brain regions, including the prefrontal cortex, anterior cingulate, basal ganglia, cerebellum, motor and sensory regions, and association regions of the cerebral cortex.
19-1	2823-2826	The	_
19-2	2827-2835	thalamus	_
19-3	2836-2838	is	_
19-4	2839-2847	composed	_
19-5	2848-2850	of	_
19-6	2851-2852	a	_
19-7	2853-2857	very	_
19-8	2858-2865	complex	_
19-9	2866-2875	circuitry	_
19-10	2876-2883	between	_
19-11	2884-2892	multiple	_
19-12	2893-2898	brain	_
19-13	2899-2906	regions	_
19-14	2906-2907	,	_
19-15	2908-2917	including	_
19-16	2918-2921	the	_
19-17	2922-2932	prefrontal	_
19-18	2933-2939	cortex	_
19-19	2939-2940	,	_
19-20	2941-2949	anterior	_
19-21	2950-2959	cingulate	_
19-22	2959-2960	,	_
19-23	2961-2966	basal	_
19-24	2967-2974	ganglia	_
19-25	2974-2975	,	_
19-26	2976-2986	cerebellum	_
19-27	2986-2987	,	_
19-28	2988-2993	motor	_
19-29	2994-2997	and	_
19-30	2998-3005	sensory	_
19-31	3006-3013	regions	_
19-32	3013-3014	,	_
19-33	3015-3018	and	_
19-34	3019-3030	association	_
19-35	3031-3038	regions	_
19-36	3039-3041	of	_
19-37	3042-3045	the	_
19-38	3046-3054	cerebral	_
19-39	3055-3061	cortex	_
19-40	3061-3062	.	_

#Text=Thus, the thalamus may play a role as an active partner in the whole brain of cortical computations.
20-1	3063-3067	Thus	_
20-2	3067-3068	,	_
20-3	3069-3072	the	_
20-4	3073-3081	thalamus	_
20-5	3082-3085	may	_
20-6	3086-3090	play	_
20-7	3091-3092	a	_
20-8	3093-3097	role	_
20-9	3098-3100	as	_
20-10	3101-3103	an	_
20-11	3104-3110	active	_
20-12	3111-3118	partner	_
20-13	3119-3121	in	_
20-14	3122-3125	the	_
20-15	3126-3131	whole	_
20-16	3132-3137	brain	_
20-17	3138-3140	of	_
20-18	3141-3149	cortical	_
20-19	3150-3162	computations	_
20-20	3162-3163	.	_

#Text=Disintegration in the thalamocortical network is a change associated with addiction, it also suggests it plays a mechanistic role in the 'switch' from recreational to dysregulated drug seeking.
21-1	3164-3178	Disintegration	_
21-2	3179-3181	in	_
21-3	3182-3185	the	_
21-4	3186-3201	thalamocortical	_
21-5	3202-3209	network	_
21-6	3210-3212	is	_
21-7	3213-3214	a	_
21-8	3215-3221	change	_
21-9	3222-3232	associated	_
21-10	3233-3237	with	_
21-11	3238-3247	addiction	_
21-12	3247-3248	,	_
21-13	3249-3251	it	_
21-14	3252-3256	also	_
21-15	3257-3265	suggests	_
21-16	3266-3268	it	_
21-17	3269-3274	plays	_
21-18	3275-3276	a	_
21-19	3277-3288	mechanistic	_
21-20	3289-3293	role	_
21-21	3294-3296	in	_
21-22	3297-3300	the	_
21-23	3301-3302	'	_
21-24	3302-3308	switch	_
21-25	3308-3309	'	_
21-26	3310-3314	from	_
21-27	3315-3327	recreational	_
21-28	3328-3330	to	_
21-29	3331-3343	dysregulated	_
21-30	3344-3348	drug	_
21-31	3349-3356	seeking	_
21-32	3356-3357	.	_

#Text=Resting state functional connectivity is a relatively novel fMRI approach that provides insight for investigations in intrinsic brain connections, critical neurocircuits and pathophysiological alterations in a variety of neuropsychiatric disorders, including schizophrenia and addiction.
22-1	3358-3365	Resting	_
22-2	3366-3371	state	_
22-3	3372-3382	functional	_
22-4	3383-3395	connectivity	_
22-5	3396-3398	is	_
22-6	3399-3400	a	_
22-7	3401-3411	relatively	_
22-8	3412-3417	novel	_
22-9	3418-3422	fMRI	_
22-10	3423-3431	approach	_
22-11	3432-3436	that	_
22-12	3437-3445	provides	_
22-13	3446-3453	insight	_
22-14	3454-3457	for	_
22-15	3458-3472	investigations	_
22-16	3473-3475	in	_
22-17	3476-3485	intrinsic	_
22-18	3486-3491	brain	_
22-19	3492-3503	connections	_
22-20	3503-3504	,	_
22-21	3505-3513	critical	_
22-22	3514-3527	neurocircuits	_
22-23	3528-3531	and	_
22-24	3532-3550	pathophysiological	_
22-25	3551-3562	alterations	_
22-26	3563-3565	in	_
22-27	3566-3567	a	_
22-28	3568-3575	variety	_
22-29	3576-3578	of	_
22-30	3579-3595	neuropsychiatric	_
22-31	3596-3605	disorders	_
22-32	3605-3606	,	_
22-33	3607-3616	including	_
22-34	3617-3630	schizophrenia	_
22-35	3631-3634	and	_
22-36	3635-3644	addiction	_
22-37	3644-3645	.	_

#Text=A functional connectivity study demonstrated the relationship of resting brain hyperconnectivity and schizophrenia-like symptoms produced by ketamine infusion in 22 healthy humans.
23-1	3646-3647	A	_
23-2	3648-3658	functional	_
23-3	3659-3671	connectivity	_
23-4	3672-3677	study	_
23-5	3678-3690	demonstrated	_
23-6	3691-3694	the	_
23-7	3695-3707	relationship	_
23-8	3708-3710	of	_
23-9	3711-3718	resting	_
23-10	3719-3724	brain	_
23-11	3725-3742	hyperconnectivity	_
23-12	3743-3746	and	_
23-13	3747-3765	schizophrenia-like	_
23-14	3766-3774	symptoms	_
23-15	3775-3783	produced	_
23-16	3784-3786	by	_
23-17	3787-3795	ketamine	_
23-18	3796-3804	infusion	_
23-19	3805-3807	in	_
23-20	3808-3810	22	_
23-21	3811-3818	healthy	_
23-22	3819-3825	humans	_
23-23	3825-3826	.	_

#Text=Understanding chronic use of ketamine and its impact on resting state functional connectivity may help us to understand the neurobiological mechanism for addiction, and given its special role in neuropsychiatric disorders may provide some implications in treatment-resistant depression and schizophrenia.
24-1	3827-3840	Understanding	_
24-2	3841-3848	chronic	_
24-3	3849-3852	use	_
24-4	3853-3855	of	_
24-5	3856-3864	ketamine	_
24-6	3865-3868	and	_
24-7	3869-3872	its	_
24-8	3873-3879	impact	_
24-9	3880-3882	on	_
24-10	3883-3890	resting	_
24-11	3891-3896	state	_
24-12	3897-3907	functional	_
24-13	3908-3920	connectivity	_
24-14	3921-3924	may	_
24-15	3925-3929	help	_
24-16	3930-3932	us	_
24-17	3933-3935	to	_
24-18	3936-3946	understand	_
24-19	3947-3950	the	_
24-20	3951-3966	neurobiological	_
24-21	3967-3976	mechanism	_
24-22	3977-3980	for	_
24-23	3981-3990	addiction	_
24-24	3990-3991	,	_
24-25	3992-3995	and	_
24-26	3996-4001	given	_
24-27	4002-4005	its	_
24-28	4006-4013	special	_
24-29	4014-4018	role	_
24-30	4019-4021	in	_
24-31	4022-4038	neuropsychiatric	_
24-32	4039-4048	disorders	_
24-33	4049-4052	may	_
24-34	4053-4060	provide	_
24-35	4061-4065	some	_
24-36	4066-4078	implications	_
24-37	4079-4081	in	_
24-38	4082-4101	treatment-resistant	_
24-39	4102-4112	depression	_
24-40	4113-4116	and	_
24-41	4117-4130	schizophrenia	_
24-42	4130-4131	.	_

#Text=In this study we used rsfMRI to test whether thalamocortical connectivity is altered in chronic ketamine users.
25-1	4132-4134	In	_
25-2	4135-4139	this	_
25-3	4140-4145	study	_
25-4	4146-4148	we	_
25-5	4149-4153	used	_
25-6	4154-4160	rsfMRI	_
25-7	4161-4163	to	_
25-8	4164-4168	test	_
25-9	4169-4176	whether	_
25-10	4177-4192	thalamocortical	_
25-11	4193-4205	connectivity	_
25-12	4206-4208	is	_
25-13	4209-4216	altered	_
25-14	4217-4219	in	_
25-15	4220-4227	chronic	_
25-16	4228-4236	ketamine	_
25-17	4237-4242	users	_
25-18	4242-4243	.	_

#Text=Evidence shows that learning and performance factors are integrated into a network centered on the mediodorsal thalamus.
26-1	4244-4252	Evidence	_
26-2	4253-4258	shows	_
26-3	4259-4263	that	_
26-4	4264-4272	learning	_
26-5	4273-4276	and	_
26-6	4277-4288	performance	_
26-7	4289-4296	factors	_
26-8	4297-4300	are	_
26-9	4301-4311	integrated	_
26-10	4312-4316	into	_
26-11	4317-4318	a	_
26-12	4319-4326	network	_
26-13	4327-4335	centered	_
26-14	4336-4338	on	_
26-15	4339-4342	the	_
26-16	4343-4354	mediodorsal	_
26-17	4355-4363	thalamus	_
26-18	4363-4364	.	_

#Text=Additionally, deficits in goal-directed control and a consequent dysregulation of habit learning processes could result in compulsive drug seeking.
27-1	4365-4377	Additionally	_
27-2	4377-4378	,	_
27-3	4379-4387	deficits	_
27-4	4388-4390	in	_
27-5	4391-4404	goal-directed	_
27-6	4405-4412	control	_
27-7	4413-4416	and	_
27-8	4417-4418	a	_
27-9	4419-4429	consequent	_
27-10	4430-4443	dysregulation	_
27-11	4444-4446	of	_
27-12	4447-4452	habit	_
27-13	4453-4461	learning	_
27-14	4462-4471	processes	_
27-15	4472-4477	could	_
27-16	4478-4484	result	_
27-17	4485-4487	in	_
27-18	4488-4498	compulsive	_
27-19	4499-4503	drug	_
27-20	4504-4511	seeking	_
27-21	4511-4512	.	_

#Text=Given this evidence we hypothesize that thalamic nuclear groups would show altered resting state functional connectivity (RSFC) in the cerebral cortex of chronic ketamine users (ketamine addicts) when compared with healthy controls.
28-1	4513-4518	Given	_
28-2	4519-4523	this	_
28-3	4524-4532	evidence	_
28-4	4533-4535	we	_
28-5	4536-4547	hypothesize	_
28-6	4548-4552	that	_
28-7	4553-4561	thalamic	_
28-8	4562-4569	nuclear	_
28-9	4570-4576	groups	_
28-10	4577-4582	would	_
28-11	4583-4587	show	_
28-12	4588-4595	altered	_
28-13	4596-4603	resting	_
28-14	4604-4609	state	_
28-15	4610-4620	functional	_
28-16	4621-4633	connectivity	_
28-17	4634-4635	(	_
28-18	4635-4639	RSFC	_
28-19	4639-4640	)	_
28-20	4641-4643	in	_
28-21	4644-4647	the	_
28-22	4648-4656	cerebral	_
28-23	4657-4663	cortex	_
28-24	4664-4666	of	_
28-25	4667-4674	chronic	_
28-26	4675-4683	ketamine	_
28-27	4684-4689	users	_
28-28	4690-4691	(	_
28-29	4691-4699	ketamine	_
28-30	4700-4707	addicts	_
28-31	4707-4708	)	_
28-32	4709-4713	when	_
28-33	4714-4722	compared	_
28-34	4723-4727	with	_
28-35	4728-4735	healthy	_
28-36	4736-4744	controls	_
28-37	4744-4745	.	_

#Text=Methods
#Text=Study population
#Text=One hundred and thirty subjects (41 ketamine dependent subjects and 89 drug-free healthy subjects) were enrolled in this study.
29-1	4746-4753	Methods	http://www.case.edu/ProvCaRe/provcare#StudyMethod
29-2	4754-4759	Study	_
29-3	4760-4770	population	_
29-4	4771-4774	One	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
29-5	4775-4782	hundred	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
29-6	4783-4786	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
29-7	4787-4793	thirty	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
29-8	4794-4802	subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
29-9	4803-4804	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
29-10	4804-4806	41	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
29-11	4807-4815	ketamine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#HarmfulUseofKetamine[12]
29-12	4816-4825	dependent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#HarmfulUseofKetamine[12]
29-13	4826-4834	subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#HarmfulUseofKetamine[12]
29-14	4835-4838	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
29-15	4839-4841	89	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
29-16	4842-4851	drug-free	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[13]
29-17	4852-4859	healthy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[13]
29-18	4860-4868	subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[13]
29-19	4868-4869	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
29-20	4870-4874	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
29-21	4875-4883	enrolled	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
29-22	4884-4886	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
29-23	4887-4891	this	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
29-24	4892-4897	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
29-25	4897-4898	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]

#Text=All subjects were Han Chinese and between the ages of 19–39 with normal or corrected-to-normal vision.
30-1	4899-4902	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
30-2	4903-4911	subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
30-3	4912-4916	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
30-4	4917-4920	Han	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
30-5	4921-4928	Chinese	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
30-6	4929-4932	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
30-7	4933-4940	between	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
30-8	4941-4944	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
30-9	4945-4949	ages	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
30-10	4950-4952	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
30-11	4953-4955	19	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
30-12	4955-4956	–	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
30-13	4956-4958	39	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
30-14	4959-4963	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
30-15	4964-4970	normal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
30-16	4971-4973	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
30-17	4974-4993	corrected-to-normal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
30-18	4994-5000	vision	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
30-19	5000-5001	.	_

#Text=Ketamine dependent volunteers were recruited from two sites in Changsha city: the Kangda Voluntary Drug Rehabilitation Centers in Hunan Province and the Department of Addiction Medicine, Hunan Brain Hospital.
31-1	5002-5010	Ketamine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]|http://maven.renci.org/NeuroBridge/neurobridge#HarmfulUseofKetamine[15]
31-2	5011-5020	dependent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]|http://maven.renci.org/NeuroBridge/neurobridge#HarmfulUseofKetamine[15]
31-3	5021-5031	volunteers	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
31-4	5032-5036	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
31-5	5037-5046	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
31-6	5047-5051	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
31-7	5052-5055	two	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
31-8	5056-5061	sites	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
31-9	5062-5064	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
31-10	5065-5073	Changsha	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
31-11	5074-5078	city	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
31-12	5078-5079	:	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
31-13	5080-5083	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
31-14	5084-5090	Kangda	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
31-15	5091-5100	Voluntary	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
31-16	5101-5105	Drug	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
31-17	5106-5120	Rehabilitation	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
31-18	5121-5128	Centers	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
31-19	5129-5131	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
31-20	5132-5137	Hunan	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
31-21	5138-5146	Province	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
31-22	5147-5150	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
31-23	5151-5154	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
31-24	5155-5165	Department	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
31-25	5166-5168	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
31-26	5169-5178	Addiction	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
31-27	5179-5187	Medicine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
31-28	5187-5188	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
31-29	5189-5194	Hunan	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
31-30	5195-5200	Brain	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
31-31	5201-5209	Hospital	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]
31-32	5209-5210	.	_

#Text=All ketamine users met the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria for lifetime ketamine dependence determined by the Structured Clinical Interview (SCID).
32-1	5211-5214	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
32-2	5215-5223	ketamine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]|http://maven.renci.org/NeuroBridge/neurobridge#HarmfulUseofKetamine[17]
32-3	5224-5229	users	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]|http://maven.renci.org/NeuroBridge/neurobridge#HarmfulUseofKetamine[17]
32-4	5230-5233	met	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
32-5	5234-5237	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
32-6	5238-5248	Diagnostic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
32-7	5249-5252	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
32-8	5253-5264	Statistical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
32-9	5265-5271	Manual	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
32-10	5272-5274	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
32-11	5275-5281	Mental	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
32-12	5282-5291	Disorders	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
32-13	5292-5293	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
32-14	5293-5299	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
32-15	5299-5300	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
32-16	5301-5309	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
32-17	5310-5313	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
32-18	5314-5322	lifetime	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
32-19	5323-5331	ketamine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]|http://maven.renci.org/NeuroBridge/neurobridge#HarmfulUseofKetamine[18]
32-20	5332-5342	dependence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]|http://maven.renci.org/NeuroBridge/neurobridge#HarmfulUseofKetamine[18]
32-21	5343-5353	determined	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
32-22	5354-5356	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
32-23	5357-5360	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
32-24	5361-5371	Structured	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[19]
32-25	5372-5380	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[19]
32-26	5381-5390	Interview	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[19]
32-27	5391-5392	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[19]
32-28	5392-5396	SCID	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[19]
32-29	5396-5397	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[19]
32-30	5397-5398	.	_

#Text=Ketamine subjects were excluded if they met criteria for other substance dependence (excluding nicotine dependence) at any time, past and present.
33-1	5399-5407	Ketamine	_
33-2	5408-5416	subjects	_
33-3	5417-5421	were	_
33-4	5422-5430	excluded	_
33-5	5431-5433	if	_
33-6	5434-5438	they	_
33-7	5439-5442	met	_
33-8	5443-5451	criteria	_
33-9	5452-5455	for	_
33-10	5456-5461	other	_
33-11	5462-5471	substance	http://maven.renci.org/NeuroBridge/neurobridge#DrugDependence[20]
33-12	5472-5482	dependence	http://maven.renci.org/NeuroBridge/neurobridge#DrugDependence[20]
33-13	5483-5484	(	_
33-14	5484-5493	excluding	_
33-15	5494-5502	nicotine	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse[21]
33-16	5503-5513	dependence	http://maven.renci.org/NeuroBridge/neurobridge#NicotineAbuse[21]
33-17	5513-5514	)	_
33-18	5515-5517	at	_
33-19	5518-5521	any	_
33-20	5522-5526	time	_
33-21	5526-5527	,	_
33-22	5528-5532	past	_
33-23	5533-5536	and	_
33-24	5537-5544	present	_
33-25	5544-5545	.	_

#Text=Drug free healthy control subjects were recruited through a combination of targeted site sampling, advertisement, and snowball sampling referrals.
34-1	5546-5550	Drug	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
34-2	5551-5555	free	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
34-3	5556-5563	healthy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
34-4	5564-5571	control	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[23]
34-5	5572-5580	subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
34-6	5581-5585	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
34-7	5586-5595	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
34-8	5596-5603	through	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
34-9	5604-5605	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
34-10	5606-5617	combination	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
34-11	5618-5620	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
34-12	5621-5629	targeted	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
34-13	5630-5634	site	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
34-14	5635-5643	sampling	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
34-15	5643-5644	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
34-16	5645-5658	advertisement	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
34-17	5658-5659	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
34-18	5660-5663	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
34-19	5664-5672	snowball	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
34-20	5673-5681	sampling	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
34-21	5682-5691	referrals	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]
34-22	5691-5692	.	_

#Text=All participants were Han Chinese with no history of neurological disorder or other psychiatric illness; neither did they have a first degree relative with substance abuse or a history of psychiatric illness.
35-1	5693-5696	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
35-2	5697-5709	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
35-3	5710-5714	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
35-4	5715-5718	Han	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
35-5	5719-5726	Chinese	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
35-6	5727-5731	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
35-7	5732-5734	no	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
35-8	5735-5742	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
35-9	5743-5745	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
35-10	5746-5758	neurological	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
35-11	5759-5767	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
35-12	5768-5770	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
35-13	5771-5776	other	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
35-14	5777-5788	psychiatric	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
35-15	5789-5796	illness	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
35-16	5796-5797	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
35-17	5798-5805	neither	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
35-18	5806-5809	did	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
35-19	5810-5814	they	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
35-20	5815-5819	have	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
35-21	5820-5821	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
35-22	5822-5827	first	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
35-23	5828-5834	degree	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
35-24	5835-5843	relative	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
35-25	5844-5848	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
35-26	5849-5858	substance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
35-27	5859-5864	abuse	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
35-28	5865-5867	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
35-29	5868-5869	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
35-30	5870-5877	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
35-31	5878-5880	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
35-32	5881-5892	psychiatric	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
35-33	5893-5900	illness	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
35-34	5900-5901	.	_

#Text=Additionally, any participant that tested positive for pregnancy was excluded from participation.
36-1	5902-5914	Additionally	_
36-2	5914-5915	,	_
36-3	5916-5919	any	_
36-4	5920-5931	participant	_
36-5	5932-5936	that	_
36-6	5937-5943	tested	_
36-7	5944-5952	positive	_
36-8	5953-5956	for	_
36-9	5957-5966	pregnancy	_
36-10	5967-5970	was	_
36-11	5971-5979	excluded	_
36-12	5980-5984	from	_
36-13	5985-5998	participation	_
36-14	5998-5999	.	_

#Text=A licensed psychiatrist conducted all clinical interviews.
37-1	6000-6001	A	_
37-2	6002-6010	licensed	_
37-3	6011-6023	psychiatrist	_
37-4	6024-6033	conducted	_
37-5	6034-6037	all	_
37-6	6038-6046	clinical	_
37-7	6047-6057	interviews	_
37-8	6057-6058	.	_

#Text=The protocol was approved by the university ethics committee (The Second Xiangya Hospital of Central South University Review Board, No.
38-1	6059-6062	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
38-2	6063-6071	protocol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
38-3	6072-6075	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
38-4	6076-6084	approved	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
38-5	6085-6087	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
38-6	6088-6091	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
38-7	6092-6102	university	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
38-8	6103-6109	ethics	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
38-9	6110-6119	committee	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
38-10	6120-6121	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
38-11	6121-6124	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
38-12	6125-6131	Second	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
38-13	6132-6139	Xiangya	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
38-14	6140-6148	Hospital	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
38-15	6149-6151	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
38-16	6152-6159	Central	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
38-17	6160-6165	South	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
38-18	6166-6176	University	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
38-19	6177-6183	Review	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
38-20	6184-6189	Board	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
38-21	6189-6190	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
38-22	6191-6193	No	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
38-23	6193-6194	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]

#Text=S054, 2008) as well as carried out in accordance with the Declaration of Helsinki.
39-1	6195-6199	S054	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]
39-2	6199-6200	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]
39-3	6201-6205	2008	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]
39-4	6205-6206	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]
39-5	6207-6209	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]
39-6	6210-6214	well	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]
39-7	6215-6217	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]
39-8	6218-6225	carried	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]
39-9	6226-6229	out	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]
39-10	6230-6232	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]
39-11	6233-6243	accordance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]
39-12	6244-6248	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]
39-13	6249-6252	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]
39-14	6253-6264	Declaration	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]
39-15	6265-6267	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]
39-16	6268-6276	Helsinki	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]
39-17	6276-6277	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[26]

#Text=All subjects were informed about all procedures and any potential risks associated with the procedures.
40-1	6278-6281	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]
40-2	6282-6290	subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]
40-3	6291-6295	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]
40-4	6296-6304	informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]
40-5	6305-6310	about	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]
40-6	6311-6314	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]
40-7	6315-6325	procedures	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]
40-8	6326-6329	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]
40-9	6330-6333	any	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]
40-10	6334-6343	potential	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]
40-11	6344-6349	risks	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]
40-12	6350-6360	associated	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]
40-13	6361-6365	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]
40-14	6366-6369	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]
40-15	6370-6380	procedures	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]
40-16	6380-6381	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]

#Text=Once provided this information, written informed consent was obtained by all subjects.
41-1	6382-6386	Once	_
41-2	6387-6395	provided	_
41-3	6396-6400	this	_
41-4	6401-6412	information	_
41-5	6412-6413	,	_
41-6	6414-6421	written	_
41-7	6422-6430	informed	_
41-8	6431-6438	consent	_
41-9	6439-6442	was	_
41-10	6443-6451	obtained	_
41-11	6452-6454	by	_
41-12	6455-6458	all	_
41-13	6459-6467	subjects	_
41-14	6467-6468	.	_

#Text=Craving for both ketamine and smoking were assessed by The Visual Analogue Scale for Craving (VASc).
42-1	6469-6476	Craving	_
42-2	6477-6480	for	_
42-3	6481-6485	both	_
42-4	6486-6494	ketamine	_
42-5	6495-6498	and	_
42-6	6499-6506	smoking	_
42-7	6507-6511	were	_
42-8	6512-6520	assessed	_
42-9	6521-6523	by	_
42-10	6524-6527	The	http://www.case.edu/ProvCaRe/provcare#Scale[28]
42-11	6528-6534	Visual	http://www.case.edu/ProvCaRe/provcare#Scale[28]
42-12	6535-6543	Analogue	http://www.case.edu/ProvCaRe/provcare#Scale[28]
42-13	6544-6549	Scale	http://www.case.edu/ProvCaRe/provcare#Scale[28]
42-14	6550-6553	for	http://www.case.edu/ProvCaRe/provcare#Scale[28]
42-15	6554-6561	Craving	http://www.case.edu/ProvCaRe/provcare#Scale[28]
42-16	6562-6563	(	http://www.case.edu/ProvCaRe/provcare#Scale[28]
42-17	6563-6567	VASc	http://www.case.edu/ProvCaRe/provcare#Scale[28]
42-18	6567-6568	)	http://www.case.edu/ProvCaRe/provcare#Scale[28]
42-19	6568-6569	.	_

#Text=The VASc assesses craving using a scale from 0–10, where a score of 0 represents null craving and a score of 10 represents the most extreme craving.
43-1	6570-6573	The	_
43-2	6574-6578	VASc	http://www.case.edu/ProvCaRe/provcare#Scale
43-3	6579-6587	assesses	_
43-4	6588-6595	craving	_
43-5	6596-6601	using	_
43-6	6602-6603	a	_
43-7	6604-6609	scale	_
43-8	6610-6614	from	_
43-9	6615-6616	0	_
43-10	6616-6617	–	_
43-11	6617-6619	10	_
43-12	6619-6620	,	_
43-13	6621-6626	where	_
43-14	6627-6628	a	_
43-15	6629-6634	score	_
43-16	6635-6637	of	_
43-17	6638-6639	0	_
43-18	6640-6650	represents	_
43-19	6651-6655	null	_
43-20	6656-6663	craving	_
43-21	6664-6667	and	_
43-22	6668-6669	a	_
43-23	6670-6675	score	_
43-24	6676-6678	of	_
43-25	6679-6681	10	_
43-26	6682-6692	represents	_
43-27	6693-6696	the	_
43-28	6697-6701	most	_
43-29	6702-6709	extreme	_
43-30	6710-6717	craving	_
43-31	6717-6718	.	_

#Text=The Digit Symbol Test (DST), Trail Making Test A (TMTA) and The Stroop Color—Word Test (CWT) were also used to measure subject’s cognitive functioning.
44-1	6719-6722	The	_
44-2	6723-6728	Digit	_
44-3	6729-6735	Symbol	_
44-4	6736-6740	Test	_
44-5	6741-6742	(	_
44-6	6742-6745	DST	_
44-7	6745-6746	)	_
44-8	6746-6747	,	_
44-9	6748-6753	Trail	_
44-10	6754-6760	Making	_
44-11	6761-6765	Test	_
44-12	6766-6767	A	_
44-13	6768-6769	(	_
44-14	6769-6773	TMTA	_
44-15	6773-6774	)	_
44-16	6775-6778	and	_
44-17	6779-6782	The	_
44-18	6783-6789	Stroop	_
44-19	6790-6800	Color—Word	_
44-20	6801-6805	Test	_
44-21	6806-6807	(	_
44-22	6807-6810	CWT	_
44-23	6810-6811	)	_
44-24	6812-6816	were	_
44-25	6817-6821	also	_
44-26	6822-6826	used	_
44-27	6827-6829	to	_
44-28	6830-6837	measure	_
44-29	6838-6845	subject	_
44-30	6845-6846	’	_
44-31	6846-6847	s	_
44-32	6848-6857	cognitive	_
44-33	6858-6869	functioning	_
44-34	6869-6870	.	_

#Text=Scan acquisition
#Text=MR imaging was carried out using a Siemens Magnetom Trio 3.0T MR scanner (Erlangen, Germany).
45-1	6871-6875	Scan	_
45-2	6876-6887	acquisition	_
45-3	6888-6890	MR	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[29]
45-4	6891-6898	imaging	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[29]
45-5	6899-6902	was	_
45-6	6903-6910	carried	_
45-7	6911-6914	out	_
45-8	6915-6920	using	_
45-9	6921-6922	a	_
45-10	6923-6930	Siemens	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[30]
45-11	6931-6939	Magnetom	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[30]
45-12	6940-6944	Trio	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[30]
45-13	6945-6949	3.0T	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[30]
45-14	6950-6952	MR	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[30]
45-15	6953-6960	scanner	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[30]
45-16	6961-6962	(	_
45-17	6962-6970	Erlangen	_
45-18	6970-6971	,	_
45-19	6972-6979	Germany	_
45-20	6979-6980	)	_
45-21	6980-6981	.	_

#Text=Functional images were collected axially by using an echo-planar imaging (EPI) sequence sensitive to BOLD contrast.
46-1	6982-6992	Functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[31]
46-2	6993-6999	images	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[31]
46-3	7000-7004	were	_
46-4	7005-7014	collected	_
46-5	7015-7022	axially	_
46-6	7023-7025	by	_
46-7	7026-7031	using	_
46-8	7032-7034	an	_
46-9	7035-7046	echo-planar	_
46-10	7047-7054	imaging	_
46-11	7055-7056	(	_
46-12	7056-7059	EPI	_
46-13	7059-7060	)	_
46-14	7061-7069	sequence	_
46-15	7070-7079	sensitive	_
46-16	7080-7082	to	_
46-17	7083-7087	BOLD	_
46-18	7088-7096	contrast	_
46-19	7096-7097	.	_

#Text=The acquisition parameters were as follows: 36 slices, 3000/30 ms (TR/TE), 4 mm thickness, 220×220 mm (FOV), 64×64 (resolution within slice), 90° (flip angle).
47-1	7098-7101	The	_
47-2	7102-7113	acquisition	_
47-3	7114-7124	parameters	_
47-4	7125-7129	were	_
47-5	7130-7132	as	_
47-6	7133-7140	follows	_
47-7	7140-7141	:	_
47-8	7142-7144	36	_
47-9	7145-7151	slices	_
47-10	7151-7152	,	_
47-11	7153-7157	3000	_
47-12	7157-7158	/	_
47-13	7158-7160	30	_
47-14	7161-7163	ms	_
47-15	7164-7165	(	_
47-16	7165-7167	TR	_
47-17	7167-7168	/	_
47-18	7168-7170	TE	_
47-19	7170-7171	)	_
47-20	7171-7172	,	_
47-21	7173-7174	4	_
47-22	7175-7177	mm	_
47-23	7178-7187	thickness	_
47-24	7187-7188	,	_
47-25	7189-7192	220	_
47-26	7192-7193	×	_
47-27	7193-7196	220	_
47-28	7197-7199	mm	_
47-29	7200-7201	(	_
47-30	7201-7204	FOV	_
47-31	7204-7205	)	_
47-32	7205-7206	,	_
47-33	7207-7209	64	_
47-34	7209-7210	×	_
47-35	7210-7212	64	_
47-36	7213-7214	(	_
47-37	7214-7224	resolution	_
47-38	7225-7231	within	_
47-39	7232-7237	slice	_
47-40	7237-7238	)	_
47-41	7238-7239	,	_
47-42	7240-7242	90	_
47-43	7242-7243	°	_
47-44	7244-7245	(	_
47-45	7245-7249	flip	_
47-46	7250-7255	angle	_
47-47	7255-7256	)	_
47-48	7256-7257	.	_

#Text=The FOV covered all brain regions for all participants.
48-1	7258-7261	The	_
48-2	7262-7265	FOV	_
48-3	7266-7273	covered	_
48-4	7274-7277	all	_
48-5	7278-7283	brain	_
48-6	7284-7291	regions	_
48-7	7292-7295	for	_
48-8	7296-7299	all	_
48-9	7300-7312	participants	_
48-10	7312-7313	.	_

#Text=Resting state was collected during the fMRI and lasted 9 minutes with 180 volumes obtained.
49-1	7314-7321	Resting	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[32]
49-2	7322-7327	state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[32]
49-3	7328-7331	was	_
49-4	7332-7341	collected	_
49-5	7342-7348	during	_
49-6	7349-7352	the	_
49-7	7353-7357	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
49-8	7358-7361	and	_
49-9	7362-7368	lasted	_
49-10	7369-7370	9	_
49-11	7371-7378	minutes	_
49-12	7379-7383	with	_
49-13	7384-7387	180	_
49-14	7388-7395	volumes	_
49-15	7396-7404	obtained	_
49-16	7404-7405	.	_

#Text=During the resting state scan all subjects were instructed to stay as motionless as possible with their eyes closed and to not think of anything in particular.
50-1	7406-7412	During	_
50-2	7413-7416	the	_
50-3	7417-7424	resting	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[33]
50-4	7425-7430	state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[33]
50-5	7431-7435	scan	_
50-6	7436-7439	all	_
50-7	7440-7448	subjects	_
50-8	7449-7453	were	_
50-9	7454-7464	instructed	_
50-10	7465-7467	to	_
50-11	7468-7472	stay	_
50-12	7473-7475	as	_
50-13	7476-7486	motionless	_
50-14	7487-7489	as	_
50-15	7490-7498	possible	_
50-16	7499-7503	with	_
50-17	7504-7509	their	_
50-18	7510-7514	eyes	_
50-19	7515-7521	closed	_
50-20	7522-7525	and	_
50-21	7526-7528	to	_
50-22	7529-7532	not	_
50-23	7533-7538	think	_
50-24	7539-7541	of	_
50-25	7542-7550	anything	_
50-26	7551-7553	in	_
50-27	7554-7564	particular	_
50-28	7564-7565	.	_

#Text=Additionally, for spatial normalization, each participant received a 3D anatomical MRI image with a T1-weighted magnetization-prepared rapid-acquisition gradient echo (MP-RAGE).
51-1	7566-7578	Additionally	_
51-2	7578-7579	,	_
51-3	7580-7583	for	_
51-4	7584-7591	spatial	_
51-5	7592-7605	normalization	_
51-6	7605-7606	,	_
51-7	7607-7611	each	_
51-8	7612-7623	participant	_
51-9	7624-7632	received	_
51-10	7633-7634	a	_
51-11	7635-7637	3D	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[34]
51-12	7638-7648	anatomical	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[34]
51-13	7649-7652	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[34]
51-14	7653-7658	image	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[34]
51-15	7659-7663	with	_
51-16	7664-7665	a	_
51-17	7666-7668	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[35]
51-18	7668-7669	-	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[35]
51-19	7669-7677	weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[35]
51-20	7678-7700	magnetization-prepared	_
51-21	7701-7718	rapid-acquisition	_
51-22	7719-7727	gradient	_
51-23	7728-7732	echo	_
51-24	7733-7734	(	_
51-25	7734-7741	MP-RAGE	_
51-26	7741-7742	)	_
51-27	7742-7743	.	_

#Text=The protocol was as follows: sagittal, repetition time = 2000 ms, echo time = 2.26 ms, inversion time = 900 ms, flip angle = 8°, slice thickness = 1 mm, FOV = 256 × 256 mm2, in-plane resolution = 1 × 1 mm2.
52-1	7744-7747	The	_
52-2	7748-7756	protocol	_
52-3	7757-7760	was	_
52-4	7761-7763	as	_
52-5	7764-7771	follows	_
52-6	7771-7772	:	_
52-7	7773-7781	sagittal	_
52-8	7781-7782	,	_
52-9	7783-7793	repetition	_
52-10	7794-7798	time	_
52-11	7799-7800	=	_
52-12	7801-7805	2000	_
52-13	7806-7808	ms	_
52-14	7808-7809	,	_
52-15	7810-7814	echo	_
52-16	7815-7819	time	_
52-17	7820-7821	=	_
52-18	7822-7826	2.26	_
52-19	7827-7829	ms	_
52-20	7829-7830	,	_
52-21	7831-7840	inversion	_
52-22	7841-7845	time	_
52-23	7846-7847	=	_
52-24	7848-7851	900	_
52-25	7852-7854	ms	_
52-26	7854-7855	,	_
52-27	7856-7860	flip	_
52-28	7861-7866	angle	_
52-29	7867-7868	=	_
52-30	7869-7870	8	_
52-31	7870-7871	°	_
52-32	7871-7872	,	_
52-33	7873-7878	slice	_
52-34	7879-7888	thickness	_
52-35	7889-7890	=	_
52-36	7891-7892	1	_
52-37	7893-7895	mm	_
52-38	7895-7896	,	_
52-39	7897-7900	FOV	_
52-40	7901-7902	=	_
52-41	7903-7906	256	_
52-42	7907-7908	×	_
52-43	7909-7912	256	_
52-44	7913-7916	mm2	_
52-45	7916-7917	,	_
52-46	7918-7926	in-plane	_
52-47	7927-7937	resolution	_
52-48	7938-7939	=	_
52-49	7940-7941	1	_
52-50	7942-7943	×	_
52-51	7944-7945	1	_
52-52	7946-7949	mm2	_
52-53	7949-7950	.	_

#Text=Data preprocessing
#Text=Functional MRIs were preprocessed using SPM8 and in-house programs on the Matlab 2010 platform.
53-1	7951-7955	Data	_
53-2	7956-7969	preprocessing	_
53-3	7970-7980	Functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[36]
53-4	7981-7985	MRIs	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[36]
53-5	7986-7990	were	_
53-6	7991-8003	preprocessed	_
53-7	8004-8009	using	_
53-8	8010-8014	SPM8	_
53-9	8015-8018	and	_
53-10	8019-8027	in-house	_
53-11	8028-8036	programs	_
53-12	8037-8039	on	_
53-13	8040-8043	the	_
53-14	8044-8050	Matlab	_
53-15	8051-8055	2010	_
53-16	8056-8064	platform	_
53-17	8064-8065	.	_

#Text=Of the 180 scans obtained for each participant, the first 5 were discarded to allow the MR signal to reach a steady state.
54-1	8066-8068	Of	_
54-2	8069-8072	the	_
54-3	8073-8076	180	_
54-4	8077-8082	scans	_
54-5	8083-8091	obtained	_
54-6	8092-8095	for	_
54-7	8096-8100	each	_
54-8	8101-8112	participant	_
54-9	8112-8113	,	_
54-10	8114-8117	the	_
54-11	8118-8123	first	_
54-12	8124-8125	5	_
54-13	8126-8130	were	_
54-14	8131-8140	discarded	_
54-15	8141-8143	to	_
54-16	8144-8149	allow	_
54-17	8150-8153	the	_
54-18	8154-8156	MR	_
54-19	8157-8163	signal	_
54-20	8164-8166	to	_
54-21	8167-8172	reach	_
54-22	8173-8174	a	_
54-23	8175-8181	steady	_
54-24	8182-8187	state	_
54-25	8187-8188	.	_

#Text=The remaining fMRI scans underwent preprocessing that included slice timing, motion correction, registration and normalization to a standard Montreal Neurological Institute (MNI) space, and resampling to a stereoscopic 3 mm3.
55-1	8189-8192	The	_
55-2	8193-8202	remaining	_
55-3	8203-8207	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
55-4	8208-8213	scans	_
55-5	8214-8223	underwent	_
55-6	8224-8237	preprocessing	_
55-7	8238-8242	that	_
55-8	8243-8251	included	_
55-9	8252-8257	slice	_
55-10	8258-8264	timing	_
55-11	8264-8265	,	_
55-12	8266-8272	motion	_
55-13	8273-8283	correction	_
55-14	8283-8284	,	_
55-15	8285-8297	registration	_
55-16	8298-8301	and	_
55-17	8302-8315	normalization	_
55-18	8316-8318	to	_
55-19	8319-8320	a	_
55-20	8321-8329	standard	_
55-21	8330-8338	Montreal	_
55-22	8339-8351	Neurological	_
55-23	8352-8361	Institute	_
55-24	8362-8363	(	_
55-25	8363-8366	MNI	_
55-26	8366-8367	)	_
55-27	8368-8373	space	_
55-28	8373-8374	,	_
55-29	8375-8378	and	_
55-30	8379-8389	resampling	_
55-31	8390-8392	to	_
55-32	8393-8394	a	_
55-33	8395-8407	stereoscopic	_
55-34	8408-8409	3	_
55-35	8410-8413	mm3	_
55-36	8413-8414	.	_

#Text=The resulting data were checked to ensure alignment and spatial correspondence.
56-1	8415-8418	The	_
56-2	8419-8428	resulting	_
56-3	8429-8433	data	_
56-4	8434-8438	were	_
56-5	8439-8446	checked	_
56-6	8447-8449	to	_
56-7	8450-8456	ensure	_
56-8	8457-8466	alignment	_
56-9	8467-8470	and	_
56-10	8471-8478	spatial	_
56-11	8479-8493	correspondence	_
56-12	8493-8494	.	_

#Text=Next, any linear trend shifts and head motion were removed voxel wise by regression.
57-1	8495-8499	Next	_
57-2	8499-8500	,	_
57-3	8501-8504	any	_
57-4	8505-8511	linear	_
57-5	8512-8517	trend	_
57-6	8518-8524	shifts	_
57-7	8525-8528	and	_
57-8	8529-8533	head	_
57-9	8534-8540	motion	_
57-10	8541-8545	were	_
57-11	8546-8553	removed	_
57-12	8554-8559	voxel	_
57-13	8560-8564	wise	_
57-14	8565-8567	by	_
57-15	8568-8578	regression	_
57-16	8578-8579	.	_

#Text=Finally, to reduce low-frequency drift and high-frequency noise, the fMRI data were temporally filtered using a band-pass range between 0.01 and 0.08 Hz with AFNI (http://afni.nimh.nih.gov/).
58-1	8580-8587	Finally	_
58-2	8587-8588	,	_
58-3	8589-8591	to	_
58-4	8592-8598	reduce	_
58-5	8599-8612	low-frequency	_
58-6	8613-8618	drift	_
58-7	8619-8622	and	_
58-8	8623-8637	high-frequency	_
58-9	8638-8643	noise	_
58-10	8643-8644	,	_
58-11	8645-8648	the	_
58-12	8649-8653	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
58-13	8654-8658	data	_
58-14	8659-8663	were	_
58-15	8664-8674	temporally	_
58-16	8675-8683	filtered	_
58-17	8684-8689	using	_
58-18	8690-8691	a	_
58-19	8692-8701	band-pass	_
58-20	8702-8707	range	_
58-21	8708-8715	between	_
58-22	8716-8720	0.01	_
58-23	8721-8724	and	_
58-24	8725-8729	0.08	_
58-25	8730-8732	Hz	_
58-26	8733-8737	with	_
58-27	8738-8742	AFNI	_
58-28	8743-8744	(	_
58-29	8744-8748	http	_
58-30	8748-8749	:	_
58-31	8749-8750	/	_
58-32	8750-8751	/	_
58-33	8751-8768	afni.nimh.nih.gov	_
58-34	8768-8769	/	_
58-35	8769-8770	)	_
58-36	8770-8771	.	_

#Text=It is noted that the spatial smoothing was omitted to maximize resolution in the analyses of thalamus nuclei groups, which are smaller brain structures.
59-1	8772-8774	It	_
59-2	8775-8777	is	_
59-3	8778-8783	noted	_
59-4	8784-8788	that	_
59-5	8789-8792	the	_
59-6	8793-8800	spatial	_
59-7	8801-8810	smoothing	_
59-8	8811-8814	was	_
59-9	8815-8822	omitted	_
59-10	8823-8825	to	_
59-11	8826-8834	maximize	_
59-12	8835-8845	resolution	_
59-13	8846-8848	in	_
59-14	8849-8852	the	_
59-15	8853-8861	analyses	_
59-16	8862-8864	of	_
59-17	8865-8873	thalamus	_
59-18	8874-8880	nuclei	_
59-19	8881-8887	groups	_
59-20	8887-8888	,	_
59-21	8889-8894	which	_
59-22	8895-8898	are	_
59-23	8899-8906	smaller	_
59-24	8907-8912	brain	_
59-25	8913-8923	structures	_
59-26	8923-8924	.	_

#Text=Additionally, we found that the average BOLD signal across all voxels in the brain was significantly correlated with the average time series within the thalamus as reported in other studies.
60-1	8925-8937	Additionally	_
60-2	8937-8938	,	_
60-3	8939-8941	we	_
60-4	8942-8947	found	_
60-5	8948-8952	that	_
60-6	8953-8956	the	_
60-7	8957-8964	average	_
60-8	8965-8969	BOLD	_
60-9	8970-8976	signal	_
60-10	8977-8983	across	_
60-11	8984-8987	all	_
60-12	8988-8994	voxels	_
60-13	8995-8997	in	_
60-14	8998-9001	the	_
60-15	9002-9007	brain	_
60-16	9008-9011	was	_
60-17	9012-9025	significantly	_
60-18	9026-9036	correlated	_
60-19	9037-9041	with	_
60-20	9042-9045	the	_
60-21	9046-9053	average	_
60-22	9054-9058	time	_
60-23	9059-9065	series	_
60-24	9066-9072	within	_
60-25	9073-9076	the	_
60-26	9077-9085	thalamus	_
60-27	9086-9088	as	_
60-28	9089-9097	reported	_
60-29	9098-9100	in	_
60-30	9101-9106	other	_
60-31	9107-9114	studies	_
60-32	9114-9115	.	_

#Text=These results confirm that the study did not regress out of the global signal within the brain.
61-1	9116-9121	These	_
61-2	9122-9129	results	_
61-3	9130-9137	confirm	_
61-4	9138-9142	that	_
61-5	9143-9146	the	_
61-6	9147-9152	study	_
61-7	9153-9156	did	_
61-8	9157-9160	not	_
61-9	9161-9168	regress	_
61-10	9169-9172	out	_
61-11	9173-9175	of	_
61-12	9176-9179	the	_
61-13	9180-9186	global	_
61-14	9187-9193	signal	_
61-15	9194-9200	within	_
61-16	9201-9204	the	_
61-17	9205-9210	brain	_
61-18	9210-9211	.	_

#Text=Cortical ROI definition
#Text=To investigate the specific functional relationships between the cortex and the thalamus, nuclei groups within the thalamus were partitioned into several nuclei groups using the methods proposed in previous studies.
62-1	9212-9220	Cortical	_
62-2	9221-9224	ROI	_
62-3	9225-9235	definition	_
62-4	9236-9238	To	_
62-5	9239-9250	investigate	_
62-6	9251-9254	the	_
62-7	9255-9263	specific	_
62-8	9264-9274	functional	_
62-9	9275-9288	relationships	_
62-10	9289-9296	between	_
62-11	9297-9300	the	_
62-12	9301-9307	cortex	_
62-13	9308-9311	and	_
62-14	9312-9315	the	_
62-15	9316-9324	thalamus	_
62-16	9324-9325	,	_
62-17	9326-9332	nuclei	_
62-18	9333-9339	groups	_
62-19	9340-9346	within	_
62-20	9347-9350	the	_
62-21	9351-9359	thalamus	_
62-22	9360-9364	were	_
62-23	9365-9376	partitioned	_
62-24	9377-9381	into	_
62-25	9382-9389	several	_
62-26	9390-9396	nuclei	_
62-27	9397-9403	groups	_
62-28	9404-9409	using	_
62-29	9410-9413	the	_
62-30	9414-9421	methods	_
62-31	9422-9430	proposed	_
62-32	9431-9433	in	_
62-33	9434-9442	previous	_
62-34	9443-9450	studies	_
62-35	9450-9451	.	_

#Text=Since there are distinct connections between thalamic sub-regions and the cerebral cortex, specific functional relationships between them can be used to parcel the thalamus into nuclear subdivisions.
63-1	9452-9457	Since	_
63-2	9458-9463	there	_
63-3	9464-9467	are	_
63-4	9468-9476	distinct	_
63-5	9477-9488	connections	_
63-6	9489-9496	between	_
63-7	9497-9505	thalamic	_
63-8	9506-9517	sub-regions	_
63-9	9518-9521	and	_
63-10	9522-9525	the	_
63-11	9526-9534	cerebral	_
63-12	9535-9541	cortex	_
63-13	9541-9542	,	_
63-14	9543-9551	specific	_
63-15	9552-9562	functional	_
63-16	9563-9576	relationships	_
63-17	9577-9584	between	_
63-18	9585-9589	them	_
63-19	9590-9593	can	_
63-20	9594-9596	be	_
63-21	9597-9601	used	_
63-22	9602-9604	to	_
63-23	9605-9611	parcel	_
63-24	9612-9615	the	_
63-25	9616-9624	thalamus	_
63-26	9625-9629	into	_
63-27	9630-9637	nuclear	_
63-28	9638-9650	subdivisions	_
63-29	9650-9651	.	_

#Text=In concurrence with relevant research knowledge this study divided the cortex into 6 non-overlapping regions of interest: the prefrontal cortex, motor cortex/supplementary motor area, somatosensory cortex, temporal cortex, posterior parietal cortex, and occipital cortex.
64-1	9652-9654	In	_
64-2	9655-9666	concurrence	_
64-3	9667-9671	with	_
64-4	9672-9680	relevant	_
64-5	9681-9689	research	_
64-6	9690-9699	knowledge	_
64-7	9700-9704	this	_
64-8	9705-9710	study	_
64-9	9711-9718	divided	_
64-10	9719-9722	the	_
64-11	9723-9729	cortex	_
64-12	9730-9734	into	_
64-13	9735-9736	6	_
64-14	9737-9752	non-overlapping	_
64-15	9753-9760	regions	_
64-16	9761-9763	of	_
64-17	9764-9772	interest	_
64-18	9772-9773	:	_
64-19	9774-9777	the	_
64-20	9778-9788	prefrontal	_
64-21	9789-9795	cortex	_
64-22	9795-9796	,	_
64-23	9797-9802	motor	_
64-24	9803-9809	cortex	_
64-25	9809-9810	/	_
64-26	9810-9823	supplementary	_
64-27	9824-9829	motor	_
64-28	9830-9834	area	_
64-29	9834-9835	,	_
64-30	9836-9849	somatosensory	_
64-31	9850-9856	cortex	_
64-32	9856-9857	,	_
64-33	9858-9866	temporal	_
64-34	9867-9873	cortex	_
64-35	9873-9874	,	_
64-36	9875-9884	posterior	_
64-37	9885-9893	parietal	_
64-38	9894-9900	cortex	_
64-39	9900-9901	,	_
64-40	9902-9905	and	_
64-41	9906-9915	occipital	_
64-42	9916-9922	cortex	_
64-43	9922-9923	.	_

#Text=We used the Harvard-Oxford maximum probabilistic atlas of cortical structures (http://www.fmrib.ox.ac.uk/fsl/) to construct these regions of interest as shown in a previous study.
65-1	9924-9926	We	_
65-2	9927-9931	used	_
65-3	9932-9935	the	_
65-4	9936-9950	Harvard-Oxford	_
65-5	9951-9958	maximum	_
65-6	9959-9972	probabilistic	_
65-7	9973-9978	atlas	_
65-8	9979-9981	of	_
65-9	9982-9990	cortical	_
65-10	9991-10001	structures	_
65-11	10002-10003	(	_
65-12	10003-10007	http	_
65-13	10007-10008	:	_
65-14	10008-10009	/	_
65-15	10009-10010	/	_
65-16	10010-10028	www.fmrib.ox.ac.uk	_
65-17	10028-10029	/	_
65-18	10029-10032	fsl	_
65-19	10032-10033	/	_
65-20	10033-10034	)	_
65-21	10035-10037	to	_
65-22	10038-10047	construct	_
65-23	10048-10053	these	_
65-24	10054-10061	regions	_
65-25	10062-10064	of	_
65-26	10065-10073	interest	_
65-27	10074-10076	as	_
65-28	10077-10082	shown	_
65-29	10083-10085	in	_
65-30	10086-10087	a	_
65-31	10088-10096	previous	_
65-32	10097-10102	study	_
65-33	10102-10103	.	_

#Text=The cortical regions of interest (ROIs) are shown in Fig 1A, along with the details of the six regions of interest listed in S1 Table.
66-1	10104-10107	The	_
66-2	10108-10116	cortical	_
66-3	10117-10124	regions	_
66-4	10125-10127	of	_
66-5	10128-10136	interest	_
66-6	10137-10138	(	_
66-7	10138-10142	ROIs	_
66-8	10142-10143	)	_
66-9	10144-10147	are	_
66-10	10148-10153	shown	_
66-11	10154-10156	in	_
66-12	10157-10160	Fig	_
66-13	10161-10163	1A	_
66-14	10163-10164	,	_
66-15	10165-10170	along	_
66-16	10171-10175	with	_
66-17	10176-10179	the	_
66-18	10180-10187	details	_
66-19	10188-10190	of	_
66-20	10191-10194	the	_
66-21	10195-10198	six	_
66-22	10199-10206	regions	_
66-23	10207-10209	of	_
66-24	10210-10218	interest	_
66-25	10219-10225	listed	_
66-26	10226-10228	in	_
66-27	10229-10231	S1	_
66-28	10232-10237	Table	_
66-29	10237-10238	.	_

#Text=In short, the prefrontal cortex ROI consisted of the superior, middle, and inferior frontal gyri, the middle and lateral orbitofrontal gyri, the gyrus rectus, and the anterior cingulate gyrus.
67-1	10239-10241	In	_
67-2	10242-10247	short	_
67-3	10247-10248	,	_
67-4	10249-10252	the	_
67-5	10253-10263	prefrontal	_
67-6	10264-10270	cortex	_
67-7	10271-10274	ROI	_
67-8	10275-10284	consisted	_
67-9	10285-10287	of	_
67-10	10288-10291	the	_
67-11	10292-10300	superior	_
67-12	10300-10301	,	_
67-13	10302-10308	middle	_
67-14	10308-10309	,	_
67-15	10310-10313	and	_
67-16	10314-10322	inferior	_
67-17	10323-10330	frontal	_
67-18	10331-10335	gyri	_
67-19	10335-10336	,	_
67-20	10337-10340	the	_
67-21	10341-10347	middle	_
67-22	10348-10351	and	_
67-23	10352-10359	lateral	_
67-24	10360-10373	orbitofrontal	_
67-25	10374-10378	gyri	_
67-26	10378-10379	,	_
67-27	10380-10383	the	_
67-28	10384-10389	gyrus	_
67-29	10390-10396	rectus	_
67-30	10396-10397	,	_
67-31	10398-10401	and	_
67-32	10402-10405	the	_
67-33	10406-10414	anterior	_
67-34	10415-10424	cingulate	_
67-35	10425-10430	gyrus	_
67-36	10430-10431	.	_

#Text=Additionally, the motor cortex/supplementary motor area ROIs consisted of the precentral gyrus and the supplementary motor area.
68-1	10432-10444	Additionally	_
68-2	10444-10445	,	_
68-3	10446-10449	the	_
68-4	10450-10455	motor	_
68-5	10456-10462	cortex	_
68-6	10462-10463	/	_
68-7	10463-10476	supplementary	_
68-8	10477-10482	motor	_
68-9	10483-10487	area	_
68-10	10488-10492	ROIs	_
68-11	10493-10502	consisted	_
68-12	10503-10505	of	_
68-13	10506-10509	the	_
68-14	10510-10520	precentral	_
68-15	10521-10526	gyrus	_
68-16	10527-10530	and	_
68-17	10531-10534	the	_
68-18	10535-10548	supplementary	_
68-19	10549-10554	motor	_
68-20	10555-10559	area	_
68-21	10559-10560	.	_

#Text=The somatosensory region of interest was the postcentral gyrus.
69-1	10561-10564	The	_
69-2	10565-10578	somatosensory	_
69-3	10579-10585	region	_
69-4	10586-10588	of	_
69-5	10589-10597	interest	_
69-6	10598-10601	was	_
69-7	10602-10605	the	_
69-8	10606-10617	postcentral	_
69-9	10618-10623	gyrus	_
69-10	10623-10624	.	_

#Text=The temporal lobe region of interest consisted of the superior, middle, and inferior temporal gyri, the parahippocampal gyrus, and the fusiform gyrus.
70-1	10625-10628	The	_
70-2	10629-10637	temporal	_
70-3	10638-10642	lobe	_
70-4	10643-10649	region	_
70-5	10650-10652	of	_
70-6	10653-10661	interest	_
70-7	10662-10671	consisted	_
70-8	10672-10674	of	_
70-9	10675-10678	the	_
70-10	10679-10687	superior	_
70-11	10687-10688	,	_
70-12	10689-10695	middle	_
70-13	10695-10696	,	_
70-14	10697-10700	and	_
70-15	10701-10709	inferior	_
70-16	10710-10718	temporal	_
70-17	10719-10723	gyri	_
70-18	10723-10724	,	_
70-19	10725-10728	the	_
70-20	10729-10744	parahippocampal	_
70-21	10745-10750	gyrus	_
70-22	10750-10751	,	_
70-23	10752-10755	and	_
70-24	10756-10759	the	_
70-25	10760-10768	fusiform	_
70-26	10769-10774	gyrus	_
70-27	10774-10775	.	_

#Text=The posterior parietal region of interest consisted of the superior parietal, the supramarginal, the angular gyri, the posterior cingulate, and the precuneus.
71-1	10776-10779	The	_
71-2	10780-10789	posterior	_
71-3	10790-10798	parietal	_
71-4	10799-10805	region	_
71-5	10806-10808	of	_
71-6	10809-10817	interest	_
71-7	10818-10827	consisted	_
71-8	10828-10830	of	_
71-9	10831-10834	the	_
71-10	10835-10843	superior	_
71-11	10844-10852	parietal	_
71-12	10852-10853	,	_
71-13	10854-10857	the	_
71-14	10858-10871	supramarginal	_
71-15	10871-10872	,	_
71-16	10873-10876	the	_
71-17	10877-10884	angular	_
71-18	10885-10889	gyri	_
71-19	10889-10890	,	_
71-20	10891-10894	the	_
71-21	10895-10904	posterior	_
71-22	10905-10914	cingulate	_
71-23	10914-10915	,	_
71-24	10916-10919	and	_
71-25	10920-10923	the	_
71-26	10924-10933	precuneus	_
71-27	10933-10934	.	_

#Text=Finally, the occipital region of interest consisted of the superior, middle, and inferior occipital gyri, the lingual gyrus, and the cuneus.
72-1	10935-10942	Finally	_
72-2	10942-10943	,	_
72-3	10944-10947	the	_
72-4	10948-10957	occipital	_
72-5	10958-10964	region	_
72-6	10965-10967	of	_
72-7	10968-10976	interest	_
72-8	10977-10986	consisted	_
72-9	10987-10989	of	_
72-10	10990-10993	the	_
72-11	10994-11002	superior	_
72-12	11002-11003	,	_
72-13	11004-11010	middle	_
72-14	11010-11011	,	_
72-15	11012-11015	and	_
72-16	11016-11024	inferior	_
72-17	11025-11034	occipital	_
72-18	11035-11039	gyri	_
72-19	11039-11040	,	_
72-20	11041-11044	the	_
72-21	11045-11052	lingual	_
72-22	11053-11058	gyrus	_
72-23	11058-11059	,	_
72-24	11060-11063	and	_
72-25	11064-11067	the	_
72-26	11068-11074	cuneus	_
72-27	11074-11075	.	_

#Text=The diffusively decreased thalamocortical connectivity in ketamine-dependent subjects.
73-1	11076-11079	The	_
73-2	11080-11091	diffusively	_
73-3	11092-11101	decreased	_
73-4	11102-11117	thalamocortical	_
73-5	11118-11130	connectivity	_
73-6	11131-11133	in	_
73-7	11134-11152	ketamine-dependent	_
73-8	11153-11161	subjects	_
73-9	11161-11162	.	_

#Text=A.
74-1	11163-11164	A	_
74-2	11164-11165	.	_

#Text=The 6 cortical regions-of-interest.
75-1	11166-11169	The	_
75-2	11170-11171	6	_
75-3	11172-11180	cortical	_
75-4	11181-11200	regions-of-interest	_
75-5	11200-11201	.	_

#Text=B.
76-1	11202-11203	B	_
76-2	11203-11204	.	_

#Text=Thalamocortical connectivity of the drug-free control subjects.
77-1	11205-11220	Thalamocortical	_
77-2	11221-11233	connectivity	_
77-3	11234-11236	of	_
77-4	11237-11240	the	_
77-5	11241-11250	drug-free	_
77-6	11251-11258	control	_
77-7	11259-11267	subjects	_
77-8	11267-11268	.	_

#Text=C.
78-1	11269-11270	C	_
78-2	11270-11271	.	_

#Text=Thalamocortical connectivity of the ketamine-dependent subjects.
79-1	11272-11287	Thalamocortical	_
79-2	11288-11300	connectivity	_
79-3	11301-11303	of	_
79-4	11304-11307	the	_
79-5	11308-11326	ketamine-dependent	_
79-6	11327-11335	subjects	_
79-7	11335-11336	.	_

#Text=D.
80-1	11337-11338	D	_
80-2	11338-11339	.	_

#Text=Group differences in thalamocortical connectivity for the drug-free control subjects and the ketamine-dependent subjects.
81-1	11340-11345	Group	_
81-2	11346-11357	differences	_
81-3	11358-11360	in	_
81-4	11361-11376	thalamocortical	_
81-5	11377-11389	connectivity	_
81-6	11390-11393	for	_
81-7	11394-11397	the	_
81-8	11398-11407	drug-free	_
81-9	11408-11415	control	_
81-10	11416-11424	subjects	_
81-11	11425-11428	and	_
81-12	11429-11432	the	_
81-13	11433-11451	ketamine-dependent	_
81-14	11452-11460	subjects	_
81-15	11460-11461	.	_

#Text=All shown clusters in this study were corrected for multiple comparisons with the corrected statistical threshold of P<0.05 using the AlphaSim program (single voxele p value<0.01, and ≥108 mm3 (4 adjacent voxels).
82-1	11462-11465	All	_
82-2	11466-11471	shown	_
82-3	11472-11480	clusters	_
82-4	11481-11483	in	_
82-5	11484-11488	this	_
82-6	11489-11494	study	_
82-7	11495-11499	were	_
82-8	11500-11509	corrected	_
82-9	11510-11513	for	_
82-10	11514-11522	multiple	_
82-11	11523-11534	comparisons	_
82-12	11535-11539	with	_
82-13	11540-11543	the	_
82-14	11544-11553	corrected	_
82-15	11554-11565	statistical	_
82-16	11566-11575	threshold	_
82-17	11576-11578	of	_
82-18	11579-11580	P	_
82-19	11580-11581	<	_
82-20	11581-11585	0.05	_
82-21	11586-11591	using	_
82-22	11592-11595	the	_
82-23	11596-11604	AlphaSim	_
82-24	11605-11612	program	_
82-25	11613-11614	(	_
82-26	11614-11620	single	_
82-27	11621-11627	voxele	_
82-28	11628-11629	p	_
82-29	11630-11635	value	_
82-30	11635-11636	<	_
82-31	11636-11640	0.01	_
82-32	11640-11641	,	_
82-33	11642-11645	and	_
82-34	11646-11647	≥	_
82-35	11647-11650	108	_
82-36	11651-11654	mm3	_
82-37	11655-11656	(	_
82-38	11656-11657	4	_
82-39	11658-11666	adjacent	_
82-40	11667-11673	voxels	_
82-41	11673-11674	)	_
82-42	11674-11675	.	_

#Text=A presentation formation referred to the previous study.
83-1	11676-11677	A	_
83-2	11678-11690	presentation	_
83-3	11691-11700	formation	_
83-4	11701-11709	referred	_
83-5	11710-11712	to	_
83-6	11713-11716	the	_
83-7	11717-11725	previous	_
83-8	11726-11731	study	_
83-9	11731-11732	.	_

#Text=Partial correlation mapping between cortical regions-of-interest and thalamus
#Text=The average fMRI time course was extracted from each cortical ROI.
84-1	11733-11740	Partial	_
84-2	11741-11752	correlation	_
84-3	11753-11760	mapping	_
84-4	11761-11768	between	_
84-5	11769-11777	cortical	_
84-6	11778-11797	regions-of-interest	_
84-7	11798-11801	and	_
84-8	11802-11810	thalamus	_
84-9	11811-11814	The	_
84-10	11815-11822	average	_
84-11	11823-11827	fMRI	_
84-12	11828-11832	time	_
84-13	11833-11839	course	_
84-14	11840-11843	was	_
84-15	11844-11853	extracted	_
84-16	11854-11858	from	_
84-17	11859-11863	each	_
84-18	11864-11872	cortical	_
84-19	11873-11876	ROI	_
84-20	11876-11877	.	_

#Text=Partial correlations were computed for each voxel in the thalamus using these time courses.
85-1	11878-11885	Partial	_
85-2	11886-11898	correlations	_
85-3	11899-11903	were	_
85-4	11904-11912	computed	_
85-5	11913-11916	for	_
85-6	11917-11921	each	_
85-7	11922-11927	voxel	_
85-8	11928-11930	in	_
85-9	11931-11934	the	_
85-10	11935-11943	thalamus	_
85-11	11944-11949	using	_
85-12	11950-11955	these	_
85-13	11956-11960	time	_
85-14	11961-11968	courses	_
85-15	11968-11969	.	_

#Text=Specifically, after eliminating the influence of all other cortical ROIs, the results show a partial correlation between the local thalamic signal and the cortical ROI.
86-1	11970-11982	Specifically	_
86-2	11982-11983	,	_
86-3	11984-11989	after	_
86-4	11990-12001	eliminating	_
86-5	12002-12005	the	_
86-6	12006-12015	influence	_
86-7	12016-12018	of	_
86-8	12019-12022	all	_
86-9	12023-12028	other	_
86-10	12029-12037	cortical	_
86-11	12038-12042	ROIs	_
86-12	12042-12043	,	_
86-13	12044-12047	the	_
86-14	12048-12055	results	_
86-15	12056-12060	show	_
86-16	12061-12062	a	_
86-17	12063-12070	partial	_
86-18	12071-12082	correlation	_
86-19	12083-12090	between	_
86-20	12091-12094	the	_
86-21	12095-12100	local	_
86-22	12101-12109	thalamic	_
86-23	12110-12116	signal	_
86-24	12117-12120	and	_
86-25	12121-12124	the	_
86-26	12125-12133	cortical	_
86-27	12134-12137	ROI	_
86-28	12137-12138	.	_

#Text=To calculate statistical significance partial correlation coefficients were converted to a normal distribution using Fisher’s R-to-Z transformation.
87-1	12139-12141	To	_
87-2	12142-12151	calculate	_
87-3	12152-12163	statistical	_
87-4	12164-12176	significance	_
87-5	12177-12184	partial	_
87-6	12185-12196	correlation	_
87-7	12197-12209	coefficients	_
87-8	12210-12214	were	_
87-9	12215-12224	converted	_
87-10	12225-12227	to	_
87-11	12228-12229	a	_
87-12	12230-12236	normal	_
87-13	12237-12249	distribution	_
87-14	12250-12255	using	_
87-15	12256-12262	Fisher	_
87-16	12262-12263	’	_
87-17	12263-12264	s	_
87-18	12265-12271	R-to-Z	_
87-19	12272-12286	transformation	_
87-20	12286-12287	.	_

#Text=From this conversion we computed partial correlations between each thalamic voxel and each of the six cortical ROIs for each subject.
88-1	12288-12292	From	_
88-2	12293-12297	this	_
88-3	12298-12308	conversion	_
88-4	12309-12311	we	_
88-5	12312-12320	computed	_
88-6	12321-12328	partial	_
88-7	12329-12341	correlations	_
88-8	12342-12349	between	_
88-9	12350-12354	each	_
88-10	12355-12363	thalamic	_
88-11	12364-12369	voxel	_
88-12	12370-12373	and	_
88-13	12374-12378	each	_
88-14	12379-12381	of	_
88-15	12382-12385	the	_
88-16	12386-12389	six	_
88-17	12390-12398	cortical	_
88-18	12399-12403	ROIs	_
88-19	12404-12407	for	_
88-20	12408-12412	each	_
88-21	12413-12420	subject	_
88-22	12420-12421	.	_

#Text=Group-level Statistical analysis
#Text=For both ketamine-dependent subjects and drug free healthy controls we checked the thalamocortical connectivity patterns between the six regions of interest in the cortex compared to the distinct areas of the thalamus using a one-sample t-test.
89-1	12422-12433	Group-level	_
89-2	12434-12445	Statistical	_
89-3	12446-12454	analysis	_
89-4	12455-12458	For	_
89-5	12459-12463	both	_
89-6	12464-12482	ketamine-dependent	_
89-7	12483-12491	subjects	_
89-8	12492-12495	and	_
89-9	12496-12500	drug	_
89-10	12501-12505	free	_
89-11	12506-12513	healthy	_
89-12	12514-12522	controls	_
89-13	12523-12525	we	_
89-14	12526-12533	checked	_
89-15	12534-12537	the	_
89-16	12538-12553	thalamocortical	_
89-17	12554-12566	connectivity	_
89-18	12567-12575	patterns	_
89-19	12576-12583	between	_
89-20	12584-12587	the	_
89-21	12588-12591	six	_
89-22	12592-12599	regions	_
89-23	12600-12602	of	_
89-24	12603-12611	interest	_
89-25	12612-12614	in	_
89-26	12615-12618	the	_
89-27	12619-12625	cortex	_
89-28	12626-12634	compared	_
89-29	12635-12637	to	_
89-30	12638-12641	the	_
89-31	12642-12650	distinct	_
89-32	12651-12656	areas	_
89-33	12657-12659	of	_
89-34	12660-12663	the	_
89-35	12664-12672	thalamus	_
89-36	12673-12678	using	_
89-37	12679-12680	a	_
89-38	12681-12691	one-sample	_
89-39	12692-12698	t-test	_
89-40	12698-12699	.	_

#Text=Then, we used a two-sample t-test to investigate whether there were significant differences in the thalamocortical connectivity patterns between the two groups.
90-1	12700-12704	Then	_
90-2	12704-12705	,	_
90-3	12706-12708	we	_
90-4	12709-12713	used	_
90-5	12714-12715	a	_
90-6	12716-12726	two-sample	_
90-7	12727-12733	t-test	_
90-8	12734-12736	to	_
90-9	12737-12748	investigate	_
90-10	12749-12756	whether	_
90-11	12757-12762	there	_
90-12	12763-12767	were	_
90-13	12768-12779	significant	_
90-14	12780-12791	differences	_
90-15	12792-12794	in	_
90-16	12795-12798	the	_
90-17	12799-12814	thalamocortical	_
90-18	12815-12827	connectivity	_
90-19	12828-12836	patterns	_
90-20	12837-12844	between	_
90-21	12845-12848	the	_
90-22	12849-12852	two	_
90-23	12853-12859	groups	_
90-24	12859-12860	.	_

#Text=In this study, the AlphaSim program of the AFNI software package was used to correct for multiple comparisons.
91-1	12861-12863	In	_
91-2	12864-12868	this	_
91-3	12869-12874	study	_
91-4	12874-12875	,	_
91-5	12876-12879	the	_
91-6	12880-12888	AlphaSim	_
91-7	12889-12896	program	_
91-8	12897-12899	of	_
91-9	12900-12903	the	_
91-10	12904-12908	AFNI	_
91-11	12909-12917	software	_
91-12	12918-12925	package	_
91-13	12926-12929	was	_
91-14	12930-12934	used	_
91-15	12935-12937	to	_
91-16	12938-12945	correct	_
91-17	12946-12949	for	_
91-18	12950-12958	multiple	_
91-19	12959-12970	comparisons	_
91-20	12970-12971	.	_

#Text=Parameters were as follows: single P value = 0.01, FWHM = 0, cluster connection radius r = 6.00 mm, mask of the thalamus with a resolution of 3*3*3 mm, and a number of Monte Carlo iterations = 1000.
92-1	12972-12982	Parameters	_
92-2	12983-12987	were	_
92-3	12988-12990	as	_
92-4	12991-12998	follows	_
92-5	12998-12999	:	_
92-6	13000-13006	single	_
92-7	13007-13008	P	_
92-8	13009-13014	value	_
92-9	13015-13016	=	_
92-10	13017-13021	0.01	_
92-11	13021-13022	,	_
92-12	13023-13027	FWHM	_
92-13	13028-13029	=	_
92-14	13030-13031	0	_
92-15	13031-13032	,	_
92-16	13033-13040	cluster	_
92-17	13041-13051	connection	_
92-18	13052-13058	radius	_
92-19	13059-13060	r	_
92-20	13061-13062	=	_
92-21	13063-13067	6.00	_
92-22	13068-13070	mm	_
92-23	13070-13071	,	_
92-24	13072-13076	mask	_
92-25	13077-13079	of	_
92-26	13080-13083	the	_
92-27	13084-13092	thalamus	_
92-28	13093-13097	with	_
92-29	13098-13099	a	_
92-30	13100-13110	resolution	_
92-31	13111-13113	of	_
92-32	13114-13115	3	_
92-33	13115-13116	*	_
92-34	13116-13117	3	_
92-35	13117-13118	*	_
92-36	13118-13119	3	_
92-37	13120-13122	mm	_
92-38	13122-13123	,	_
92-39	13124-13127	and	_
92-40	13128-13129	a	_
92-41	13130-13136	number	_
92-42	13137-13139	of	_
92-43	13140-13145	Monte	_
92-44	13146-13151	Carlo	_
92-45	13152-13162	iterations	_
92-46	13163-13164	=	_
92-47	13165-13169	1000	_
92-48	13169-13170	.	_

#Text=Finally, we explored whether there was a significant Pearson’s correlation between the strength of partial correlation and various ketamine use variables and behavioral scores in the ketamine dependent subjects.
93-1	13171-13178	Finally	_
93-2	13178-13179	,	_
93-3	13180-13182	we	_
93-4	13183-13191	explored	_
93-5	13192-13199	whether	_
93-6	13200-13205	there	_
93-7	13206-13209	was	_
93-8	13210-13211	a	_
93-9	13212-13223	significant	_
93-10	13224-13231	Pearson	_
93-11	13231-13232	’	_
93-12	13232-13233	s	_
93-13	13234-13245	correlation	_
93-14	13246-13253	between	_
93-15	13254-13257	the	_
93-16	13258-13266	strength	_
93-17	13267-13269	of	_
93-18	13270-13277	partial	_
93-19	13278-13289	correlation	_
93-20	13290-13293	and	_
93-21	13294-13301	various	_
93-22	13302-13310	ketamine	_
93-23	13311-13314	use	_
93-24	13315-13324	variables	_
93-25	13325-13328	and	_
93-26	13329-13339	behavioral	_
93-27	13340-13346	scores	_
93-28	13347-13349	in	_
93-29	13350-13353	the	_
93-30	13354-13362	ketamine	_
93-31	13363-13372	dependent	_
93-32	13373-13381	subjects	_
93-33	13381-13382	.	_

#Text=Behavioral scores included duration of ketamine abuse, daily average use of ketamine, total quantity of ketamine use, ketamine craving scores and cognitive test scores.
94-1	13383-13393	Behavioral	_
94-2	13394-13400	scores	_
94-3	13401-13409	included	_
94-4	13410-13418	duration	_
94-5	13419-13421	of	_
94-6	13422-13430	ketamine	_
94-7	13431-13436	abuse	_
94-8	13436-13437	,	_
94-9	13438-13443	daily	_
94-10	13444-13451	average	_
94-11	13452-13455	use	_
94-12	13456-13458	of	_
94-13	13459-13467	ketamine	_
94-14	13467-13468	,	_
94-15	13469-13474	total	_
94-16	13475-13483	quantity	_
94-17	13484-13486	of	_
94-18	13487-13495	ketamine	_
94-19	13496-13499	use	_
94-20	13499-13500	,	_
94-21	13501-13509	ketamine	_
94-22	13510-13517	craving	_
94-23	13518-13524	scores	_
94-24	13525-13528	and	_
94-25	13529-13538	cognitive	_
94-26	13539-13543	test	_
94-27	13544-13550	scores	_
94-28	13550-13551	.	_

#Text=Results
#Text=Demographic characteristics
#Text=One ketamine dependent subject and one control subject had severe head motion and as a result were not included in statistical analysis.
95-1	13552-13559	Results	_
95-2	13560-13571	Demographic	_
95-3	13572-13587	characteristics	_
95-4	13588-13591	One	_
95-5	13592-13600	ketamine	_
95-6	13601-13610	dependent	_
95-7	13611-13618	subject	_
95-8	13619-13622	and	_
95-9	13623-13626	one	_
95-10	13627-13634	control	_
95-11	13635-13642	subject	_
95-12	13643-13646	had	_
95-13	13647-13653	severe	_
95-14	13654-13658	head	_
95-15	13659-13665	motion	_
95-16	13666-13669	and	_
95-17	13670-13672	as	_
95-18	13673-13674	a	_
95-19	13675-13681	result	_
95-20	13682-13686	were	_
95-21	13687-13690	not	_
95-22	13691-13699	included	_
95-23	13700-13702	in	_
95-24	13703-13714	statistical	_
95-25	13715-13723	analysis	_
95-26	13723-13724	.	_

#Text=For other participants, the maximum displacement in the cardinal direction was not greater than 3 mm and the maximum spin was not greater than 3°.
96-1	13725-13728	For	_
96-2	13729-13734	other	_
96-3	13735-13747	participants	_
96-4	13747-13748	,	_
96-5	13749-13752	the	_
96-6	13753-13760	maximum	_
96-7	13761-13773	displacement	_
96-8	13774-13776	in	_
96-9	13777-13780	the	_
96-10	13781-13789	cardinal	_
96-11	13790-13799	direction	_
96-12	13800-13803	was	_
96-13	13804-13807	not	_
96-14	13808-13815	greater	_
96-15	13816-13820	than	_
96-16	13821-13822	3	_
96-17	13823-13825	mm	_
96-18	13826-13829	and	_
96-19	13830-13833	the	_
96-20	13834-13841	maximum	_
96-21	13842-13846	spin	_
96-22	13847-13850	was	_
96-23	13851-13854	not	_
96-24	13855-13862	greater	_
96-25	13863-13867	than	_
96-26	13868-13869	3	_
96-27	13869-13870	°	_
96-28	13870-13871	.	_

#Text=Therefore, the final data set consisted of one hundred and twenty-eight (40 ketamine dependent subjects and 88 drug-free control subjects) subjects.
97-1	13872-13881	Therefore	_
97-2	13881-13882	,	_
97-3	13883-13886	the	_
97-4	13887-13892	final	_
97-5	13893-13897	data	_
97-6	13898-13901	set	_
97-7	13902-13911	consisted	_
97-8	13912-13914	of	_
97-9	13915-13918	one	_
97-10	13919-13926	hundred	_
97-11	13927-13930	and	_
97-12	13931-13943	twenty-eight	_
97-13	13944-13945	(	_
97-14	13945-13947	40	_
97-15	13948-13956	ketamine	_
97-16	13957-13966	dependent	_
97-17	13967-13975	subjects	_
97-18	13976-13979	and	_
97-19	13980-13982	88	_
97-20	13983-13992	drug-free	_
97-21	13993-14000	control	_
97-22	14001-14009	subjects	_
97-23	14009-14010	)	_
97-24	14011-14019	subjects	_
97-25	14019-14020	.	_

#Text=Detailed demographic and clinical characteristics for the two groups (40 ketamine dependent subjects and 88 drug-free healthy subjects) are summarized in Table 1.
98-1	14021-14029	Detailed	_
98-2	14030-14041	demographic	_
98-3	14042-14045	and	_
98-4	14046-14054	clinical	_
98-5	14055-14070	characteristics	_
98-6	14071-14074	for	_
98-7	14075-14078	the	_
98-8	14079-14082	two	_
98-9	14083-14089	groups	_
98-10	14090-14091	(	_
98-11	14091-14093	40	_
98-12	14094-14102	ketamine	_
98-13	14103-14112	dependent	_
98-14	14113-14121	subjects	_
98-15	14122-14125	and	_
98-16	14126-14128	88	_
98-17	14129-14138	drug-free	_
98-18	14139-14146	healthy	_
98-19	14147-14155	subjects	_
98-20	14155-14156	)	_
98-21	14157-14160	are	_
98-22	14161-14171	summarized	_
98-23	14172-14174	in	_
98-24	14175-14180	Table	_
98-25	14181-14182	1	_
98-26	14182-14183	.	_

#Text=Demographic and drug use characteristics of ketamine dependent subjects and drug-free healthy subjects.
99-1	14184-14195	Demographic	_
99-2	14196-14199	and	_
99-3	14200-14204	drug	_
99-4	14205-14208	use	_
99-5	14209-14224	characteristics	_
99-6	14225-14227	of	_
99-7	14228-14236	ketamine	_
99-8	14237-14246	dependent	_
99-9	14247-14255	subjects	_
99-10	14256-14259	and	_
99-11	14260-14269	drug-free	_
99-12	14270-14277	healthy	_
99-13	14278-14286	subjects	_
99-14	14286-14287	.	_

#Text=Ketamine users/smokers (n = 40)\tControls (n = 88)\tTwo sample T test\tX2\t \tDemographic variables\t\t\t\t\t \tAge, years, mean±SD\t26.8 ±4.91\t27.1 ±5.14\tp = 0.731\t\t \tRange (years)\t19–39\t19–39\t\t\t \tMale/Female, %\t33/7 (17.5%)\t70/18 (20.45%)\t\tp = 0.696\t \tSubjects’ education, years, mean±SD\t11.9±2.75\t14.1±2.94\tP<0.001\t\t \tRight/left-handed, %\t39/1 (2.56%)\t85/3 (3.53%)\t\tP>0.999\t \tUnmarried/Married, %\t25/15(37.5%)\t54/34 (38.6%)\t\tP = 0.902\t \tKetamine use variables\t\t\t\t\t \tAge of first use, years, mean±SD\t23.10±5.21\t―\t\t\t \tRange (years)\t14–36\t―\t\t\t \tDuration, months, mean±SD\t41.1±21.79\t―\t\t\t \tRange (months)\t12–126\t―\t\t\t \tTimes of using ketamine/day\t1.85\t―\t\t\t \tRange (times)\t1–4\t―\t\t\t \tQuantity of using ketamine/time (g)\t0.74 ±0.52\t―\t\t\t \tRange (g)\t0.1–2.5\t―\t\t\t \tSmoking variables\t\t\t\t\t \tSmokers (>100 cigarette lifetime)\t44\t44\t\t\t \tAge of first smoking, years, mean±SD\t15.2±3.09\t17.9±4.29\tP = 0.001\t\t \tRange (years)\t10–30\t11–30\t\t\t \tDuration, years, mean±SD\t11.6±4.72\t10.4±5.67\tP = 0.286\t\t \tRange (years)\t1.5–21\t1.5–21\t\t\t \tSmoked cigarette/day,mean±SD\t16.6±7.71\t10.1±11.54\tP<0.001\t\t \tRange (cigarettes)\t8–40\t10–40\t\t\t \tOther Drugs and alcohol usea\t\t\t\t\t \tAlcoholb\t30\t48\t\t\t \tEcstasy\t28\t―\t\t\t \tMa Gu (amphetaminecaffeine)\t27\t―\t\t\t \tMethamphetamine(ice)\t23\t―\t\t\t \tMarijuana\t8\t―\t\t\t \tBenzodiazepine (only diazepam)\t6\t―\t\t\t \tHeroin\t―\t―\t\t\t \tCocaine\t―\t―\t\t\t \tDrug craving\t\t\t\t\t \tKetamine craving (cm)\t6.3±2.72\t―\t\t\t \tSmoking craving (cm)\t5.4±2.18\t6.5±1.25\tP = 0.016\t\t \tCognitive Tests\t\t\t\t\t \tDigit Symbol Test (number of symbols)\t64.5±15.83 (n = 40)\t76.43±16.54 (n = 88)\tP<0.001\t\t \tTrail Making Test A (seconds)\t39.7±11.80 (n = 39)\t39.3±12.57 (n = 88)\tP = 0.883\t\t \tThe Stroop Word Test (seconds)\t66.7±15.78 (n = 37)\t57.5±12.72 (n = 88)\tP = 0.001\t\t \tThe Stroop Color Test (seconds)\t174.5±53.81 (n = 32)\t138.5±39.74 (n = 85)\tP<0.001\t\t \t
#Text=aEach person could have tried more than one drug; drugs have been included even only tried once in the lifetime.
#Text=bFour participants reported drinking more than once/week among ketaminesubjects, and three control subjects reported drinking more than once/week.
100-1	14289-14297	Ketamine	_
100-2	14298-14303	users	_
100-3	14303-14304	/	_
100-4	14304-14311	smokers	_
100-5	14312-14313	(	_
100-6	14313-14314	n	_
100-7	14315-14316	=	_
100-8	14317-14319	40	_
100-9	14319-14320	)	_
100-10	14321-14329	Controls	_
100-11	14330-14331	(	_
100-12	14331-14332	n	_
100-13	14333-14334	=	_
100-14	14335-14337	88	_
100-15	14337-14338	)	_
100-16	14339-14342	Two	_
100-17	14343-14349	sample	_
100-18	14350-14351	T	_
100-19	14352-14356	test	_
100-20	14357-14359	X2	_
100-21	14362-14373	Demographic	_
100-22	14374-14383	variables	_
100-23	14390-14393	Age	_
100-24	14393-14394	,	_
100-25	14395-14400	years	_
100-26	14400-14401	,	_
100-27	14402-14406	mean	_
100-28	14406-14407	±	_
100-29	14407-14409	SD	_
100-30	14410-14414	26.8	_
100-31	14415-14416	±	_
100-32	14416-14420	4.91	_
100-33	14421-14425	27.1	_
100-34	14426-14427	±	_
100-35	14427-14431	5.14	_
100-36	14432-14433	p	_
100-37	14434-14435	=	_
100-38	14436-14441	0.731	_
100-39	14445-14450	Range	_
100-40	14451-14452	(	_
100-41	14452-14457	years	_
100-42	14457-14458	)	_
100-43	14459-14461	19	_
100-44	14461-14462	–	_
100-45	14462-14464	39	_
100-46	14465-14467	19	_
100-47	14467-14468	–	_
100-48	14468-14470	39	_
100-49	14475-14479	Male	_
100-50	14479-14480	/	_
100-51	14480-14486	Female	_
100-52	14486-14487	,	_
100-53	14488-14489	%	_
100-54	14490-14492	33	_
100-55	14492-14493	/	_
100-56	14493-14494	7	_
100-57	14495-14496	(	_
100-58	14496-14501	17.5%	_
100-59	14501-14502	)	_
100-60	14503-14505	70	_
100-61	14505-14506	/	_
100-62	14506-14508	18	_
100-63	14509-14510	(	_
100-64	14510-14516	20.45%	_
100-65	14516-14517	)	_
100-66	14519-14520	p	_
100-67	14521-14522	=	_
100-68	14523-14528	0.696	_
100-69	14531-14539	Subjects	_
100-70	14539-14540	’	_
100-71	14541-14550	education	_
100-72	14550-14551	,	_
100-73	14552-14557	years	_
100-74	14557-14558	,	_
100-75	14559-14563	mean	_
100-76	14563-14564	±	_
100-77	14564-14566	SD	_
100-78	14567-14571	11.9	_
100-79	14571-14572	±	_
100-80	14572-14576	2.75	_
100-81	14577-14581	14.1	_
100-82	14581-14582	±	_
100-83	14582-14586	2.94	_
100-84	14587-14588	P	_
100-85	14588-14589	<	_
100-86	14589-14594	0.001	_
100-87	14598-14603	Right	_
100-88	14603-14604	/	_
100-89	14604-14615	left-handed	_
100-90	14615-14616	,	_
100-91	14617-14618	%	_
100-92	14619-14621	39	_
100-93	14621-14622	/	_
100-94	14622-14623	1	_
100-95	14624-14625	(	_
100-96	14625-14630	2.56%	_
100-97	14630-14631	)	_
100-98	14632-14634	85	_
100-99	14634-14635	/	_
100-100	14635-14636	3	_
100-101	14637-14638	(	_
100-102	14638-14643	3.53%	_
100-103	14643-14644	)	_
100-104	14646-14647	P	_
100-105	14647-14648	>	_
100-106	14648-14653	0.999	_
100-107	14656-14665	Unmarried	_
100-108	14665-14666	/	_
100-109	14666-14673	Married	_
100-110	14673-14674	,	_
100-111	14675-14676	%	_
100-112	14677-14679	25	_
100-113	14679-14680	/	_
100-114	14680-14682	15	_
100-115	14682-14683	(	_
100-116	14683-14688	37.5%	_
100-117	14688-14689	)	_
100-118	14690-14692	54	_
100-119	14692-14693	/	_
100-120	14693-14695	34	_
100-121	14696-14697	(	_
100-122	14697-14702	38.6%	_
100-123	14702-14703	)	_
100-124	14705-14706	P	_
100-125	14707-14708	=	_
100-126	14709-14714	0.902	_
100-127	14717-14725	Ketamine	_
100-128	14726-14729	use	_
100-129	14730-14739	variables	_
100-130	14746-14749	Age	_
100-131	14750-14752	of	_
100-132	14753-14758	first	_
100-133	14759-14762	use	_
100-134	14762-14763	,	_
100-135	14764-14769	years	_
100-136	14769-14770	,	_
100-137	14771-14775	mean	_
100-138	14775-14776	±	_
100-139	14776-14778	SD	_
100-140	14779-14784	23.10	_
100-141	14784-14785	±	_
100-142	14785-14789	5.21	_
100-143	14790-14791	―	_
100-144	14796-14801	Range	_
100-145	14802-14803	(	_
100-146	14803-14808	years	_
100-147	14808-14809	)	_
100-148	14810-14812	14	_
100-149	14812-14813	–	_
100-150	14813-14815	36	_
100-151	14816-14817	―	_
100-152	14822-14830	Duration	_
100-153	14830-14831	,	_
100-154	14832-14838	months	_
100-155	14838-14839	,	_
100-156	14840-14844	mean	_
100-157	14844-14845	±	_
100-158	14845-14847	SD	_
100-159	14848-14852	41.1	_
100-160	14852-14853	±	_
100-161	14853-14858	21.79	_
100-162	14859-14860	―	_
100-163	14865-14870	Range	_
100-164	14871-14872	(	_
100-165	14872-14878	months	_
100-166	14878-14879	)	_
100-167	14880-14882	12	_
100-168	14882-14883	–	_
100-169	14883-14886	126	_
100-170	14887-14888	―	_
100-171	14893-14898	Times	_
100-172	14899-14901	of	_
100-173	14902-14907	using	_
100-174	14908-14916	ketamine	_
100-175	14916-14917	/	_
100-176	14917-14920	day	_
100-177	14921-14925	1.85	_
100-178	14926-14927	―	_
100-179	14932-14937	Range	_
100-180	14938-14939	(	_
100-181	14939-14944	times	_
100-182	14944-14945	)	_
100-183	14946-14947	1	_
100-184	14947-14948	–	_
100-185	14948-14949	4	_
100-186	14950-14951	―	_
100-187	14956-14964	Quantity	_
100-188	14965-14967	of	_
100-189	14968-14973	using	_
100-190	14974-14982	ketamine	_
100-191	14982-14983	/	_
100-192	14983-14987	time	_
100-193	14988-14989	(	_
100-194	14989-14990	g	_
100-195	14990-14991	)	_
100-196	14992-14996	0.74	_
100-197	14997-14998	±	_
100-198	14998-15002	0.52	_
100-199	15003-15004	―	_
100-200	15009-15014	Range	_
100-201	15015-15016	(	_
100-202	15016-15017	g	_
100-203	15017-15018	)	_
100-204	15019-15022	0.1	_
100-205	15022-15023	–	_
100-206	15023-15026	2.5	_
100-207	15027-15028	―	_
100-208	15033-15040	Smoking	_
100-209	15041-15050	variables	_
100-210	15057-15064	Smokers	_
100-211	15065-15066	(	_
100-212	15066-15067	>	_
100-213	15067-15070	100	_
100-214	15071-15080	cigarette	_
100-215	15081-15089	lifetime	_
100-216	15089-15090	)	_
100-217	15091-15093	44	_
100-218	15094-15096	44	_
100-219	15101-15104	Age	_
100-220	15105-15107	of	_
100-221	15108-15113	first	_
100-222	15114-15121	smoking	_
100-223	15121-15122	,	_
100-224	15123-15128	years	_
100-225	15128-15129	,	_
100-226	15130-15134	mean	_
100-227	15134-15135	±	_
100-228	15135-15137	SD	_
100-229	15138-15142	15.2	_
100-230	15142-15143	±	_
100-231	15143-15147	3.09	_
100-232	15148-15152	17.9	_
100-233	15152-15153	±	_
100-234	15153-15157	4.29	_
100-235	15158-15159	P	_
100-236	15160-15161	=	_
100-237	15162-15167	0.001	_
100-238	15171-15176	Range	_
100-239	15177-15178	(	_
100-240	15178-15183	years	_
100-241	15183-15184	)	_
100-242	15185-15187	10	_
100-243	15187-15188	–	_
100-244	15188-15190	30	_
100-245	15191-15193	11	_
100-246	15193-15194	–	_
100-247	15194-15196	30	_
100-248	15201-15209	Duration	_
100-249	15209-15210	,	_
100-250	15211-15216	years	_
100-251	15216-15217	,	_
100-252	15218-15222	mean	_
100-253	15222-15223	±	_
100-254	15223-15225	SD	_
100-255	15226-15230	11.6	_
100-256	15230-15231	±	_
100-257	15231-15235	4.72	_
100-258	15236-15240	10.4	_
100-259	15240-15241	±	_
100-260	15241-15245	5.67	_
100-261	15246-15247	P	_
100-262	15248-15249	=	_
100-263	15250-15255	0.286	_
100-264	15259-15264	Range	_
100-265	15265-15266	(	_
100-266	15266-15271	years	_
100-267	15271-15272	)	_
100-268	15273-15276	1.5	_
100-269	15276-15277	–	_
100-270	15277-15279	21	_
100-271	15280-15283	1.5	_
100-272	15283-15284	–	_
100-273	15284-15286	21	_
100-274	15291-15297	Smoked	_
100-275	15298-15307	cigarette	_
100-276	15307-15308	/	_
100-277	15308-15311	day	_
100-278	15311-15312	,	_
100-279	15312-15316	mean	_
100-280	15316-15317	±	_
100-281	15317-15319	SD	_
100-282	15320-15324	16.6	_
100-283	15324-15325	±	_
100-284	15325-15329	7.71	_
100-285	15330-15334	10.1	_
100-286	15334-15335	±	_
100-287	15335-15340	11.54	_
100-288	15341-15342	P	_
100-289	15342-15343	<	_
100-290	15343-15348	0.001	_
100-291	15352-15357	Range	_
100-292	15358-15359	(	_
100-293	15359-15369	cigarettes	_
100-294	15369-15370	)	_
100-295	15371-15372	8	_
100-296	15372-15373	–	_
100-297	15373-15375	40	_
100-298	15376-15378	10	_
100-299	15378-15379	–	_
100-300	15379-15381	40	_
100-301	15386-15391	Other	_
100-302	15392-15397	Drugs	_
100-303	15398-15401	and	_
100-304	15402-15409	alcohol	_
100-305	15410-15414	usea	_
100-306	15421-15429	Alcoholb	_
100-307	15430-15432	30	_
100-308	15433-15435	48	_
100-309	15440-15447	Ecstasy	_
100-310	15448-15450	28	_
100-311	15451-15452	―	_
100-312	15457-15459	Ma	_
100-313	15460-15462	Gu	_
100-314	15463-15464	(	_
100-315	15464-15483	amphetaminecaffeine	_
100-316	15483-15484	)	_
100-317	15485-15487	27	_
100-318	15488-15489	―	_
100-319	15494-15509	Methamphetamine	_
100-320	15509-15510	(	_
100-321	15510-15513	ice	_
100-322	15513-15514	)	_
100-323	15515-15517	23	_
100-324	15518-15519	―	_
100-325	15524-15533	Marijuana	_
100-326	15534-15535	8	_
100-327	15536-15537	―	_
100-328	15542-15556	Benzodiazepine	_
100-329	15557-15558	(	_
100-330	15558-15562	only	_
100-331	15563-15571	diazepam	_
100-332	15571-15572	)	_
100-333	15573-15574	6	_
100-334	15575-15576	―	_
100-335	15581-15587	Heroin	_
100-336	15588-15589	―	_
100-337	15590-15591	―	_
100-338	15596-15603	Cocaine	_
100-339	15604-15605	―	_
100-340	15606-15607	―	_
100-341	15612-15616	Drug	_
100-342	15617-15624	craving	_
100-343	15631-15639	Ketamine	_
100-344	15640-15647	craving	_
100-345	15648-15649	(	_
100-346	15649-15651	cm	_
100-347	15651-15652	)	_
100-348	15653-15656	6.3	_
100-349	15656-15657	±	_
100-350	15657-15661	2.72	_
100-351	15662-15663	―	_
100-352	15668-15675	Smoking	_
100-353	15676-15683	craving	_
100-354	15684-15685	(	_
100-355	15685-15687	cm	_
100-356	15687-15688	)	_
100-357	15689-15692	5.4	_
100-358	15692-15693	±	_
100-359	15693-15697	2.18	_
100-360	15698-15701	6.5	_
100-361	15701-15702	±	_
100-362	15702-15706	1.25	_
100-363	15707-15708	P	_
100-364	15709-15710	=	_
100-365	15711-15716	0.016	_
100-366	15720-15729	Cognitive	_
100-367	15730-15735	Tests	_
100-368	15742-15747	Digit	_
100-369	15748-15754	Symbol	_
100-370	15755-15759	Test	_
100-371	15760-15761	(	_
100-372	15761-15767	number	_
100-373	15768-15770	of	_
100-374	15771-15778	symbols	_
100-375	15778-15779	)	_
100-376	15780-15784	64.5	_
100-377	15784-15785	±	_
100-378	15785-15790	15.83	_
100-379	15791-15792	(	_
100-380	15792-15793	n	_
100-381	15794-15795	=	_
100-382	15796-15798	40	_
100-383	15798-15799	)	_
100-384	15800-15805	76.43	_
100-385	15805-15806	±	_
100-386	15806-15811	16.54	_
100-387	15812-15813	(	_
100-388	15813-15814	n	_
100-389	15815-15816	=	_
100-390	15817-15819	88	_
100-391	15819-15820	)	_
100-392	15821-15822	P	_
100-393	15822-15823	<	_
100-394	15823-15828	0.001	_
100-395	15832-15837	Trail	_
100-396	15838-15844	Making	_
100-397	15845-15849	Test	_
100-398	15850-15851	A	_
100-399	15852-15853	(	_
100-400	15853-15860	seconds	_
100-401	15860-15861	)	_
100-402	15862-15866	39.7	_
100-403	15866-15867	±	_
100-404	15867-15872	11.80	_
100-405	15873-15874	(	_
100-406	15874-15875	n	_
100-407	15876-15877	=	_
100-408	15878-15880	39	_
100-409	15880-15881	)	_
100-410	15882-15886	39.3	_
100-411	15886-15887	±	_
100-412	15887-15892	12.57	_
100-413	15893-15894	(	_
100-414	15894-15895	n	_
100-415	15896-15897	=	_
100-416	15898-15900	88	_
100-417	15900-15901	)	_
100-418	15902-15903	P	_
100-419	15904-15905	=	_
100-420	15906-15911	0.883	_
100-421	15915-15918	The	_
100-422	15919-15925	Stroop	_
100-423	15926-15930	Word	_
100-424	15931-15935	Test	_
100-425	15936-15937	(	_
100-426	15937-15944	seconds	_
100-427	15944-15945	)	_
100-428	15946-15950	66.7	_
100-429	15950-15951	±	_
100-430	15951-15956	15.78	_
100-431	15957-15958	(	_
100-432	15958-15959	n	_
100-433	15960-15961	=	_
100-434	15962-15964	37	_
100-435	15964-15965	)	_
100-436	15966-15970	57.5	_
100-437	15970-15971	±	_
100-438	15971-15976	12.72	_
100-439	15977-15978	(	_
100-440	15978-15979	n	_
100-441	15980-15981	=	_
100-442	15982-15984	88	_
100-443	15984-15985	)	_
100-444	15986-15987	P	_
100-445	15988-15989	=	_
100-446	15990-15995	0.001	_
100-447	15999-16002	The	_
100-448	16003-16009	Stroop	_
100-449	16010-16015	Color	_
100-450	16016-16020	Test	_
100-451	16021-16022	(	_
100-452	16022-16029	seconds	_
100-453	16029-16030	)	_
100-454	16031-16036	174.5	_
100-455	16036-16037	±	_
100-456	16037-16042	53.81	_
100-457	16043-16044	(	_
100-458	16044-16045	n	_
100-459	16046-16047	=	_
100-460	16048-16050	32	_
100-461	16050-16051	)	_
100-462	16052-16057	138.5	_
100-463	16057-16058	±	_
100-464	16058-16063	39.74	_
100-465	16064-16065	(	_
100-466	16065-16066	n	_
100-467	16067-16068	=	_
100-468	16069-16071	85	_
100-469	16071-16072	)	_
100-470	16073-16074	P	_
100-471	16074-16075	<	_
100-472	16075-16080	0.001	_
100-473	16085-16090	aEach	_
100-474	16091-16097	person	_
100-475	16098-16103	could	_
100-476	16104-16108	have	_
100-477	16109-16114	tried	_
100-478	16115-16119	more	_
100-479	16120-16124	than	_
100-480	16125-16128	one	_
100-481	16129-16133	drug	_
100-482	16133-16134	;	_
100-483	16135-16140	drugs	_
100-484	16141-16145	have	_
100-485	16146-16150	been	_
100-486	16151-16159	included	_
100-487	16160-16164	even	_
100-488	16165-16169	only	_
100-489	16170-16175	tried	_
100-490	16176-16180	once	_
100-491	16181-16183	in	_
100-492	16184-16187	the	_
100-493	16188-16196	lifetime	_
100-494	16196-16197	.	_
100-495	16198-16203	bFour	_
100-496	16204-16216	participants	_
100-497	16217-16225	reported	_
100-498	16226-16234	drinking	_
100-499	16235-16239	more	_
100-500	16240-16244	than	_
100-501	16245-16249	once	_
100-502	16249-16250	/	_
100-503	16250-16254	week	_
100-504	16255-16260	among	_
100-505	16261-16277	ketaminesubjects	_
100-506	16277-16278	,	_
100-507	16279-16282	and	_
100-508	16283-16288	three	_
100-509	16289-16296	control	_
100-510	16297-16305	subjects	_
100-511	16306-16314	reported	_
100-512	16315-16323	drinking	_
100-513	16324-16328	more	_
100-514	16329-16333	than	_
100-515	16334-16338	once	_
100-516	16338-16339	/	_
100-517	16339-16343	week	_
100-518	16343-16344	.	_

#Text=Thalamocortical connectivity
#Text=Drug-free Control subjects
#Text=Each cortical region of interest was connected to distinct, largely non-overlapping regions of the thalamus, as shown in Fig 1B.
101-1	16345-16360	Thalamocortical	_
101-2	16361-16373	connectivity	_
101-3	16374-16383	Drug-free	_
101-4	16384-16391	Control	_
101-5	16392-16400	subjects	_
101-6	16401-16405	Each	_
101-7	16406-16414	cortical	_
101-8	16415-16421	region	_
101-9	16422-16424	of	_
101-10	16425-16433	interest	_
101-11	16434-16437	was	_
101-12	16438-16447	connected	_
101-13	16448-16450	to	_
101-14	16451-16459	distinct	_
101-15	16459-16460	,	_
101-16	16461-16468	largely	_
101-17	16469-16484	non-overlapping	_
101-18	16485-16492	regions	_
101-19	16493-16495	of	_
101-20	16496-16499	the	_
101-21	16500-16508	thalamus	_
101-22	16508-16509	,	_
101-23	16510-16512	as	_
101-24	16513-16518	shown	_
101-25	16519-16521	in	_
101-26	16522-16525	Fig	_
101-27	16526-16528	1B	_
101-28	16528-16529	.	_

#Text=Although our methods in this study were not identical to previous studies the results are virtually identical.
102-1	16530-16538	Although	_
102-2	16539-16542	our	_
102-3	16543-16550	methods	_
102-4	16551-16553	in	_
102-5	16554-16558	this	_
102-6	16559-16564	study	_
102-7	16565-16569	were	_
102-8	16570-16573	not	_
102-9	16574-16583	identical	_
102-10	16584-16586	to	_
102-11	16587-16595	previous	_
102-12	16596-16603	studies	_
102-13	16604-16607	the	_
102-14	16608-16615	results	_
102-15	16616-16619	are	_
102-16	16620-16629	virtually	_
102-17	16630-16639	identical	_
102-18	16639-16640	.	_

#Text=Specifically, the prefrontal cortex was functionally correlated to the anterior and dorsomedial regions of the thalamus.
103-1	16641-16653	Specifically	_
103-2	16653-16654	,	_
103-3	16655-16658	the	_
103-4	16659-16669	prefrontal	_
103-5	16670-16676	cortex	_
103-6	16677-16680	was	_
103-7	16681-16693	functionally	_
103-8	16694-16704	correlated	_
103-9	16705-16707	to	_
103-10	16708-16711	the	_
103-11	16712-16720	anterior	_
103-12	16721-16724	and	_
103-13	16725-16736	dorsomedial	_
103-14	16737-16744	regions	_
103-15	16745-16747	of	_
103-16	16748-16751	the	_
103-17	16752-16760	thalamus	_
103-18	16760-16761	.	_

#Text=The motor cortex/supplementary motor area showed strong correlation with ventral lateral portions of the thalamus.
104-1	16762-16765	The	_
104-2	16766-16771	motor	_
104-3	16772-16778	cortex	_
104-4	16778-16779	/	_
104-5	16779-16792	supplementary	_
104-6	16793-16798	motor	_
104-7	16799-16803	area	_
104-8	16804-16810	showed	_
104-9	16811-16817	strong	_
104-10	16818-16829	correlation	_
104-11	16830-16834	with	_
104-12	16835-16842	ventral	_
104-13	16843-16850	lateral	_
104-14	16851-16859	portions	_
104-15	16860-16862	of	_
104-16	16863-16866	the	_
104-17	16867-16875	thalamus	_
104-18	16875-16876	.	_

#Text=The somatosensory regions of interest showed significant connection to ventral posterior-lateral portions of the thalamus and the posterior parietal cortex was robustly connected with the posterior nucleus and the pulvinar.
105-1	16877-16880	The	_
105-2	16881-16894	somatosensory	_
105-3	16895-16902	regions	_
105-4	16903-16905	of	_
105-5	16906-16914	interest	_
105-6	16915-16921	showed	_
105-7	16922-16933	significant	_
105-8	16934-16944	connection	_
105-9	16945-16947	to	_
105-10	16948-16955	ventral	_
105-11	16956-16973	posterior-lateral	_
105-12	16974-16982	portions	_
105-13	16983-16985	of	_
105-14	16986-16989	the	_
105-15	16990-16998	thalamus	_
105-16	16999-17002	and	_
105-17	17003-17006	the	_
105-18	17007-17016	posterior	_
105-19	17017-17025	parietal	_
105-20	17026-17032	cortex	_
105-21	17033-17036	was	_
105-22	17037-17045	robustly	_
105-23	17046-17055	connected	_
105-24	17056-17060	with	_
105-25	17061-17064	the	_
105-26	17065-17074	posterior	_
105-27	17075-17082	nucleus	_
105-28	17083-17086	and	_
105-29	17087-17090	the	_
105-30	17091-17099	pulvinar	_
105-31	17099-17100	.	_

#Text=Additionally, the temporal lobe and occipital cortex directly correlated with posterior medial and lateral areas of the thalamus, which appears consistent with the medial geniculate nucleus and the lateral geniculate nucleus, respectively.
106-1	17101-17113	Additionally	_
106-2	17113-17114	,	_
106-3	17115-17118	the	_
106-4	17119-17127	temporal	_
106-5	17128-17132	lobe	_
106-6	17133-17136	and	_
106-7	17137-17146	occipital	_
106-8	17147-17153	cortex	_
106-9	17154-17162	directly	_
106-10	17163-17173	correlated	_
106-11	17174-17178	with	_
106-12	17179-17188	posterior	_
106-13	17189-17195	medial	_
106-14	17196-17199	and	_
106-15	17200-17207	lateral	_
106-16	17208-17213	areas	_
106-17	17214-17216	of	_
106-18	17217-17220	the	_
106-19	17221-17229	thalamus	_
106-20	17229-17230	,	_
106-21	17231-17236	which	_
106-22	17237-17244	appears	_
106-23	17245-17255	consistent	_
106-24	17256-17260	with	_
106-25	17261-17264	the	_
106-26	17265-17271	medial	_
106-27	17272-17282	geniculate	_
106-28	17283-17290	nucleus	_
106-29	17291-17294	and	_
106-30	17295-17298	the	_
106-31	17299-17306	lateral	_
106-32	17307-17317	geniculate	_
106-33	17318-17325	nucleus	_
106-34	17325-17326	,	_
106-35	17327-17339	respectively	_
106-36	17339-17340	.	_

#Text=Ketamine dependent subjects
#Text=A similar pattern of functional connectivity between the cortex and thalamus was demonstrated in the ketamine dependent subjects as shown in Fig 1C.
107-1	17341-17349	Ketamine	_
107-2	17350-17359	dependent	_
107-3	17360-17368	subjects	_
107-4	17369-17370	A	_
107-5	17371-17378	similar	_
107-6	17379-17386	pattern	_
107-7	17387-17389	of	_
107-8	17390-17400	functional	_
107-9	17401-17413	connectivity	_
107-10	17414-17421	between	_
107-11	17422-17425	the	_
107-12	17426-17432	cortex	_
107-13	17433-17436	and	_
107-14	17437-17445	thalamus	_
107-15	17446-17449	was	_
107-16	17450-17462	demonstrated	_
107-17	17463-17465	in	_
107-18	17466-17469	the	_
107-19	17470-17478	ketamine	_
107-20	17479-17488	dependent	_
107-21	17489-17497	subjects	_
107-22	17498-17500	as	_
107-23	17501-17506	shown	_
107-24	17507-17509	in	_
107-25	17510-17513	Fig	_
107-26	17514-17516	1C	_
107-27	17516-17517	.	_

#Text=However, there were qualitative differences between the ketamine dependent subjects and the drug free control subjects.
108-1	17518-17525	However	_
108-2	17525-17526	,	_
108-3	17527-17532	there	_
108-4	17533-17537	were	_
108-5	17538-17549	qualitative	_
108-6	17550-17561	differences	_
108-7	17562-17569	between	_
108-8	17570-17573	the	_
108-9	17574-17582	ketamine	_
108-10	17583-17592	dependent	_
108-11	17593-17601	subjects	_
108-12	17602-17605	and	_
108-13	17606-17609	the	_
108-14	17610-17614	drug	_
108-15	17615-17619	free	_
108-16	17620-17627	control	_
108-17	17628-17636	subjects	_
108-18	17636-17637	.	_

#Text=Particularly, in the ketamine dependent subjects the connectivity between the motor cortex/supplementary motor area, the posterior parietal cortex and the specific nucleus of the thalamus appeared markedly less weak.
109-1	17638-17650	Particularly	_
109-2	17650-17651	,	_
109-3	17652-17654	in	_
109-4	17655-17658	the	_
109-5	17659-17667	ketamine	_
109-6	17668-17677	dependent	_
109-7	17678-17686	subjects	_
109-8	17687-17690	the	_
109-9	17691-17703	connectivity	_
109-10	17704-17711	between	_
109-11	17712-17715	the	_
109-12	17716-17721	motor	_
109-13	17722-17728	cortex	_
109-14	17728-17729	/	_
109-15	17729-17742	supplementary	_
109-16	17743-17748	motor	_
109-17	17749-17753	area	_
109-18	17753-17754	,	_
109-19	17755-17758	the	_
109-20	17759-17768	posterior	_
109-21	17769-17777	parietal	_
109-22	17778-17784	cortex	_
109-23	17785-17788	and	_
109-24	17789-17792	the	_
109-25	17793-17801	specific	_
109-26	17802-17809	nucleus	_
109-27	17810-17812	of	_
109-28	17813-17816	the	_
109-29	17817-17825	thalamus	_
109-30	17826-17834	appeared	_
109-31	17835-17843	markedly	_
109-32	17844-17848	less	_
109-33	17849-17853	weak	_
109-34	17853-17854	.	_

#Text=Group differences in thalamocortical connectivity
#Text=Group differences in thalamocortical connectivity were summarized in Table 2 and shown graphically in Fig 1D.
110-1	17855-17860	Group	_
110-2	17861-17872	differences	_
110-3	17873-17875	in	_
110-4	17876-17891	thalamocortical	_
110-5	17892-17904	connectivity	_
110-6	17905-17910	Group	_
110-7	17911-17922	differences	_
110-8	17923-17925	in	_
110-9	17926-17941	thalamocortical	_
110-10	17942-17954	connectivity	_
110-11	17955-17959	were	_
110-12	17960-17970	summarized	_
110-13	17971-17973	in	_
110-14	17974-17979	Table	_
110-15	17980-17981	2	_
110-16	17982-17985	and	_
110-17	17986-17991	shown	_
110-18	17992-18003	graphically	_
110-19	18004-18006	in	_
110-20	18007-18010	Fig	_
110-21	18011-18013	1D	_
110-22	18013-18014	.	_

#Text=The ketamine dependent subjects demonstrated less connectivity between the specific nucleus of the thalamus and the cortical regions, including the prefrontal cortex, the motor cortex /supplementary motor area, and the posterior parietal cortex.
111-1	18015-18018	The	_
111-2	18019-18027	ketamine	_
111-3	18028-18037	dependent	_
111-4	18038-18046	subjects	_
111-5	18047-18059	demonstrated	_
111-6	18060-18064	less	_
111-7	18065-18077	connectivity	_
111-8	18078-18085	between	_
111-9	18086-18089	the	_
111-10	18090-18098	specific	_
111-11	18099-18106	nucleus	_
111-12	18107-18109	of	_
111-13	18110-18113	the	_
111-14	18114-18122	thalamus	_
111-15	18123-18126	and	_
111-16	18127-18130	the	_
111-17	18131-18139	cortical	_
111-18	18140-18147	regions	_
111-19	18147-18148	,	_
111-20	18149-18158	including	_
111-21	18159-18162	the	_
111-22	18163-18173	prefrontal	_
111-23	18174-18180	cortex	_
111-24	18180-18181	,	_
111-25	18182-18185	the	_
111-26	18186-18191	motor	_
111-27	18192-18198	cortex	_
111-28	18199-18200	/	_
111-29	18200-18213	supplementary	_
111-30	18214-18219	motor	_
111-31	18220-18224	area	_
111-32	18224-18225	,	_
111-33	18226-18229	and	_
111-34	18230-18233	the	_
111-35	18234-18243	posterior	_
111-36	18244-18252	parietal	_
111-37	18253-18259	cortex	_
111-38	18259-18260	.	_

#Text=No increased thalamic connectivity was observed for the ketamine dependent subjects in comparison with the control subjects.
112-1	18261-18263	No	_
112-2	18264-18273	increased	_
112-3	18274-18282	thalamic	_
112-4	18283-18295	connectivity	_
112-5	18296-18299	was	_
112-6	18300-18308	observed	_
112-7	18309-18312	for	_
112-8	18313-18316	the	_
112-9	18317-18325	ketamine	_
112-10	18326-18335	dependent	_
112-11	18336-18344	subjects	_
112-12	18345-18347	in	_
112-13	18348-18358	comparison	_
112-14	18359-18363	with	_
112-15	18364-18367	the	_
112-16	18368-18375	control	_
112-17	18376-18384	subjects	_
112-18	18384-18385	.	_

#Text=Differences in thalamocortical connectivity between these two groups (ketamine dependent subjects and drug-free control subjects).
113-1	18386-18397	Differences	_
113-2	18398-18400	in	_
113-3	18401-18416	thalamocortical	_
113-4	18417-18429	connectivity	_
113-5	18430-18437	between	_
113-6	18438-18443	these	_
113-7	18444-18447	two	_
113-8	18448-18454	groups	_
113-9	18455-18456	(	_
113-10	18456-18464	ketamine	_
113-11	18465-18474	dependent	_
113-12	18475-18483	subjects	_
113-13	18484-18487	and	_
113-14	18488-18497	drug-free	_
113-15	18498-18505	control	_
113-16	18506-18514	subjects	_
113-17	18514-18515	)	_
113-18	18515-18516	.	_

#Text=Seed Region of Interest, Contrast, and Brain regions\tMontreal neurological Coordinates (x,y,z)\tPeak t value\tCluster size (mm3)\t \tPrefrontal\t\t\t\t \tHealthy controls > ketamine dependent subjects\t\t\t\t \t    Left medial dorsal nucleus\t-3, -18, 9\t3.72\t270\t \tMotor/supplementary motor area\t\t\t\t \tHealthy controls > ketamine dependent subjects\t\t\t\t \t    Left ventral posterior lateral nucleus\t-12, -18, 6\t3.41\t459\t \t    Right ventral lateral nucleus\t12, -15, 3\t3.34\t135\t \tPosterior parietal\t\t\t\t \tHealthy controls > ketamine dependent subjects\t\t\t\t \t    Right pulvinar\t9, -27, 6\t3.72\t243\t \t    Left pulvinar\t-18, -33, 6\t2.76\t108\t \t    Left pulvinar\t-18, -27, 12\t3.87\t378\t \t    Left medial dorsal nucleus\t-3, -9, 3\t4.32\t108\t \t    Right ventral lateral nucleus\t12, -3, 6\t3.20\t162\t \t    Right lateral dorsal nucleus\t12, -18, 15\t3.53\t405\t \t
#Text=The ketamine dependent subjects group demonstrated significantly less connectivity between the thalamus and the cortical regions-of-interest, including the prefrontal cortex, the motor cortex /supplementary motor area, and the posterior parietal cortex.
114-1	18517-18521	Seed	_
114-2	18522-18528	Region	_
114-3	18529-18531	of	_
114-4	18532-18540	Interest	_
114-5	18540-18541	,	_
114-6	18542-18550	Contrast	_
114-7	18550-18551	,	_
114-8	18552-18555	and	_
114-9	18556-18561	Brain	_
114-10	18562-18569	regions	_
114-11	18570-18578	Montreal	_
114-12	18579-18591	neurological	_
114-13	18592-18603	Coordinates	_
114-14	18604-18605	(	_
114-15	18605-18606	x	_
114-16	18606-18607	,	_
114-17	18607-18608	y	_
114-18	18608-18609	,	_
114-19	18609-18610	z	_
114-20	18610-18611	)	_
114-21	18612-18616	Peak	_
114-22	18617-18618	t	_
114-23	18619-18624	value	_
114-24	18625-18632	Cluster	_
114-25	18633-18637	size	_
114-26	18638-18639	(	_
114-27	18639-18642	mm3	_
114-28	18642-18643	)	_
114-29	18646-18656	Prefrontal	_
114-30	18662-18669	Healthy	_
114-31	18670-18678	controls	_
114-32	18679-18680	>	_
114-33	18681-18689	ketamine	_
114-34	18690-18699	dependent	_
114-35	18700-18708	subjects	_
114-36	18714-18718	    	_
114-37	18718-18722	Left	_
114-38	18723-18729	medial	_
114-39	18730-18736	dorsal	_
114-40	18737-18744	nucleus	_
114-41	18745-18746	-	_
114-42	18746-18747	3	_
114-43	18747-18748	,	_
114-44	18749-18750	-	_
114-45	18750-18752	18	_
114-46	18752-18753	,	_
114-47	18754-18755	9	_
114-48	18756-18760	3.72	_
114-49	18761-18764	270	_
114-50	18767-18772	Motor	_
114-51	18772-18773	/	_
114-52	18773-18786	supplementary	_
114-53	18787-18792	motor	_
114-54	18793-18797	area	_
114-55	18803-18810	Healthy	_
114-56	18811-18819	controls	_
114-57	18820-18821	>	_
114-58	18822-18830	ketamine	_
114-59	18831-18840	dependent	_
114-60	18841-18849	subjects	_
114-61	18855-18859	    	_
114-62	18859-18863	Left	_
114-63	18864-18871	ventral	_
114-64	18872-18881	posterior	_
114-65	18882-18889	lateral	_
114-66	18890-18897	nucleus	_
114-67	18898-18899	-	_
114-68	18899-18901	12	_
114-69	18901-18902	,	_
114-70	18903-18904	-	_
114-71	18904-18906	18	_
114-72	18906-18907	,	_
114-73	18908-18909	6	_
114-74	18910-18914	3.41	_
114-75	18915-18918	459	_
114-76	18921-18925	    	_
114-77	18925-18930	Right	_
114-78	18931-18938	ventral	_
114-79	18939-18946	lateral	_
114-80	18947-18954	nucleus	_
114-81	18955-18957	12	_
114-82	18957-18958	,	_
114-83	18959-18960	-	_
114-84	18960-18962	15	_
114-85	18962-18963	,	_
114-86	18964-18965	3	_
114-87	18966-18970	3.34	_
114-88	18971-18974	135	_
114-89	18977-18986	Posterior	_
114-90	18987-18995	parietal	_
114-91	19001-19008	Healthy	_
114-92	19009-19017	controls	_
114-93	19018-19019	>	_
114-94	19020-19028	ketamine	_
114-95	19029-19038	dependent	_
114-96	19039-19047	subjects	_
114-97	19053-19057	    	_
114-98	19057-19062	Right	_
114-99	19063-19071	pulvinar	_
114-100	19072-19073	9	_
114-101	19073-19074	,	_
114-102	19075-19076	-	_
114-103	19076-19078	27	_
114-104	19078-19079	,	_
114-105	19080-19081	6	_
114-106	19082-19086	3.72	_
114-107	19087-19090	243	_
114-108	19093-19097	    	_
114-109	19097-19101	Left	_
114-110	19102-19110	pulvinar	_
114-111	19111-19112	-	_
114-112	19112-19114	18	_
114-113	19114-19115	,	_
114-114	19116-19117	-	_
114-115	19117-19119	33	_
114-116	19119-19120	,	_
114-117	19121-19122	6	_
114-118	19123-19127	2.76	_
114-119	19128-19131	108	_
114-120	19134-19138	    	_
114-121	19138-19142	Left	_
114-122	19143-19151	pulvinar	_
114-123	19152-19153	-	_
114-124	19153-19155	18	_
114-125	19155-19156	,	_
114-126	19157-19158	-	_
114-127	19158-19160	27	_
114-128	19160-19161	,	_
114-129	19162-19164	12	_
114-130	19165-19169	3.87	_
114-131	19170-19173	378	_
114-132	19176-19180	    	_
114-133	19180-19184	Left	_
114-134	19185-19191	medial	_
114-135	19192-19198	dorsal	_
114-136	19199-19206	nucleus	_
114-137	19207-19208	-	_
114-138	19208-19209	3	_
114-139	19209-19210	,	_
114-140	19211-19212	-	_
114-141	19212-19213	9	_
114-142	19213-19214	,	_
114-143	19215-19216	3	_
114-144	19217-19221	4.32	_
114-145	19222-19225	108	_
114-146	19228-19232	    	_
114-147	19232-19237	Right	_
114-148	19238-19245	ventral	_
114-149	19246-19253	lateral	_
114-150	19254-19261	nucleus	_
114-151	19262-19264	12	_
114-152	19264-19265	,	_
114-153	19266-19267	-	_
114-154	19267-19268	3	_
114-155	19268-19269	,	_
114-156	19270-19271	6	_
114-157	19272-19276	3.20	_
114-158	19277-19280	162	_
114-159	19283-19287	    	_
114-160	19287-19292	Right	_
114-161	19293-19300	lateral	_
114-162	19301-19307	dorsal	_
114-163	19308-19315	nucleus	_
114-164	19316-19318	12	_
114-165	19318-19319	,	_
114-166	19320-19321	-	_
114-167	19321-19323	18	_
114-168	19323-19324	,	_
114-169	19325-19327	15	_
114-170	19328-19332	3.53	_
114-171	19333-19336	405	_
114-172	19340-19343	The	_
114-173	19344-19352	ketamine	_
114-174	19353-19362	dependent	_
114-175	19363-19371	subjects	_
114-176	19372-19377	group	_
114-177	19378-19390	demonstrated	_
114-178	19391-19404	significantly	_
114-179	19405-19409	less	_
114-180	19410-19422	connectivity	_
114-181	19423-19430	between	_
114-182	19431-19434	the	_
114-183	19435-19443	thalamus	_
114-184	19444-19447	and	_
114-185	19448-19451	the	_
114-186	19452-19460	cortical	_
114-187	19461-19480	regions-of-interest	_
114-188	19480-19481	,	_
114-189	19482-19491	including	_
114-190	19492-19495	the	_
114-191	19496-19506	prefrontal	_
114-192	19507-19513	cortex	_
114-193	19513-19514	,	_
114-194	19515-19518	the	_
114-195	19519-19524	motor	_
114-196	19525-19531	cortex	_
114-197	19532-19533	/	_
114-198	19533-19546	supplementary	_
114-199	19547-19552	motor	_
114-200	19553-19557	area	_
114-201	19557-19558	,	_
114-202	19559-19562	and	_
114-203	19563-19566	the	_
114-204	19567-19576	posterior	_
114-205	19577-19585	parietal	_
114-206	19586-19592	cortex	_
114-207	19592-19593	.	_

#Text=No increased thalamic connectivity was observed for the ketamine dependent subjects in comparison with the control subjects.
115-1	19594-19596	No	_
115-2	19597-19606	increased	_
115-3	19607-19615	thalamic	_
115-4	19616-19628	connectivity	_
115-5	19629-19632	was	_
115-6	19633-19641	observed	_
115-7	19642-19645	for	_
115-8	19646-19649	the	_
115-9	19650-19658	ketamine	_
115-10	19659-19668	dependent	_
115-11	19669-19677	subjects	_
115-12	19678-19680	in	_
115-13	19681-19691	comparison	_
115-14	19692-19696	with	_
115-15	19697-19700	the	_
115-16	19701-19708	control	_
115-17	19709-19717	subjects	_
115-18	19717-19718	.	_

#Text=Correlations between thalamocortical connectivity and individual behavior scores in ketamine dependent subjects
#Text=We also examined the relationship between connectivity changes and ketamine use related variables; these included age of first use (years), duration of use (months), frequency of use (how many times per day), quantity of ketamine use per time (grams), ketamine craving (cm) and scores of cognitive testing.
116-1	19719-19731	Correlations	_
116-2	19732-19739	between	_
116-3	19740-19755	thalamocortical	_
116-4	19756-19768	connectivity	_
116-5	19769-19772	and	_
116-6	19773-19783	individual	_
116-7	19784-19792	behavior	_
116-8	19793-19799	scores	_
116-9	19800-19802	in	_
116-10	19803-19811	ketamine	_
116-11	19812-19821	dependent	_
116-12	19822-19830	subjects	_
116-13	19831-19833	We	_
116-14	19834-19838	also	_
116-15	19839-19847	examined	_
116-16	19848-19851	the	_
116-17	19852-19864	relationship	_
116-18	19865-19872	between	_
116-19	19873-19885	connectivity	_
116-20	19886-19893	changes	_
116-21	19894-19897	and	_
116-22	19898-19906	ketamine	_
116-23	19907-19910	use	_
116-24	19911-19918	related	_
116-25	19919-19928	variables	_
116-26	19928-19929	;	_
116-27	19930-19935	these	_
116-28	19936-19944	included	_
116-29	19945-19948	age	_
116-30	19949-19951	of	_
116-31	19952-19957	first	_
116-32	19958-19961	use	_
116-33	19962-19963	(	_
116-34	19963-19968	years	_
116-35	19968-19969	)	_
116-36	19969-19970	,	_
116-37	19971-19979	duration	_
116-38	19980-19982	of	_
116-39	19983-19986	use	_
116-40	19987-19988	(	_
116-41	19988-19994	months	_
116-42	19994-19995	)	_
116-43	19995-19996	,	_
116-44	19997-20006	frequency	_
116-45	20007-20009	of	_
116-46	20010-20013	use	_
116-47	20014-20015	(	_
116-48	20015-20018	how	_
116-49	20019-20023	many	_
116-50	20024-20029	times	_
116-51	20030-20033	per	_
116-52	20034-20037	day	_
116-53	20037-20038	)	_
116-54	20038-20039	,	_
116-55	20040-20048	quantity	_
116-56	20049-20051	of	_
116-57	20052-20060	ketamine	_
116-58	20061-20064	use	_
116-59	20065-20068	per	_
116-60	20069-20073	time	_
116-61	20074-20075	(	_
116-62	20075-20080	grams	_
116-63	20080-20081	)	_
116-64	20081-20082	,	_
116-65	20083-20091	ketamine	_
116-66	20092-20099	craving	_
116-67	20100-20101	(	_
116-68	20101-20103	cm	_
116-69	20103-20104	)	_
116-70	20105-20108	and	_
116-71	20109-20115	scores	_
116-72	20116-20118	of	_
116-73	20119-20128	cognitive	_
116-74	20129-20136	testing	_
116-75	20136-20137	.	_

#Text=We only found that the functional connectivity between the posterior parietal area and the right lateral dorsal nucleus (MNI [x, y, z] coordinate: (12, -18, 15)) was significantly correlated to individual ketamine craving scores (p<0.05, corrected) (Fig 2).
117-1	20138-20140	We	_
117-2	20141-20145	only	_
117-3	20146-20151	found	_
117-4	20152-20156	that	_
117-5	20157-20160	the	_
117-6	20161-20171	functional	_
117-7	20172-20184	connectivity	_
117-8	20185-20192	between	_
117-9	20193-20196	the	_
117-10	20197-20206	posterior	_
117-11	20207-20215	parietal	_
117-12	20216-20220	area	_
117-13	20221-20224	and	_
117-14	20225-20228	the	_
117-15	20229-20234	right	_
117-16	20235-20242	lateral	_
117-17	20243-20249	dorsal	_
117-18	20250-20257	nucleus	_
117-19	20258-20259	(	_
117-20	20259-20262	MNI	_
117-21	20263-20264	[	_
117-22	20264-20265	x	_
117-23	20265-20266	,	_
117-24	20267-20268	y	_
117-25	20268-20269	,	_
117-26	20270-20271	z	_
117-27	20271-20272	]	_
117-28	20273-20283	coordinate	_
117-29	20283-20284	:	_
117-30	20285-20286	(	_
117-31	20286-20288	12	_
117-32	20288-20289	,	_
117-33	20290-20291	-	_
117-34	20291-20293	18	_
117-35	20293-20294	,	_
117-36	20295-20297	15	_
117-37	20297-20298	)	_
117-38	20298-20299	)	_
117-39	20300-20303	was	_
117-40	20304-20317	significantly	_
117-41	20318-20328	correlated	_
117-42	20329-20331	to	_
117-43	20332-20342	individual	_
117-44	20343-20351	ketamine	_
117-45	20352-20359	craving	_
117-46	20360-20366	scores	_
117-47	20367-20368	(	_
117-48	20368-20369	p	_
117-49	20369-20370	<	_
117-50	20370-20374	0.05	_
117-51	20374-20375	,	_
117-52	20376-20385	corrected	_
117-53	20385-20386	)	_
117-54	20387-20388	(	_
117-55	20388-20391	Fig	_
117-56	20392-20393	2	_
117-57	20393-20394	)	_
117-58	20394-20395	.	_

#Text=We also calculated the correlation among all behavior scores and cognitive tests scores.
118-1	20396-20398	We	_
118-2	20399-20403	also	_
118-3	20404-20414	calculated	_
118-4	20415-20418	the	_
118-5	20419-20430	correlation	_
118-6	20431-20436	among	_
118-7	20437-20440	all	_
118-8	20441-20449	behavior	_
118-9	20450-20456	scores	_
118-10	20457-20460	and	_
118-11	20461-20470	cognitive	_
118-12	20471-20476	tests	_
118-13	20477-20483	scores	_
118-14	20483-20484	.	_

#Text=We found that there are significant correlations between total ketamine intake and ketamine craving scores (Pearson’s r = 0.5963, p = 0.003), while there were no significant correlations between any behavioral and cognitive testing scores.
119-1	20485-20487	We	_
119-2	20488-20493	found	_
119-3	20494-20498	that	_
119-4	20499-20504	there	_
119-5	20505-20508	are	_
119-6	20509-20520	significant	_
119-7	20521-20533	correlations	_
119-8	20534-20541	between	_
119-9	20542-20547	total	_
119-10	20548-20556	ketamine	_
119-11	20557-20563	intake	_
119-12	20564-20567	and	_
119-13	20568-20576	ketamine	_
119-14	20577-20584	craving	_
119-15	20585-20591	scores	_
119-16	20592-20593	(	_
119-17	20593-20600	Pearson	_
119-18	20600-20601	’	_
119-19	20601-20602	s	_
119-20	20603-20604	r	_
119-21	20605-20606	=	_
119-22	20607-20613	0.5963	_
119-23	20613-20614	,	_
119-24	20615-20616	p	_
119-25	20617-20618	=	_
119-26	20619-20624	0.003	_
119-27	20624-20625	)	_
119-28	20625-20626	,	_
119-29	20627-20632	while	_
119-30	20633-20638	there	_
119-31	20639-20643	were	_
119-32	20644-20646	no	_
119-33	20647-20658	significant	_
119-34	20659-20671	correlations	_
119-35	20672-20679	between	_
119-36	20680-20683	any	_
119-37	20684-20694	behavioral	_
119-38	20695-20698	and	_
119-39	20699-20708	cognitive	_
119-40	20709-20716	testing	_
119-41	20717-20723	scores	_
119-42	20723-20724	.	_

#Text=Functional connectivity patterns between the posterior parietal area and the right lateral dorsal nucleus (MNI (x,y,z) coordinate: (12, -18, 15)).
120-1	20725-20735	Functional	_
120-2	20736-20748	connectivity	_
120-3	20749-20757	patterns	_
120-4	20758-20765	between	_
120-5	20766-20769	the	_
120-6	20770-20779	posterior	_
120-7	20780-20788	parietal	_
120-8	20789-20793	area	_
120-9	20794-20797	and	_
120-10	20798-20801	the	_
120-11	20802-20807	right	_
120-12	20808-20815	lateral	_
120-13	20816-20822	dorsal	_
120-14	20823-20830	nucleus	_
120-15	20831-20832	(	_
120-16	20832-20835	MNI	_
120-17	20836-20837	(	_
120-18	20837-20838	x	_
120-19	20838-20839	,	_
120-20	20839-20840	y	_
120-21	20840-20841	,	_
120-22	20841-20842	z	_
120-23	20842-20843	)	_
120-24	20844-20854	coordinate	_
120-25	20854-20855	:	_
120-26	20856-20857	(	_
120-27	20857-20859	12	_
120-28	20859-20860	,	_
120-29	20861-20862	-	_
120-30	20862-20864	18	_
120-31	20864-20865	,	_
120-32	20866-20868	15	_
120-33	20868-20869	)	_
120-34	20869-20870	)	_
120-35	20870-20871	.	_

#Text=Functional connection patterns of thalamic nuclei with the cortex
#Text=We computed the functional connection patterns of thalamic nuclei with the cortex by first extracting the six thalamus subregions as ROIs, as shown in Fig 3.
121-1	20872-20882	Functional	_
121-2	20883-20893	connection	_
121-3	20894-20902	patterns	_
121-4	20903-20905	of	_
121-5	20906-20914	thalamic	_
121-6	20915-20921	nuclei	_
121-7	20922-20926	with	_
121-8	20927-20930	the	_
121-9	20931-20937	cortex	_
121-10	20938-20940	We	_
121-11	20941-20949	computed	_
121-12	20950-20953	the	_
121-13	20954-20964	functional	_
121-14	20965-20975	connection	_
121-15	20976-20984	patterns	_
121-16	20985-20987	of	_
121-17	20988-20996	thalamic	_
121-18	20997-21003	nuclei	_
121-19	21004-21008	with	_
121-20	21009-21012	the	_
121-21	21013-21019	cortex	_
121-22	21020-21022	by	_
121-23	21023-21028	first	_
121-24	21029-21039	extracting	_
121-25	21040-21043	the	_
121-26	21044-21047	six	_
121-27	21048-21056	thalamus	_
121-28	21057-21067	subregions	_
121-29	21068-21070	as	_
121-30	21071-21075	ROIs	_
121-31	21075-21076	,	_
121-32	21077-21079	as	_
121-33	21080-21085	shown	_
121-34	21086-21088	in	_
121-35	21089-21092	Fig	_
121-36	21093-21094	3	_
121-37	21094-21095	.	_

#Text=Specifically, in the T map of one sample t-test of the thalamocortical connectivity of the drug-free control subjects (as shown in Fig 1B in the main manuscript), the voxel with the peak T value and its surrounding region with a relatively large T value (75% ~ 85% of the peak T value for different ROIs) was extracted as an ROI.
122-1	21096-21108	Specifically	_
122-2	21108-21109	,	_
122-3	21110-21112	in	_
122-4	21113-21116	the	_
122-5	21117-21118	T	_
122-6	21119-21122	map	_
122-7	21123-21125	of	_
122-8	21126-21129	one	_
122-9	21130-21136	sample	_
122-10	21137-21143	t-test	_
122-11	21144-21146	of	_
122-12	21147-21150	the	_
122-13	21151-21166	thalamocortical	_
122-14	21167-21179	connectivity	_
122-15	21180-21182	of	_
122-16	21183-21186	the	_
122-17	21187-21196	drug-free	_
122-18	21197-21204	control	_
122-19	21205-21213	subjects	_
122-20	21214-21215	(	_
122-21	21215-21217	as	_
122-22	21218-21223	shown	_
122-23	21224-21226	in	_
122-24	21227-21230	Fig	_
122-25	21231-21233	1B	_
122-26	21234-21236	in	_
122-27	21237-21240	the	_
122-28	21241-21245	main	_
122-29	21246-21256	manuscript	_
122-30	21256-21257	)	_
122-31	21257-21258	,	_
122-32	21259-21262	the	_
122-33	21263-21268	voxel	_
122-34	21269-21273	with	_
122-35	21274-21277	the	_
122-36	21278-21282	peak	_
122-37	21283-21284	T	_
122-38	21285-21290	value	_
122-39	21291-21294	and	_
122-40	21295-21298	its	_
122-41	21299-21310	surrounding	_
122-42	21311-21317	region	_
122-43	21318-21322	with	_
122-44	21323-21324	a	_
122-45	21325-21335	relatively	_
122-46	21336-21341	large	_
122-47	21342-21343	T	_
122-48	21344-21349	value	_
122-49	21350-21351	(	_
122-50	21351-21354	75%	_
122-51	21355-21356	~	_
122-52	21357-21360	85%	_
122-53	21361-21363	of	_
122-54	21364-21367	the	_
122-55	21368-21372	peak	_
122-56	21373-21374	T	_
122-57	21375-21380	value	_
122-58	21381-21384	for	_
122-59	21385-21394	different	_
122-60	21395-21399	ROIs	_
122-61	21399-21400	)	_
122-62	21401-21404	was	_
122-63	21405-21414	extracted	_
122-64	21415-21417	as	_
122-65	21418-21420	an	_
122-66	21421-21424	ROI	_
122-67	21424-21425	.	_

#Text=Only right thalami ROIs are extracted.
123-1	21426-21430	Only	_
123-2	21431-21436	right	_
123-3	21437-21444	thalami	_
123-4	21445-21449	ROIs	_
123-5	21450-21453	are	_
123-6	21454-21463	extracted	_
123-7	21463-21464	.	_

#Text=Then, we checked that the six ROIs contained no overlapping regions.
124-1	21465-21469	Then	_
124-2	21469-21470	,	_
124-3	21471-21473	we	_
124-4	21474-21481	checked	_
124-5	21482-21486	that	_
124-6	21487-21490	the	_
124-7	21491-21494	six	_
124-8	21495-21499	ROIs	_
124-9	21500-21509	contained	_
124-10	21510-21512	no	_
124-11	21513-21524	overlapping	_
124-12	21525-21532	regions	_
124-13	21532-21533	.	_

#Text=In detail, the ROI_1 (dark blue) was located at the anterior and dorsomedial regions of the right thalamus, the ROI_2 (light blue) was located at ventral lateral portions of the thalamus, the ROI_3 (dark green) was located at ventral posterior-lateral portions of the thalamus, the ROI_4 (light green) was located at the posterior nucleus and the pulvinar, and the ROI_5 (red) and ROI_6 (yellow) were located at posterior medial and lateral areas of the thalamus, respectively (Fig 3).
125-1	21534-21536	In	_
125-2	21537-21543	detail	_
125-3	21543-21544	,	_
125-4	21545-21548	the	_
125-5	21549-21552	ROI	_
125-6	21552-21553	_	_
125-7	21553-21554	1	_
125-8	21555-21556	(	_
125-9	21556-21560	dark	_
125-10	21561-21565	blue	_
125-11	21565-21566	)	_
125-12	21567-21570	was	_
125-13	21571-21578	located	_
125-14	21579-21581	at	_
125-15	21582-21585	the	_
125-16	21586-21594	anterior	_
125-17	21595-21598	and	_
125-18	21599-21610	dorsomedial	_
125-19	21611-21618	regions	_
125-20	21619-21621	of	_
125-21	21622-21625	the	_
125-22	21626-21631	right	_
125-23	21632-21640	thalamus	_
125-24	21640-21641	,	_
125-25	21642-21645	the	_
125-26	21646-21649	ROI	_
125-27	21649-21650	_	_
125-28	21650-21651	2	_
125-29	21652-21653	(	_
125-30	21653-21658	light	_
125-31	21659-21663	blue	_
125-32	21663-21664	)	_
125-33	21665-21668	was	_
125-34	21669-21676	located	_
125-35	21677-21679	at	_
125-36	21680-21687	ventral	_
125-37	21688-21695	lateral	_
125-38	21696-21704	portions	_
125-39	21705-21707	of	_
125-40	21708-21711	the	_
125-41	21712-21720	thalamus	_
125-42	21720-21721	,	_
125-43	21722-21725	the	_
125-44	21726-21729	ROI	_
125-45	21729-21730	_	_
125-46	21730-21731	3	_
125-47	21732-21733	(	_
125-48	21733-21737	dark	_
125-49	21738-21743	green	_
125-50	21743-21744	)	_
125-51	21745-21748	was	_
125-52	21749-21756	located	_
125-53	21757-21759	at	_
125-54	21760-21767	ventral	_
125-55	21768-21785	posterior-lateral	_
125-56	21786-21794	portions	_
125-57	21795-21797	of	_
125-58	21798-21801	the	_
125-59	21802-21810	thalamus	_
125-60	21810-21811	,	_
125-61	21812-21815	the	_
125-62	21816-21819	ROI	_
125-63	21819-21820	_	_
125-64	21820-21821	4	_
125-65	21822-21823	(	_
125-66	21823-21828	light	_
125-67	21829-21834	green	_
125-68	21834-21835	)	_
125-69	21836-21839	was	_
125-70	21840-21847	located	_
125-71	21848-21850	at	_
125-72	21851-21854	the	_
125-73	21855-21864	posterior	_
125-74	21865-21872	nucleus	_
125-75	21873-21876	and	_
125-76	21877-21880	the	_
125-77	21881-21889	pulvinar	_
125-78	21889-21890	,	_
125-79	21891-21894	and	_
125-80	21895-21898	the	_
125-81	21899-21902	ROI	_
125-82	21902-21903	_	_
125-83	21903-21904	5	_
125-84	21905-21906	(	_
125-85	21906-21909	red	_
125-86	21909-21910	)	_
125-87	21911-21914	and	_
125-88	21915-21918	ROI	_
125-89	21918-21919	_	_
125-90	21919-21920	6	_
125-91	21921-21922	(	_
125-92	21922-21928	yellow	_
125-93	21928-21929	)	_
125-94	21930-21934	were	_
125-95	21935-21942	located	_
125-96	21943-21945	at	_
125-97	21946-21955	posterior	_
125-98	21956-21962	medial	_
125-99	21963-21966	and	_
125-100	21967-21974	lateral	_
125-101	21975-21980	areas	_
125-102	21981-21983	of	_
125-103	21984-21987	the	_
125-104	21988-21996	thalamus	_
125-105	21996-21997	,	_
125-106	21998-22010	respectively	_
125-107	22011-22012	(	_
125-108	22012-22015	Fig	_
125-109	22016-22017	3	_
125-110	22017-22018	)	_
125-111	22018-22019	.	_

#Text=Next, the average fMRI time course was extracted from each thalamus ROI.
126-1	22020-22024	Next	_
126-2	22024-22025	,	_
126-3	22026-22029	the	_
126-4	22030-22037	average	_
126-5	22038-22042	fMRI	_
126-6	22043-22047	time	_
126-7	22048-22054	course	_
126-8	22055-22058	was	_
126-9	22059-22068	extracted	_
126-10	22069-22073	from	_
126-11	22074-22078	each	_
126-12	22079-22087	thalamus	_
126-13	22088-22091	ROI	_
126-14	22091-22092	.	_

#Text=Using these time courses, partial correlations were computed for each voxel in the brain.
127-1	22093-22098	Using	_
127-2	22099-22104	these	_
127-3	22105-22109	time	_
127-4	22110-22117	courses	_
127-5	22117-22118	,	_
127-6	22119-22126	partial	_
127-7	22127-22139	correlations	_
127-8	22140-22144	were	_
127-9	22145-22153	computed	_
127-10	22154-22157	for	_
127-11	22158-22162	each	_
127-12	22163-22168	voxel	_
127-13	22169-22171	in	_
127-14	22172-22175	the	_
127-15	22176-22181	brain	_
127-16	22181-22182	.	_

#Text=Then, the one sample t-test was used to obtain connectivity patterns of each thalamus ROI, separately for the drug free control subject group and the ketamine user group, as shown in Fig 4.
128-1	22183-22187	Then	_
128-2	22187-22188	,	_
128-3	22189-22192	the	_
128-4	22193-22196	one	_
128-5	22197-22203	sample	_
128-6	22204-22210	t-test	_
128-7	22211-22214	was	_
128-8	22215-22219	used	_
128-9	22220-22222	to	_
128-10	22223-22229	obtain	_
128-11	22230-22242	connectivity	_
128-12	22243-22251	patterns	_
128-13	22252-22254	of	_
128-14	22255-22259	each	_
128-15	22260-22268	thalamus	_
128-16	22269-22272	ROI	_
128-17	22272-22273	,	_
128-18	22274-22284	separately	_
128-19	22285-22288	for	_
128-20	22289-22292	the	_
128-21	22293-22297	drug	_
128-22	22298-22302	free	_
128-23	22303-22310	control	_
128-24	22311-22318	subject	_
128-25	22319-22324	group	_
128-26	22325-22328	and	_
128-27	22329-22332	the	_
128-28	22333-22341	ketamine	_
128-29	22342-22346	user	_
128-30	22347-22352	group	_
128-31	22352-22353	,	_
128-32	22354-22356	as	_
128-33	22357-22362	shown	_
128-34	22363-22365	in	_
128-35	22366-22369	Fig	_
128-36	22370-22371	4	_
128-37	22371-22372	.	_

#Text=We think that these connectivity patterns are very consistent with our hypothesis, that is, different thalamic nuclei have significant distinctive connection patterns with the cortex.
129-1	22373-22375	We	_
129-2	22376-22381	think	_
129-3	22382-22386	that	_
129-4	22387-22392	these	_
129-5	22393-22405	connectivity	_
129-6	22406-22414	patterns	_
129-7	22415-22418	are	_
129-8	22419-22423	very	_
129-9	22424-22434	consistent	_
129-10	22435-22439	with	_
129-11	22440-22443	our	_
129-12	22444-22454	hypothesis	_
129-13	22454-22455	,	_
129-14	22456-22460	that	_
129-15	22461-22463	is	_
129-16	22463-22464	,	_
129-17	22465-22474	different	_
129-18	22475-22483	thalamic	_
129-19	22484-22490	nuclei	_
129-20	22491-22495	have	_
129-21	22496-22507	significant	_
129-22	22508-22519	distinctive	_
129-23	22520-22530	connection	_
129-24	22531-22539	patterns	_
129-25	22540-22544	with	_
129-26	22545-22548	the	_
129-27	22549-22555	cortex	_
129-28	22555-22556	.	_

#Text=For example, the thalamus ROI_1 shows strong connections with the prefrontal cortex, while the thalamus ROI_2 shows significant connection with the primary motor cortex and the supplementary motor area.
130-1	22557-22560	For	_
130-2	22561-22568	example	_
130-3	22568-22569	,	_
130-4	22570-22573	the	_
130-5	22574-22582	thalamus	_
130-6	22583-22586	ROI	_
130-7	22586-22587	_	_
130-8	22587-22588	1	_
130-9	22589-22594	shows	_
130-10	22595-22601	strong	_
130-11	22602-22613	connections	_
130-12	22614-22618	with	_
130-13	22619-22622	the	_
130-14	22623-22633	prefrontal	_
130-15	22634-22640	cortex	_
130-16	22640-22641	,	_
130-17	22642-22647	while	_
130-18	22648-22651	the	_
130-19	22652-22660	thalamus	_
130-20	22661-22664	ROI	_
130-21	22664-22665	_	_
130-22	22665-22666	2	_
130-23	22667-22672	shows	_
130-24	22673-22684	significant	_
130-25	22685-22695	connection	_
130-26	22696-22700	with	_
130-27	22701-22704	the	_
130-28	22705-22712	primary	_
130-29	22713-22718	motor	_
130-30	22719-22725	cortex	_
130-31	22726-22729	and	_
130-32	22730-22733	the	_
130-33	22734-22747	supplementary	_
130-34	22748-22753	motor	_
130-35	22754-22758	area	_
130-36	22758-22759	.	_

#Text=In summary, we believe these results of thalamocortical connectivity are relatively reliable and are grounds for further testing.
131-1	22760-22762	In	_
131-2	22763-22770	summary	_
131-3	22770-22771	,	_
131-4	22772-22774	we	_
131-5	22775-22782	believe	_
131-6	22783-22788	these	_
131-7	22789-22796	results	_
131-8	22797-22799	of	_
131-9	22800-22815	thalamocortical	_
131-10	22816-22828	connectivity	_
131-11	22829-22832	are	_
131-12	22833-22843	relatively	_
131-13	22844-22852	reliable	_
131-14	22853-22856	and	_
131-15	22857-22860	are	_
131-16	22861-22868	grounds	_
131-17	22869-22872	for	_
131-18	22873-22880	further	_
131-19	22881-22888	testing	_
131-20	22888-22889	.	_

#Text=Finally, we used a two-sample t-test to investigate whether there were significant differences in the functional connectivity patterns of thalamus ROIs between the two groups.
132-1	22890-22897	Finally	_
132-2	22897-22898	,	_
132-3	22899-22901	we	_
132-4	22902-22906	used	_
132-5	22907-22908	a	_
132-6	22909-22919	two-sample	_
132-7	22920-22926	t-test	_
132-8	22927-22929	to	_
132-9	22930-22941	investigate	_
132-10	22942-22949	whether	_
132-11	22950-22955	there	_
132-12	22956-22960	were	_
132-13	22961-22972	significant	_
132-14	22973-22984	differences	_
132-15	22985-22987	in	_
132-16	22988-22991	the	_
132-17	22992-23002	functional	_
132-18	23003-23015	connectivity	_
132-19	23016-23024	patterns	_
132-20	23025-23027	of	_
132-21	23028-23036	thalamus	_
132-22	23037-23041	ROIs	_
132-23	23042-23049	between	_
132-24	23050-23053	the	_
132-25	23054-23057	two	_
132-26	23058-23064	groups	_
132-27	23064-23065	.	_

#Text=The significant decrease in thalamocortical connectivity in the ketamine user group is represented by the dotted purple lines in Fig 5.
133-1	23066-23069	The	_
133-2	23070-23081	significant	_
133-3	23082-23090	decrease	_
133-4	23091-23093	in	_
133-5	23094-23109	thalamocortical	_
133-6	23110-23122	connectivity	_
133-7	23123-23125	in	_
133-8	23126-23129	the	_
133-9	23130-23138	ketamine	_
133-10	23139-23143	user	_
133-11	23144-23149	group	_
133-12	23150-23152	is	_
133-13	23153-23164	represented	_
133-14	23165-23167	by	_
133-15	23168-23171	the	_
133-16	23172-23178	dotted	_
133-17	23179-23185	purple	_
133-18	23186-23191	lines	_
133-19	23192-23194	in	_
133-20	23195-23198	Fig	_
133-21	23199-23200	5	_
133-22	23200-23201	.	_

#Text=These brain areas with significantly decreased thalamocortical connectivity in ketamine user group were almost located in the corresponding cortex ROIs.
134-1	23202-23207	These	_
134-2	23208-23213	brain	_
134-3	23214-23219	areas	_
134-4	23220-23224	with	_
134-5	23225-23238	significantly	_
134-6	23239-23248	decreased	_
134-7	23249-23264	thalamocortical	_
134-8	23265-23277	connectivity	_
134-9	23278-23280	in	_
134-10	23281-23289	ketamine	_
134-11	23290-23294	user	_
134-12	23295-23300	group	_
134-13	23301-23305	were	_
134-14	23306-23312	almost	_
134-15	23313-23320	located	_
134-16	23321-23323	in	_
134-17	23324-23327	the	_
134-18	23328-23341	corresponding	_
134-19	23342-23348	cortex	_
134-20	23349-23353	ROIs	_
134-21	23353-23354	.	_

#Text=Location of thalamus subregion ROIs
#Text=Functional connectivity patterns of thalamus ROIs.
135-1	23355-23363	Location	_
135-2	23364-23366	of	_
135-3	23367-23375	thalamus	_
135-4	23376-23385	subregion	_
135-5	23386-23390	ROIs	_
135-6	23391-23401	Functional	_
135-7	23402-23414	connectivity	_
135-8	23415-23423	patterns	_
135-9	23424-23426	of	_
135-10	23427-23435	thalamus	_
135-11	23436-23440	ROIs	_
135-12	23440-23441	.	_

#Text=Differences of functional connectivity patterns of thalamus ROIs between drug-free control subject group and ketamine user group.
136-1	23442-23453	Differences	_
136-2	23454-23456	of	_
136-3	23457-23467	functional	_
136-4	23468-23480	connectivity	_
136-5	23481-23489	patterns	_
136-6	23490-23492	of	_
136-7	23493-23501	thalamus	_
136-8	23502-23506	ROIs	_
136-9	23507-23514	between	_
136-10	23515-23524	drug-free	_
136-11	23525-23532	control	_
136-12	23533-23540	subject	_
136-13	23541-23546	group	_
136-14	23547-23550	and	_
136-15	23551-23559	ketamine	_
136-16	23560-23564	user	_
136-17	23565-23570	group	_
136-18	23570-23571	.	_

#Text=The purple dotted lines show the significant different brain regions (single voxel P<0.01, cluster size>20 voxels).
137-1	23572-23575	The	_
137-2	23576-23582	purple	_
137-3	23583-23589	dotted	_
137-4	23590-23595	lines	_
137-5	23596-23600	show	_
137-6	23601-23604	the	_
137-7	23605-23616	significant	_
137-8	23617-23626	different	_
137-9	23627-23632	brain	_
137-10	23633-23640	regions	_
137-11	23641-23642	(	_
137-12	23642-23648	single	_
137-13	23649-23654	voxel	_
137-14	23655-23656	P	_
137-15	23656-23657	<	_
137-16	23657-23661	0.01	_
137-17	23661-23662	,	_
137-18	23663-23670	cluster	_
137-19	23671-23675	size	_
137-20	23675-23676	>	_
137-21	23676-23678	20	_
137-22	23679-23685	voxels	_
137-23	23685-23686	)	_
137-24	23686-23687	.	_

#Text=Discussion
#Text=This study, to the best of our knowledge, is the first to investigate resting state functional connectivity of the thalamus in chronic ketamine users compared to demographically matched drug free healthy subjects.
138-1	23688-23698	Discussion	_
138-2	23699-23703	This	_
138-3	23704-23709	study	_
138-4	23709-23710	,	_
138-5	23711-23713	to	_
138-6	23714-23717	the	_
138-7	23718-23722	best	_
138-8	23723-23725	of	_
138-9	23726-23729	our	_
138-10	23730-23739	knowledge	_
138-11	23739-23740	,	_
138-12	23741-23743	is	_
138-13	23744-23747	the	_
138-14	23748-23753	first	_
138-15	23754-23756	to	_
138-16	23757-23768	investigate	_
138-17	23769-23776	resting	_
138-18	23777-23782	state	_
138-19	23783-23793	functional	_
138-20	23794-23806	connectivity	_
138-21	23807-23809	of	_
138-22	23810-23813	the	_
138-23	23814-23822	thalamus	_
138-24	23823-23825	in	_
138-25	23826-23833	chronic	_
138-26	23834-23842	ketamine	_
138-27	23843-23848	users	_
138-28	23849-23857	compared	_
138-29	23858-23860	to	_
138-30	23861-23876	demographically	_
138-31	23877-23884	matched	_
138-32	23885-23889	drug	_
138-33	23890-23894	free	_
138-34	23895-23902	healthy	_
138-35	23903-23911	subjects	_
138-36	23911-23912	.	_

#Text=Our findings provide first evidence that chronic ketamine users show abnormal thalamocortical connectivity of resting state brain activity when compared to healthy controls.
139-1	23913-23916	Our	_
139-2	23917-23925	findings	_
139-3	23926-23933	provide	_
139-4	23934-23939	first	_
139-5	23940-23948	evidence	_
139-6	23949-23953	that	_
139-7	23954-23961	chronic	_
139-8	23962-23970	ketamine	_
139-9	23971-23976	users	_
139-10	23977-23981	show	_
139-11	23982-23990	abnormal	_
139-12	23991-24006	thalamocortical	_
139-13	24007-24019	connectivity	_
139-14	24020-24022	of	_
139-15	24023-24030	resting	_
139-16	24031-24036	state	_
139-17	24037-24042	brain	_
139-18	24043-24051	activity	_
139-19	24052-24056	when	_
139-20	24057-24065	compared	_
139-21	24066-24068	to	_
139-22	24069-24076	healthy	_
139-23	24077-24085	controls	_
139-24	24085-24086	.	_

#Text=We found that ketamine dependent subjects show significantly less connectivity between the thalamus and the cortical regions-of-interest, including the prefrontal cortex, the motor cortex /supplementary motor area, and the posterior parietal cortex.
140-1	24087-24089	We	_
140-2	24090-24095	found	_
140-3	24096-24100	that	_
140-4	24101-24109	ketamine	_
140-5	24110-24119	dependent	_
140-6	24120-24128	subjects	_
140-7	24129-24133	show	_
140-8	24134-24147	significantly	_
140-9	24148-24152	less	_
140-10	24153-24165	connectivity	_
140-11	24166-24173	between	_
140-12	24174-24177	the	_
140-13	24178-24186	thalamus	_
140-14	24187-24190	and	_
140-15	24191-24194	the	_
140-16	24195-24203	cortical	_
140-17	24204-24223	regions-of-interest	_
140-18	24223-24224	,	_
140-19	24225-24234	including	_
140-20	24235-24238	the	_
140-21	24239-24249	prefrontal	_
140-22	24250-24256	cortex	_
140-23	24256-24257	,	_
140-24	24258-24261	the	_
140-25	24262-24267	motor	_
140-26	24268-24274	cortex	_
140-27	24275-24276	/	_
140-28	24276-24289	supplementary	_
140-29	24290-24295	motor	_
140-30	24296-24300	area	_
140-31	24300-24301	,	_
140-32	24302-24305	and	_
140-33	24306-24309	the	_
140-34	24310-24319	posterior	_
140-35	24320-24328	parietal	_
140-36	24329-24335	cortex	_
140-37	24335-24336	.	_

#Text=However, no increased thalamic connectivity was observed in the ketamine dependent subjects in comparison with the control subjects.
141-1	24337-24344	However	_
141-2	24344-24345	,	_
141-3	24346-24348	no	_
141-4	24349-24358	increased	_
141-5	24359-24367	thalamic	_
141-6	24368-24380	connectivity	_
141-7	24381-24384	was	_
141-8	24385-24393	observed	_
141-9	24394-24396	in	_
141-10	24397-24400	the	_
141-11	24401-24409	ketamine	_
141-12	24410-24419	dependent	_
141-13	24420-24428	subjects	_
141-14	24429-24431	in	_
141-15	24432-24442	comparison	_
141-16	24443-24447	with	_
141-17	24448-24451	the	_
141-18	24452-24459	control	_
141-19	24460-24468	subjects	_
141-20	24468-24469	.	_

#Text=Although the current study is the first to demonstrate the changes of RSFC with chronic ketamine administration, previous studies with acute ketamine administration also showed changes of RSFC in healthy subjects.
142-1	24470-24478	Although	_
142-2	24479-24482	the	_
142-3	24483-24490	current	_
142-4	24491-24496	study	_
142-5	24497-24499	is	_
142-6	24500-24503	the	_
142-7	24504-24509	first	_
142-8	24510-24512	to	_
142-9	24513-24524	demonstrate	_
142-10	24525-24528	the	_
142-11	24529-24536	changes	_
142-12	24537-24539	of	_
142-13	24540-24544	RSFC	_
142-14	24545-24549	with	_
142-15	24550-24557	chronic	_
142-16	24558-24566	ketamine	_
142-17	24567-24581	administration	_
142-18	24581-24582	,	_
142-19	24583-24591	previous	_
142-20	24592-24599	studies	_
142-21	24600-24604	with	_
142-22	24605-24610	acute	_
142-23	24611-24619	ketamine	_
142-24	24620-24634	administration	_
142-25	24635-24639	also	_
142-26	24640-24646	showed	_
142-27	24647-24654	changes	_
142-28	24655-24657	of	_
142-29	24658-24662	RSFC	_
142-30	24663-24665	in	_
142-31	24666-24673	healthy	_
142-32	24674-24682	subjects	_
142-33	24682-24683	.	_

#Text=For example, using rsfMRI, a randomized, placebo-controlled, double-blind, crossover study demonstrated that acute ketamine administration markedly reduced RSFC of the default mode network (DMN) to the dorsal nexus (DN), the pregenual anterior cingulate (PACC) and medioprefrontal cortex (MPFC) via its representative hub, the posterior cingulate cortex (PCC) in healthy subjects compared to placebo.
143-1	24684-24687	For	_
143-2	24688-24695	example	_
143-3	24695-24696	,	_
143-4	24697-24702	using	_
143-5	24703-24709	rsfMRI	_
143-6	24709-24710	,	_
143-7	24711-24712	a	_
143-8	24713-24723	randomized	_
143-9	24723-24724	,	_
143-10	24725-24743	placebo-controlled	_
143-11	24743-24744	,	_
143-12	24745-24757	double-blind	_
143-13	24757-24758	,	_
143-14	24759-24768	crossover	_
143-15	24769-24774	study	_
143-16	24775-24787	demonstrated	_
143-17	24788-24792	that	_
143-18	24793-24798	acute	_
143-19	24799-24807	ketamine	_
143-20	24808-24822	administration	_
143-21	24823-24831	markedly	_
143-22	24832-24839	reduced	_
143-23	24840-24844	RSFC	_
143-24	24845-24847	of	_
143-25	24848-24851	the	_
143-26	24852-24859	default	_
143-27	24860-24864	mode	_
143-28	24865-24872	network	_
143-29	24873-24874	(	_
143-30	24874-24877	DMN	_
143-31	24877-24878	)	_
143-32	24879-24881	to	_
143-33	24882-24885	the	_
143-34	24886-24892	dorsal	_
143-35	24893-24898	nexus	_
143-36	24899-24900	(	_
143-37	24900-24902	DN	_
143-38	24902-24903	)	_
143-39	24903-24904	,	_
143-40	24905-24908	the	_
143-41	24909-24918	pregenual	_
143-42	24919-24927	anterior	_
143-43	24928-24937	cingulate	_
143-44	24938-24939	(	_
143-45	24939-24943	PACC	_
143-46	24943-24944	)	_
143-47	24945-24948	and	_
143-48	24949-24964	medioprefrontal	_
143-49	24965-24971	cortex	_
143-50	24972-24973	(	_
143-51	24973-24977	MPFC	_
143-52	24977-24978	)	_
143-53	24979-24982	via	_
143-54	24983-24986	its	_
143-55	24987-25001	representative	_
143-56	25002-25005	hub	_
143-57	25005-25006	,	_
143-58	25007-25010	the	_
143-59	25011-25020	posterior	_
143-60	25021-25030	cingulate	_
143-61	25031-25037	cortex	_
143-62	25038-25039	(	_
143-63	25039-25042	PCC	_
143-64	25042-25043	)	_
143-65	25044-25046	in	_
143-66	25047-25054	healthy	_
143-67	25055-25063	subjects	_
143-68	25064-25072	compared	_
143-69	25073-25075	to	_
143-70	25076-25083	placebo	_
143-71	25083-25084	.	_

#Text=However, another similar RSFC study revealed that the administration of a subanesthetic dose of ketamine significantly increased cortico-thalamic connectivity of the somatosensory and temporal cortex.
144-1	25085-25092	However	_
144-2	25092-25093	,	_
144-3	25094-25101	another	_
144-4	25102-25109	similar	_
144-5	25110-25114	RSFC	_
144-6	25115-25120	study	_
144-7	25121-25129	revealed	_
144-8	25130-25134	that	_
144-9	25135-25138	the	_
144-10	25139-25153	administration	_
144-11	25154-25156	of	_
144-12	25157-25158	a	_
144-13	25159-25172	subanesthetic	_
144-14	25173-25177	dose	_
144-15	25178-25180	of	_
144-16	25181-25189	ketamine	_
144-17	25190-25203	significantly	_
144-18	25204-25213	increased	_
144-19	25214-25230	cortico-thalamic	_
144-20	25231-25243	connectivity	_
144-21	25244-25246	of	_
144-22	25247-25250	the	_
144-23	25251-25264	somatosensory	_
144-24	25265-25268	and	_
144-25	25269-25277	temporal	_
144-26	25278-25284	cortex	_
144-27	25284-25285	.	_

#Text=One possible reason for this inconsistency may be due to the purpose of the study, the former is for treatment-resistant depression and the latter is for a schizophrenia model.
145-1	25286-25289	One	_
145-2	25290-25298	possible	_
145-3	25299-25305	reason	_
145-4	25306-25309	for	_
145-5	25310-25314	this	_
145-6	25315-25328	inconsistency	_
145-7	25329-25332	may	_
145-8	25333-25335	be	_
145-9	25336-25339	due	_
145-10	25340-25342	to	_
145-11	25343-25346	the	_
145-12	25347-25354	purpose	_
145-13	25355-25357	of	_
145-14	25358-25361	the	_
145-15	25362-25367	study	_
145-16	25367-25368	,	_
145-17	25369-25372	the	_
145-18	25373-25379	former	_
145-19	25380-25382	is	_
145-20	25383-25386	for	_
145-21	25387-25406	treatment-resistant	_
145-22	25407-25417	depression	_
145-23	25418-25421	and	_
145-24	25422-25425	the	_
145-25	25426-25432	latter	_
145-26	25433-25435	is	_
145-27	25436-25439	for	_
145-28	25440-25441	a	_
145-29	25442-25455	schizophrenia	_
145-30	25456-25461	model	_
145-31	25461-25462	.	_

#Text=Thus, these two studies focused on different circuit connectivity using similar methods.
146-1	25463-25467	Thus	_
146-2	25467-25468	,	_
146-3	25469-25474	these	_
146-4	25475-25478	two	_
146-5	25479-25486	studies	_
146-6	25487-25494	focused	_
146-7	25495-25497	on	_
146-8	25498-25507	different	_
146-9	25508-25515	circuit	_
146-10	25516-25528	connectivity	_
146-11	25529-25534	using	_
146-12	25535-25542	similar	_
146-13	25543-25550	methods	_
146-14	25550-25551	.	_

#Text=Considering that addiction is a chronic, relapsing brain disease and a state of compulsive drug use, it can include tolerance, dependence and withdrawal symptoms.
147-1	25552-25563	Considering	_
147-2	25564-25568	that	_
147-3	25569-25578	addiction	_
147-4	25579-25581	is	_
147-5	25582-25583	a	_
147-6	25584-25591	chronic	_
147-7	25591-25592	,	_
147-8	25593-25602	relapsing	_
147-9	25603-25608	brain	_
147-10	25609-25616	disease	_
147-11	25617-25620	and	_
147-12	25621-25622	a	_
147-13	25623-25628	state	_
147-14	25629-25631	of	_
147-15	25632-25642	compulsive	_
147-16	25643-25647	drug	_
147-17	25648-25651	use	_
147-18	25651-25652	,	_
147-19	25653-25655	it	_
147-20	25656-25659	can	_
147-21	25660-25667	include	_
147-22	25668-25677	tolerance	_
147-23	25677-25678	,	_
147-24	25679-25689	dependence	_
147-25	25690-25693	and	_
147-26	25694-25704	withdrawal	_
147-27	25705-25713	symptoms	_
147-28	25713-25714	.	_

#Text=And the disrupted circuit connectivity in addictive drug users may inform specific neurobiological substrates associated with addiction..
148-1	25715-25718	And	_
148-2	25719-25722	the	_
148-3	25723-25732	disrupted	_
148-4	25733-25740	circuit	_
148-5	25741-25753	connectivity	_
148-6	25754-25756	in	_
148-7	25757-25766	addictive	_
148-8	25767-25771	drug	_
148-9	25772-25777	users	_
148-10	25778-25781	may	_
148-11	25782-25788	inform	_
148-12	25789-25797	specific	_
148-13	25798-25813	neurobiological	_
148-14	25814-25824	substrates	_
148-15	25825-25835	associated	_
148-16	25836-25840	with	_
148-17	25841-25850	addiction	_
148-18	25850-25851	.	_
148-19	25851-25852	.	_

#Text=Here, we discuss results from additional RSFC studies dealing with other types of substance addiction.
149-1	25853-25857	Here	_
149-2	25857-25858	,	_
149-3	25859-25861	we	_
149-4	25862-25869	discuss	_
149-5	25870-25877	results	_
149-6	25878-25882	from	_
149-7	25883-25893	additional	_
149-8	25894-25898	RSFC	_
149-9	25899-25906	studies	_
149-10	25907-25914	dealing	_
149-11	25915-25919	with	_
149-12	25920-25925	other	_
149-13	25926-25931	types	_
149-14	25932-25934	of	_
149-15	25935-25944	substance	_
149-16	25945-25954	addiction	_
149-17	25954-25955	.	_

#Text=A line of study demonstrated decreased functional connectivity in addiction of other drugs (such as cocaine and heroine).
150-1	25956-25957	A	_
150-2	25958-25962	line	_
150-3	25963-25965	of	_
150-4	25966-25971	study	_
150-5	25972-25984	demonstrated	_
150-6	25985-25994	decreased	_
150-7	25995-26005	functional	_
150-8	26006-26018	connectivity	_
150-9	26019-26021	in	_
150-10	26022-26031	addiction	_
150-11	26032-26034	of	_
150-12	26035-26040	other	_
150-13	26041-26046	drugs	_
150-14	26047-26048	(	_
150-15	26048-26052	such	_
150-16	26053-26055	as	_
150-17	26056-26063	cocaine	_
150-18	26064-26067	and	_
150-19	26068-26075	heroine	_
150-20	26075-26076	)	_
150-21	26076-26077	.	_

#Text=For example, a study on cocaine administration followed by fMRI observed decreased functional connectivity in the human primary visual and motor cortex after acute administration of cocaine.
151-1	26078-26081	For	_
151-2	26082-26089	example	_
151-3	26089-26090	,	_
151-4	26091-26092	a	_
151-5	26093-26098	study	_
151-6	26099-26101	on	_
151-7	26102-26109	cocaine	_
151-8	26110-26124	administration	_
151-9	26125-26133	followed	_
151-10	26134-26136	by	_
151-11	26137-26141	fMRI	_
151-12	26142-26150	observed	_
151-13	26151-26160	decreased	_
151-14	26161-26171	functional	_
151-15	26172-26184	connectivity	_
151-16	26185-26187	in	_
151-17	26188-26191	the	_
151-18	26192-26197	human	_
151-19	26198-26205	primary	_
151-20	26206-26212	visual	_
151-21	26213-26216	and	_
151-22	26217-26222	motor	_
151-23	26223-26229	cortex	_
151-24	26230-26235	after	_
151-25	26236-26241	acute	_
151-26	26242-26256	administration	_
151-27	26257-26259	of	_
151-28	26260-26267	cocaine	_
151-29	26267-26268	.	_

#Text=In addition, Kelly et al. found reduced prefrontal interhemispheric resting-state functional connectivity (RSFC) in cocaine-dependent participants compared to control subjects.
152-1	26269-26271	In	_
152-2	26272-26280	addition	_
152-3	26280-26281	,	_
152-4	26282-26287	Kelly	_
152-5	26288-26290	et	_
152-6	26291-26293	al	_
152-7	26293-26294	.	_
152-8	26295-26300	found	_
152-9	26301-26308	reduced	_
152-10	26309-26319	prefrontal	_
152-11	26320-26336	interhemispheric	_
152-12	26337-26350	resting-state	_
152-13	26351-26361	functional	_
152-14	26362-26374	connectivity	_
152-15	26375-26376	(	_
152-16	26376-26380	RSFC	_
152-17	26380-26381	)	_
152-18	26382-26384	in	_
152-19	26385-26402	cocaine-dependent	_
152-20	26403-26415	participants	_
152-21	26416-26424	compared	_
152-22	26425-26427	to	_
152-23	26428-26435	control	_
152-24	26436-26444	subjects	_
152-25	26444-26445	.	_

#Text=By whole-brain resting-state fMRI connectivity analysis, Gu et al. reported almost universally reduced functional connectivity strength for six functional networks regions (ventral tegmental area, nucleus accumbens, the mediodorsal nucleus (MD) of the thalamus, amygdala, hippocampus and rostral anterior cingulate cortex) in cocaine users.
153-1	26446-26448	By	_
153-2	26449-26460	whole-brain	_
153-3	26461-26474	resting-state	_
153-4	26475-26479	fMRI	_
153-5	26480-26492	connectivity	_
153-6	26493-26501	analysis	_
153-7	26501-26502	,	_
153-8	26503-26505	Gu	_
153-9	26506-26508	et	_
153-10	26509-26511	al	_
153-11	26511-26512	.	_
153-12	26513-26521	reported	_
153-13	26522-26528	almost	_
153-14	26529-26540	universally	_
153-15	26541-26548	reduced	_
153-16	26549-26559	functional	_
153-17	26560-26572	connectivity	_
153-18	26573-26581	strength	_
153-19	26582-26585	for	_
153-20	26586-26589	six	_
153-21	26590-26600	functional	_
153-22	26601-26609	networks	_
153-23	26610-26617	regions	_
153-24	26618-26619	(	_
153-25	26619-26626	ventral	_
153-26	26627-26636	tegmental	_
153-27	26637-26641	area	_
153-28	26641-26642	,	_
153-29	26643-26650	nucleus	_
153-30	26651-26660	accumbens	_
153-31	26660-26661	,	_
153-32	26662-26665	the	_
153-33	26666-26677	mediodorsal	_
153-34	26678-26685	nucleus	_
153-35	26686-26687	(	_
153-36	26687-26689	MD	_
153-37	26689-26690	)	_
153-38	26691-26693	of	_
153-39	26694-26697	the	_
153-40	26698-26706	thalamus	_
153-41	26706-26707	,	_
153-42	26708-26716	amygdala	_
153-43	26716-26717	,	_
153-44	26718-26729	hippocampus	_
153-45	26730-26733	and	_
153-46	26734-26741	rostral	_
153-47	26742-26750	anterior	_
153-48	26751-26760	cingulate	_
153-49	26761-26767	cortex	_
153-50	26767-26768	)	_
153-51	26769-26771	in	_
153-52	26772-26779	cocaine	_
153-53	26780-26785	users	_
153-54	26785-26786	.	_

#Text=They also found that the MD thalamus seed yielded decreased rsFC within extensive striatal regions and impaired mesocorticolimbic circuits for the cocaine group.
154-1	26787-26791	They	_
154-2	26792-26796	also	_
154-3	26797-26802	found	_
154-4	26803-26807	that	_
154-5	26808-26811	the	_
154-6	26812-26814	MD	_
154-7	26815-26823	thalamus	_
154-8	26824-26828	seed	_
154-9	26829-26836	yielded	_
154-10	26837-26846	decreased	_
154-11	26847-26851	rsFC	_
154-12	26852-26858	within	_
154-13	26859-26868	extensive	_
154-14	26869-26877	striatal	_
154-15	26878-26885	regions	_
154-16	26886-26889	and	_
154-17	26890-26898	impaired	_
154-18	26899-26916	mesocorticolimbic	_
154-19	26917-26925	circuits	_
154-20	26926-26929	for	_
154-21	26930-26933	the	_
154-22	26934-26941	cocaine	_
154-23	26942-26947	group	_
154-24	26947-26948	.	_

#Text=These regions are thought to be important for focusing and maintaining desired behaviors while suppressing unwanted behaviors.
155-1	26949-26954	These	_
155-2	26955-26962	regions	_
155-3	26963-26966	are	_
155-4	26967-26974	thought	_
155-5	26975-26977	to	_
155-6	26978-26980	be	_
155-7	26981-26990	important	_
155-8	26991-26994	for	_
155-9	26995-27003	focusing	_
155-10	27004-27007	and	_
155-11	27008-27019	maintaining	_
155-12	27020-27027	desired	_
155-13	27028-27037	behaviors	_
155-14	27038-27043	while	_
155-15	27044-27055	suppressing	_
155-16	27056-27064	unwanted	_
155-17	27065-27074	behaviors	_
155-18	27074-27075	.	_

#Text=Drug dependent subjects are known to have difficulties with response inhibition, which likely contributes to the propensity to relapse in the presence of drug related cues.
156-1	27076-27080	Drug	_
156-2	27081-27090	dependent	_
156-3	27091-27099	subjects	_
156-4	27100-27103	are	_
156-5	27104-27109	known	_
156-6	27110-27112	to	_
156-7	27113-27117	have	_
156-8	27118-27130	difficulties	_
156-9	27131-27135	with	_
156-10	27136-27144	response	_
156-11	27145-27155	inhibition	_
156-12	27155-27156	,	_
156-13	27157-27162	which	_
156-14	27163-27169	likely	_
156-15	27170-27181	contributes	_
156-16	27182-27184	to	_
156-17	27185-27188	the	_
156-18	27189-27199	propensity	_
156-19	27200-27202	to	_
156-20	27203-27210	relapse	_
156-21	27211-27213	in	_
156-22	27214-27217	the	_
156-23	27218-27226	presence	_
156-24	27227-27229	of	_
156-25	27230-27234	drug	_
156-26	27235-27242	related	_
156-27	27243-27247	cues	_
156-28	27247-27248	.	_

#Text=However, both decreased and increased functional connectivity have been reported in heroin users.
157-1	27249-27256	However	_
157-2	27256-27257	,	_
157-3	27258-27262	both	_
157-4	27263-27272	decreased	_
157-5	27273-27276	and	_
157-6	27277-27286	increased	_
157-7	27287-27297	functional	_
157-8	27298-27310	connectivity	_
157-9	27311-27315	have	_
157-10	27316-27320	been	_
157-11	27321-27329	reported	_
157-12	27330-27332	in	_
157-13	27333-27339	heroin	_
157-14	27340-27345	users	_
157-15	27345-27346	.	_

#Text=For example, Ma et al. found increased functional connectivity between the nucleus accumbens and ventral/rostral anterior cingulate cortex (ACC), the nucleus accumbens and orbital frontal cortex (OFC), the amygdala and OFC, and decreased functional connectivity between prefrontal cortex and OFC and between prefrontal cortex and ACC.
158-1	27347-27350	For	_
158-2	27351-27358	example	_
158-3	27358-27359	,	_
158-4	27360-27362	Ma	_
158-5	27363-27365	et	_
158-6	27366-27368	al	_
158-7	27368-27369	.	_
158-8	27370-27375	found	_
158-9	27376-27385	increased	_
158-10	27386-27396	functional	_
158-11	27397-27409	connectivity	_
158-12	27410-27417	between	_
158-13	27418-27421	the	_
158-14	27422-27429	nucleus	_
158-15	27430-27439	accumbens	_
158-16	27440-27443	and	_
158-17	27444-27451	ventral	_
158-18	27451-27452	/	_
158-19	27452-27459	rostral	_
158-20	27460-27468	anterior	_
158-21	27469-27478	cingulate	_
158-22	27479-27485	cortex	_
158-23	27486-27487	(	_
158-24	27487-27490	ACC	_
158-25	27490-27491	)	_
158-26	27491-27492	,	_
158-27	27493-27496	the	_
158-28	27497-27504	nucleus	_
158-29	27505-27514	accumbens	_
158-30	27515-27518	and	_
158-31	27519-27526	orbital	_
158-32	27527-27534	frontal	_
158-33	27535-27541	cortex	_
158-34	27542-27543	(	_
158-35	27543-27546	OFC	_
158-36	27546-27547	)	_
158-37	27547-27548	,	_
158-38	27549-27552	the	_
158-39	27553-27561	amygdala	_
158-40	27562-27565	and	_
158-41	27566-27569	OFC	_
158-42	27569-27570	,	_
158-43	27571-27574	and	_
158-44	27575-27584	decreased	_
158-45	27585-27595	functional	_
158-46	27596-27608	connectivity	_
158-47	27609-27616	between	_
158-48	27617-27627	prefrontal	_
158-49	27628-27634	cortex	_
158-50	27635-27638	and	_
158-51	27639-27642	OFC	_
158-52	27643-27646	and	_
158-53	27647-27654	between	_
158-54	27655-27665	prefrontal	_
158-55	27666-27672	cortex	_
158-56	27673-27676	and	_
158-57	27677-27680	ACC	_
158-58	27680-27681	.	_

#Text=Additionally, evidence shows increased functional connectivity in the right hippocampus and decreased functional connectivity in the right dorsal anterior cingulate cortex and the left caudate in the default mode network (DMN) in 14 chronic heroin users compared with 13 non-addicted controls.
159-1	27682-27694	Additionally	_
159-2	27694-27695	,	_
159-3	27696-27704	evidence	_
159-4	27705-27710	shows	_
159-5	27711-27720	increased	_
159-6	27721-27731	functional	_
159-7	27732-27744	connectivity	_
159-8	27745-27747	in	_
159-9	27748-27751	the	_
159-10	27752-27757	right	_
159-11	27758-27769	hippocampus	_
159-12	27770-27773	and	_
159-13	27774-27783	decreased	_
159-14	27784-27794	functional	_
159-15	27795-27807	connectivity	_
159-16	27808-27810	in	_
159-17	27811-27814	the	_
159-18	27815-27820	right	_
159-19	27821-27827	dorsal	_
159-20	27828-27836	anterior	_
159-21	27837-27846	cingulate	_
159-22	27847-27853	cortex	_
159-23	27854-27857	and	_
159-24	27858-27861	the	_
159-25	27862-27866	left	_
159-26	27867-27874	caudate	_
159-27	27875-27877	in	_
159-28	27878-27881	the	_
159-29	27882-27889	default	_
159-30	27890-27894	mode	_
159-31	27895-27902	network	_
159-32	27903-27904	(	_
159-33	27904-27907	DMN	_
159-34	27907-27908	)	_
159-35	27909-27911	in	_
159-36	27912-27914	14	_
159-37	27915-27922	chronic	_
159-38	27923-27929	heroin	_
159-39	27930-27935	users	_
159-40	27936-27944	compared	_
159-41	27945-27949	with	_
159-42	27950-27952	13	_
159-43	27953-27965	non-addicted	_
159-44	27966-27974	controls	_
159-45	27974-27975	.	_

#Text=Using graph theory analysis (GTA), Liu et al. found dysfunctional brain connectivity among several brain regions in the network of chronic heroin users that may contribute to decreased self-control, impaired inhibitory function, as well deficits in stress regulation in twelve chronic heroin users when compared with twelve controls.
160-1	27976-27981	Using	_
160-2	27982-27987	graph	_
160-3	27988-27994	theory	_
160-4	27995-28003	analysis	_
160-5	28004-28005	(	_
160-6	28005-28008	GTA	_
160-7	28008-28009	)	_
160-8	28009-28010	,	_
160-9	28011-28014	Liu	_
160-10	28015-28017	et	_
160-11	28018-28020	al	_
160-12	28020-28021	.	_
160-13	28022-28027	found	_
160-14	28028-28041	dysfunctional	_
160-15	28042-28047	brain	_
160-16	28048-28060	connectivity	_
160-17	28061-28066	among	_
160-18	28067-28074	several	_
160-19	28075-28080	brain	_
160-20	28081-28088	regions	_
160-21	28089-28091	in	_
160-22	28092-28095	the	_
160-23	28096-28103	network	_
160-24	28104-28106	of	_
160-25	28107-28114	chronic	_
160-26	28115-28121	heroin	_
160-27	28122-28127	users	_
160-28	28128-28132	that	_
160-29	28133-28136	may	_
160-30	28137-28147	contribute	_
160-31	28148-28150	to	_
160-32	28151-28160	decreased	_
160-33	28161-28173	self-control	_
160-34	28173-28174	,	_
160-35	28175-28183	impaired	_
160-36	28184-28194	inhibitory	_
160-37	28195-28203	function	_
160-38	28203-28204	,	_
160-39	28205-28207	as	_
160-40	28208-28212	well	_
160-41	28213-28221	deficits	_
160-42	28222-28224	in	_
160-43	28225-28231	stress	_
160-44	28232-28242	regulation	_
160-45	28243-28245	in	_
160-46	28246-28252	twelve	_
160-47	28253-28260	chronic	_
160-48	28261-28267	heroin	_
160-49	28268-28273	users	_
160-50	28274-28278	when	_
160-51	28279-28287	compared	_
160-52	28288-28292	with	_
160-53	28293-28299	twelve	_
160-54	28300-28308	controls	_
160-55	28308-28309	.	_

#Text=However, these are only a few studies that have examined addiction-related alterations in thalamocortical connectivity directly.
161-1	28310-28317	However	_
161-2	28317-28318	,	_
161-3	28319-28324	these	_
161-4	28325-28328	are	_
161-5	28329-28333	only	_
161-6	28334-28335	a	_
161-7	28336-28339	few	_
161-8	28340-28347	studies	_
161-9	28348-28352	that	_
161-10	28353-28357	have	_
161-11	28358-28366	examined	_
161-12	28367-28384	addiction-related	_
161-13	28385-28396	alterations	_
161-14	28397-28399	in	_
161-15	28400-28415	thalamocortical	_
161-16	28416-28428	connectivity	_
161-17	28429-28437	directly	_
161-18	28437-28438	.	_

#Text=Thalamocortical integration deficits in instrumental learning and performance could contribute to drug addiction as it often causes deficits in cognitive and emotional processes.
162-1	28439-28454	Thalamocortical	_
162-2	28455-28466	integration	_
162-3	28467-28475	deficits	_
162-4	28476-28478	in	_
162-5	28479-28491	instrumental	_
162-6	28492-28500	learning	_
162-7	28501-28504	and	_
162-8	28505-28516	performance	_
162-9	28517-28522	could	_
162-10	28523-28533	contribute	_
162-11	28534-28536	to	_
162-12	28537-28541	drug	_
162-13	28542-28551	addiction	_
162-14	28552-28554	as	_
162-15	28555-28557	it	_
162-16	28558-28563	often	_
162-17	28564-28570	causes	_
162-18	28571-28579	deficits	_
162-19	28580-28582	in	_
162-20	28583-28592	cognitive	_
162-21	28593-28596	and	_
162-22	28597-28606	emotional	_
162-23	28607-28616	processes	_
162-24	28616-28617	.	_

#Text=With 54 cocaine dependent patients and 54 age and gender matched healthy adult subjects, a simple reaction time task-fMRI study showed alteration of error-related thalamic- ventral medial prefrontal cortex connectivity, which is associated with impaired self-control in patients with cocaine dependence.
163-1	28618-28622	With	_
163-2	28623-28625	54	_
163-3	28626-28633	cocaine	_
163-4	28634-28643	dependent	_
163-5	28644-28652	patients	_
163-6	28653-28656	and	_
163-7	28657-28659	54	_
163-8	28660-28663	age	_
163-9	28664-28667	and	_
163-10	28668-28674	gender	_
163-11	28675-28682	matched	_
163-12	28683-28690	healthy	_
163-13	28691-28696	adult	_
163-14	28697-28705	subjects	_
163-15	28705-28706	,	_
163-16	28707-28708	a	_
163-17	28709-28715	simple	_
163-18	28716-28724	reaction	_
163-19	28725-28729	time	_
163-20	28730-28739	task-fMRI	_
163-21	28740-28745	study	_
163-22	28746-28752	showed	_
163-23	28753-28763	alteration	_
163-24	28764-28766	of	_
163-25	28767-28780	error-related	_
163-26	28781-28789	thalamic	_
163-27	28789-28790	-	_
163-28	28791-28798	ventral	_
163-29	28799-28805	medial	_
163-30	28806-28816	prefrontal	_
163-31	28817-28823	cortex	_
163-32	28824-28836	connectivity	_
163-33	28836-28837	,	_
163-34	28838-28843	which	_
163-35	28844-28846	is	_
163-36	28847-28857	associated	_
163-37	28858-28862	with	_
163-38	28863-28871	impaired	_
163-39	28872-28884	self-control	_
163-40	28885-28887	in	_
163-41	28888-28896	patients	_
163-42	28897-28901	with	_
163-43	28902-28909	cocaine	_
163-44	28910-28920	dependence	_
163-45	28920-28921	.	_

#Text=An animal study with electroencephalography (EEG) examined thalamocortical function in vivo and in vitro in mice after a cocaine “binge” administration.
164-1	28922-28924	An	_
164-2	28925-28931	animal	_
164-3	28932-28937	study	_
164-4	28938-28942	with	_
164-5	28943-28965	electroencephalography	_
164-6	28966-28967	(	_
164-7	28967-28970	EEG	_
164-8	28970-28971	)	_
164-9	28972-28980	examined	_
164-10	28981-28996	thalamocortical	_
164-11	28997-29005	function	_
164-12	29006-29008	in	_
164-13	29009-29013	vivo	_
164-14	29014-29017	and	_
164-15	29018-29020	in	_
164-16	29021-29026	vitro	_
164-17	29027-29029	in	_
164-18	29030-29034	mice	_
164-19	29035-29040	after	_
164-20	29041-29042	a	_
164-21	29043-29050	cocaine	_
164-22	29051-29052	“	_
164-23	29052-29057	binge	_
164-24	29057-29058	”	_
164-25	29059-29073	administration	_
164-26	29073-29074	.	_

#Text=It illustrated that thalamocortical dysfunctions in a cocaine hydrochloride “binge” might be observed as a result of two distinct but additive events: 1.
165-1	29075-29077	It	_
165-2	29078-29089	illustrated	_
165-3	29090-29094	that	_
165-4	29095-29110	thalamocortical	_
165-5	29111-29123	dysfunctions	_
165-6	29124-29126	in	_
165-7	29127-29128	a	_
165-8	29129-29136	cocaine	_
165-9	29137-29150	hydrochloride	_
165-10	29151-29152	“	_
165-11	29152-29157	binge	_
165-12	29157-29158	”	_
165-13	29159-29164	might	_
165-14	29165-29167	be	_
165-15	29168-29176	observed	_
165-16	29177-29179	as	_
165-17	29180-29181	a	_
165-18	29182-29188	result	_
165-19	29189-29191	of	_
165-20	29192-29195	two	_
165-21	29196-29204	distinct	_
165-22	29205-29208	but	_
165-23	29209-29217	additive	_
165-24	29218-29224	events	_
165-25	29224-29225	:	_
165-26	29226-29227	1	_
165-27	29227-29228	.	_

#Text=An increase in low frequency oscillatory thalamocortical activity and 2.
166-1	29229-29231	An	_
166-2	29232-29240	increase	_
166-3	29241-29243	in	_
166-4	29244-29247	low	_
166-5	29248-29257	frequency	_
166-6	29258-29269	oscillatory	_
166-7	29270-29285	thalamocortical	_
166-8	29286-29294	activity	_
166-9	29295-29298	and	_
166-10	29299-29300	2	_
166-11	29300-29301	.	_

#Text=Over-inhibition of ventrobasal neurons that can abnormally “lock” the whole thalamocortical system at low frequencies, ultimately inducing a thalamocortical dysrhythmia-like state.
167-1	29302-29317	Over-inhibition	_
167-2	29318-29320	of	_
167-3	29321-29332	ventrobasal	_
167-4	29333-29340	neurons	_
167-5	29341-29345	that	_
167-6	29346-29349	can	_
167-7	29350-29360	abnormally	_
167-8	29361-29362	“	_
167-9	29362-29366	lock	_
167-10	29366-29367	”	_
167-11	29368-29371	the	_
167-12	29372-29377	whole	_
167-13	29378-29393	thalamocortical	_
167-14	29394-29400	system	_
167-15	29401-29403	at	_
167-16	29404-29407	low	_
167-17	29408-29419	frequencies	_
167-18	29419-29420	,	_
167-19	29421-29431	ultimately	_
167-20	29432-29440	inducing	_
167-21	29441-29442	a	_
167-22	29443-29458	thalamocortical	_
167-23	29459-29475	dysrhythmia-like	_
167-24	29476-29481	state	_
167-25	29481-29482	.	_

#Text=Considering the key role of the thalamus in information transmission, processing, and basic corticocortical communication, examining the possible roles of the thalamus in addiction, as well as identifying open questions and exploring ways to address them may provide a more precise understanding of the pathophysiological mechanisms of addiction.
168-1	29483-29494	Considering	_
168-2	29495-29498	the	_
168-3	29499-29502	key	_
168-4	29503-29507	role	_
168-5	29508-29510	of	_
168-6	29511-29514	the	_
168-7	29515-29523	thalamus	_
168-8	29524-29526	in	_
168-9	29527-29538	information	_
168-10	29539-29551	transmission	_
168-11	29551-29552	,	_
168-12	29553-29563	processing	_
168-13	29563-29564	,	_
168-14	29565-29568	and	_
168-15	29569-29574	basic	_
168-16	29575-29590	corticocortical	_
168-17	29591-29604	communication	_
168-18	29604-29605	,	_
168-19	29606-29615	examining	_
168-20	29616-29619	the	_
168-21	29620-29628	possible	_
168-22	29629-29634	roles	_
168-23	29635-29637	of	_
168-24	29638-29641	the	_
168-25	29642-29650	thalamus	_
168-26	29651-29653	in	_
168-27	29654-29663	addiction	_
168-28	29663-29664	,	_
168-29	29665-29667	as	_
168-30	29668-29672	well	_
168-31	29673-29675	as	_
168-32	29676-29687	identifying	_
168-33	29688-29692	open	_
168-34	29693-29702	questions	_
168-35	29703-29706	and	_
168-36	29707-29716	exploring	_
168-37	29717-29721	ways	_
168-38	29722-29724	to	_
168-39	29725-29732	address	_
168-40	29733-29737	them	_
168-41	29738-29741	may	_
168-42	29742-29749	provide	_
168-43	29750-29751	a	_
168-44	29752-29756	more	_
168-45	29757-29764	precise	_
168-46	29765-29778	understanding	_
168-47	29779-29781	of	_
168-48	29782-29785	the	_
168-49	29786-29804	pathophysiological	_
168-50	29805-29815	mechanisms	_
168-51	29816-29818	of	_
168-52	29819-29828	addiction	_
168-53	29828-29829	.	_

#Text=Given the multifaceted nature of this complex brain disease, circuit disruptions, such as abnormal thalamocortical connectivity in the current study, may represent one of the potential targets for future treatment development.
169-1	29830-29835	Given	_
169-2	29836-29839	the	_
169-3	29840-29852	multifaceted	_
169-4	29853-29859	nature	_
169-5	29860-29862	of	_
169-6	29863-29867	this	_
169-7	29868-29875	complex	_
169-8	29876-29881	brain	_
169-9	29882-29889	disease	_
169-10	29889-29890	,	_
169-11	29891-29898	circuit	_
169-12	29899-29910	disruptions	_
169-13	29910-29911	,	_
169-14	29912-29916	such	_
169-15	29917-29919	as	_
169-16	29920-29928	abnormal	_
169-17	29929-29944	thalamocortical	_
169-18	29945-29957	connectivity	_
169-19	29958-29960	in	_
169-20	29961-29964	the	_
169-21	29965-29972	current	_
169-22	29973-29978	study	_
169-23	29978-29979	,	_
169-24	29980-29983	may	_
169-25	29984-29993	represent	_
169-26	29994-29997	one	_
169-27	29998-30000	of	_
169-28	30001-30004	the	_
169-29	30005-30014	potential	_
169-30	30015-30022	targets	_
169-31	30023-30026	for	_
169-32	30027-30033	future	_
169-33	30034-30043	treatment	_
169-34	30044-30055	development	_
169-35	30055-30056	.	_

#Text=In this study we also found that the functional connectivity between the posterior parietal area and the right lateral dorsal nucleus was significantly correlated to individual ketamine craving scores (p<0.05, corrected).
170-1	30057-30059	In	_
170-2	30060-30064	this	_
170-3	30065-30070	study	_
170-4	30071-30073	we	_
170-5	30074-30078	also	_
170-6	30079-30084	found	_
170-7	30085-30089	that	_
170-8	30090-30093	the	_
170-9	30094-30104	functional	_
170-10	30105-30117	connectivity	_
170-11	30118-30125	between	_
170-12	30126-30129	the	_
170-13	30130-30139	posterior	_
170-14	30140-30148	parietal	_
170-15	30149-30153	area	_
170-16	30154-30157	and	_
170-17	30158-30161	the	_
170-18	30162-30167	right	_
170-19	30168-30175	lateral	_
170-20	30176-30182	dorsal	_
170-21	30183-30190	nucleus	_
170-22	30191-30194	was	_
170-23	30195-30208	significantly	_
170-24	30209-30219	correlated	_
170-25	30220-30222	to	_
170-26	30223-30233	individual	_
170-27	30234-30242	ketamine	_
170-28	30243-30250	craving	_
170-29	30251-30257	scores	_
170-30	30258-30259	(	_
170-31	30259-30260	p	_
170-32	30260-30261	<	_
170-33	30261-30265	0.05	_
170-34	30265-30266	,	_
170-35	30267-30276	corrected	_
170-36	30276-30277	)	_
170-37	30277-30278	.	_

#Text=Considering that craving is a central driving force for ongoing drug use and relapse following abstinence, using neuroimaging and other approaches to explore the neurobiology of craving is of utmost importance.
171-1	30279-30290	Considering	_
171-2	30291-30295	that	_
171-3	30296-30303	craving	_
171-4	30304-30306	is	_
171-5	30307-30308	a	_
171-6	30309-30316	central	_
171-7	30317-30324	driving	_
171-8	30325-30330	force	_
171-9	30331-30334	for	_
171-10	30335-30342	ongoing	_
171-11	30343-30347	drug	_
171-12	30348-30351	use	_
171-13	30352-30355	and	_
171-14	30356-30363	relapse	_
171-15	30364-30373	following	_
171-16	30374-30384	abstinence	_
171-17	30384-30385	,	_
171-18	30386-30391	using	_
171-19	30392-30404	neuroimaging	_
171-20	30405-30408	and	_
171-21	30409-30414	other	_
171-22	30415-30425	approaches	_
171-23	30426-30428	to	_
171-24	30429-30436	explore	_
171-25	30437-30440	the	_
171-26	30441-30453	neurobiology	_
171-27	30454-30456	of	_
171-28	30457-30464	craving	_
171-29	30465-30467	is	_
171-30	30468-30470	of	_
171-31	30471-30477	utmost	_
171-32	30478-30488	importance	_
171-33	30488-30489	.	_

#Text=Functional brain imaging in humans and animals has revealed an interconnected set of cortical and limbic brain regions that are involved in associative learning and prove to be an underlying theme for craving and relapse (see review).
172-1	30490-30500	Functional	_
172-2	30501-30506	brain	_
172-3	30507-30514	imaging	_
172-4	30515-30517	in	_
172-5	30518-30524	humans	_
172-6	30525-30528	and	_
172-7	30529-30536	animals	_
172-8	30537-30540	has	_
172-9	30541-30549	revealed	_
172-10	30550-30552	an	_
172-11	30553-30567	interconnected	_
172-12	30568-30571	set	_
172-13	30572-30574	of	_
172-14	30575-30583	cortical	_
172-15	30584-30587	and	_
172-16	30588-30594	limbic	_
172-17	30595-30600	brain	_
172-18	30601-30608	regions	_
172-19	30609-30613	that	_
172-20	30614-30617	are	_
172-21	30618-30626	involved	_
172-22	30627-30629	in	_
172-23	30630-30641	associative	_
172-24	30642-30650	learning	_
172-25	30651-30654	and	_
172-26	30655-30660	prove	_
172-27	30661-30663	to	_
172-28	30664-30666	be	_
172-29	30667-30669	an	_
172-30	30670-30680	underlying	_
172-31	30681-30686	theme	_
172-32	30687-30690	for	_
172-33	30691-30698	craving	_
172-34	30699-30702	and	_
172-35	30703-30710	relapse	_
172-36	30711-30712	(	_
172-37	30712-30715	see	_
172-38	30716-30722	review	_
172-39	30722-30723	)	_
172-40	30723-30724	.	_

#Text=However, we still do not fully understand the neurobiology and neurocircuitry mechanisms involved in drug-related craving.
173-1	30725-30732	However	_
173-2	30732-30733	,	_
173-3	30734-30736	we	_
173-4	30737-30742	still	_
173-5	30743-30745	do	_
173-6	30746-30749	not	_
173-7	30750-30755	fully	_
173-8	30756-30766	understand	_
173-9	30767-30770	the	_
173-10	30771-30783	neurobiology	_
173-11	30784-30787	and	_
173-12	30788-30802	neurocircuitry	_
173-13	30803-30813	mechanisms	_
173-14	30814-30822	involved	_
173-15	30823-30825	in	_
173-16	30826-30838	drug-related	_
173-17	30839-30846	craving	_
173-18	30846-30847	.	_

#Text=Our study has several strengths, such as a relatively large sample size, use of the human chronic ketamine administration model, and the hypothesis-driven investigation of thalamocortical functional connectivity.
174-1	30848-30851	Our	_
174-2	30852-30857	study	_
174-3	30858-30861	has	_
174-4	30862-30869	several	_
174-5	30870-30879	strengths	_
174-6	30879-30880	,	_
174-7	30881-30885	such	_
174-8	30886-30888	as	_
174-9	30889-30890	a	_
174-10	30891-30901	relatively	_
174-11	30902-30907	large	_
174-12	30908-30914	sample	_
174-13	30915-30919	size	_
174-14	30919-30920	,	_
174-15	30921-30924	use	_
174-16	30925-30927	of	_
174-17	30928-30931	the	_
174-18	30932-30937	human	_
174-19	30938-30945	chronic	_
174-20	30946-30954	ketamine	_
174-21	30955-30969	administration	_
174-22	30970-30975	model	_
174-23	30975-30976	,	_
174-24	30977-30980	and	_
174-25	30981-30984	the	_
174-26	30985-31002	hypothesis-driven	_
174-27	31003-31016	investigation	_
174-28	31017-31019	of	_
174-29	31020-31035	thalamocortical	_
174-30	31036-31046	functional	_
174-31	31047-31059	connectivity	_
174-32	31059-31060	.	_

#Text=However, we also acknowledge several limitations.
175-1	31061-31068	However	_
175-2	31068-31069	,	_
175-3	31070-31072	we	_
175-4	31073-31077	also	_
175-5	31078-31089	acknowledge	_
175-6	31090-31097	several	_
175-7	31098-31109	limitations	_
175-8	31109-31110	.	_

#Text=First, although ketamine use participants did not meet dependence for any other substances except nicotine they may have engaged in other substance use and as such would be different from the controls in this regard.
176-1	31111-31116	First	_
176-2	31116-31117	,	_
176-3	31118-31126	although	_
176-4	31127-31135	ketamine	_
176-5	31136-31139	use	_
176-6	31140-31152	participants	_
176-7	31153-31156	did	_
176-8	31157-31160	not	_
176-9	31161-31165	meet	_
176-10	31166-31176	dependence	_
176-11	31177-31180	for	_
176-12	31181-31184	any	_
176-13	31185-31190	other	_
176-14	31191-31201	substances	_
176-15	31202-31208	except	_
176-16	31209-31217	nicotine	_
176-17	31218-31222	they	_
176-18	31223-31226	may	_
176-19	31227-31231	have	_
176-20	31232-31239	engaged	_
176-21	31240-31242	in	_
176-22	31243-31248	other	_
176-23	31249-31258	substance	_
176-24	31259-31262	use	_
176-25	31263-31266	and	_
176-26	31267-31269	as	_
176-27	31270-31274	such	_
176-28	31275-31280	would	_
176-29	31281-31283	be	_
176-30	31284-31293	different	_
176-31	31294-31298	from	_
176-32	31299-31302	the	_
176-33	31303-31311	controls	_
176-34	31312-31314	in	_
176-35	31315-31319	this	_
176-36	31320-31326	regard	_
176-37	31326-31327	.	_

#Text=Second, the ketamine and control groups differed in smoking status and education.
177-1	31328-31334	Second	_
177-2	31334-31335	,	_
177-3	31336-31339	the	_
177-4	31340-31348	ketamine	_
177-5	31349-31352	and	_
177-6	31353-31360	control	_
177-7	31361-31367	groups	_
177-8	31368-31376	differed	_
177-9	31377-31379	in	_
177-10	31380-31387	smoking	_
177-11	31388-31394	status	_
177-12	31395-31398	and	_
177-13	31399-31408	education	_
177-14	31408-31409	.	_

#Text=Although our analyses suggested that decreased thalamocortical functional connectivity observed are unlikely to reflect group differences in smoking and educational levels, future studies should match groups on smoking status and levels of education.
178-1	31410-31418	Although	_
178-2	31419-31422	our	_
178-3	31423-31431	analyses	_
178-4	31432-31441	suggested	_
178-5	31442-31446	that	_
178-6	31447-31456	decreased	_
178-7	31457-31472	thalamocortical	_
178-8	31473-31483	functional	_
178-9	31484-31496	connectivity	_
178-10	31497-31505	observed	_
178-11	31506-31509	are	_
178-12	31510-31518	unlikely	_
178-13	31519-31521	to	_
178-14	31522-31529	reflect	_
178-15	31530-31535	group	_
178-16	31536-31547	differences	_
178-17	31548-31550	in	_
178-18	31551-31558	smoking	_
178-19	31559-31562	and	_
178-20	31563-31574	educational	_
178-21	31575-31581	levels	_
178-22	31581-31582	,	_
178-23	31583-31589	future	_
178-24	31590-31597	studies	_
178-25	31598-31604	should	_
178-26	31605-31610	match	_
178-27	31611-31617	groups	_
178-28	31618-31620	on	_
178-29	31621-31628	smoking	_
178-30	31629-31635	status	_
178-31	31636-31639	and	_
178-32	31640-31646	levels	_
178-33	31647-31649	of	_
178-34	31650-31659	education	_
178-35	31659-31660	.	_

#Text=Third, as is typical of studies in drug dependent populations, the sample was predominantly male.
179-1	31661-31666	Third	_
179-2	31666-31667	,	_
179-3	31668-31670	as	_
179-4	31671-31673	is	_
179-5	31674-31681	typical	_
179-6	31682-31684	of	_
179-7	31685-31692	studies	_
179-8	31693-31695	in	_
179-9	31696-31700	drug	_
179-10	31701-31710	dependent	_
179-11	31711-31722	populations	_
179-12	31722-31723	,	_
179-13	31724-31727	the	_
179-14	31728-31734	sample	_
179-15	31735-31738	was	_
179-16	31739-31752	predominantly	_
179-17	31753-31757	male	_
179-18	31757-31758	.	_

#Text=The potential role of gender differences should be examined in future studies.
180-1	31759-31762	The	_
180-2	31763-31772	potential	_
180-3	31773-31777	role	_
180-4	31778-31780	of	_
180-5	31781-31787	gender	_
180-6	31788-31799	differences	_
180-7	31800-31806	should	_
180-8	31807-31809	be	_
180-9	31810-31818	examined	_
180-10	31819-31821	in	_
180-11	31822-31828	future	_
180-12	31829-31836	studies	_
180-13	31836-31837	.	_

#Text=Additional limitations are demonstrated in the cognitive testing between the two groups, which future studies should take into consideration and instead match groups educationally in order to rule out any confounding factor.
181-1	31838-31848	Additional	_
181-2	31849-31860	limitations	_
181-3	31861-31864	are	_
181-4	31865-31877	demonstrated	_
181-5	31878-31880	in	_
181-6	31881-31884	the	_
181-7	31885-31894	cognitive	_
181-8	31895-31902	testing	_
181-9	31903-31910	between	_
181-10	31911-31914	the	_
181-11	31915-31918	two	_
181-12	31919-31925	groups	_
181-13	31925-31926	,	_
181-14	31927-31932	which	_
181-15	31933-31939	future	_
181-16	31940-31947	studies	_
181-17	31948-31954	should	_
181-18	31955-31959	take	_
181-19	31960-31964	into	_
181-20	31965-31978	consideration	_
181-21	31979-31982	and	_
181-22	31983-31990	instead	_
181-23	31991-31996	match	_
181-24	31997-32003	groups	_
181-25	32004-32017	educationally	_
181-26	32018-32020	in	_
181-27	32021-32026	order	_
181-28	32027-32029	to	_
181-29	32030-32034	rule	_
181-30	32035-32038	out	_
181-31	32039-32042	any	_
181-32	32043-32054	confounding	_
181-33	32055-32061	factor	_
181-34	32061-32062	.	_

#Text=In conclusion, this study provides first evidence for abnormal thalamocortical connectivity of resting state brain activity in chronic ketamine users.
182-1	32063-32065	In	_
182-2	32066-32076	conclusion	_
182-3	32076-32077	,	_
182-4	32078-32082	this	_
182-5	32083-32088	study	_
182-6	32089-32097	provides	_
182-7	32098-32103	first	_
182-8	32104-32112	evidence	_
182-9	32113-32116	for	_
182-10	32117-32125	abnormal	_
182-11	32126-32141	thalamocortical	_
182-12	32142-32154	connectivity	_
182-13	32155-32157	of	_
182-14	32158-32165	resting	_
182-15	32166-32171	state	_
182-16	32172-32177	brain	_
182-17	32178-32186	activity	_
182-18	32187-32189	in	_
182-19	32190-32197	chronic	_
182-20	32198-32206	ketamine	_
182-21	32207-32212	users	_
182-22	32212-32213	.	_

#Text=We found that the ketamine dependent subjects showed significantly less connectivity between the thalamus and the cortical regions-of-interest, including the prefrontal cortex, the motor cortex/supplementary motor area, and the posterior parietal cortex.
183-1	32214-32216	We	_
183-2	32217-32222	found	_
183-3	32223-32227	that	_
183-4	32228-32231	the	_
183-5	32232-32240	ketamine	_
183-6	32241-32250	dependent	_
183-7	32251-32259	subjects	_
183-8	32260-32266	showed	_
183-9	32267-32280	significantly	_
183-10	32281-32285	less	_
183-11	32286-32298	connectivity	_
183-12	32299-32306	between	_
183-13	32307-32310	the	_
183-14	32311-32319	thalamus	_
183-15	32320-32323	and	_
183-16	32324-32327	the	_
183-17	32328-32336	cortical	_
183-18	32337-32356	regions-of-interest	_
183-19	32356-32357	,	_
183-20	32358-32367	including	_
183-21	32368-32371	the	_
183-22	32372-32382	prefrontal	_
183-23	32383-32389	cortex	_
183-24	32389-32390	,	_
183-25	32391-32394	the	_
183-26	32395-32400	motor	_
183-27	32401-32407	cortex	_
183-28	32407-32408	/	_
183-29	32408-32421	supplementary	_
183-30	32422-32427	motor	_
183-31	32428-32432	area	_
183-32	32432-32433	,	_
183-33	32434-32437	and	_
183-34	32438-32441	the	_
183-35	32442-32451	posterior	_
183-36	32452-32460	parietal	_
183-37	32461-32467	cortex	_
183-38	32467-32468	.	_

#Text=However, no increased thalamic connectivity was observed for the ketamine dependent subjects in comparison with the control subjects.
184-1	32469-32476	However	_
184-2	32476-32477	,	_
184-3	32478-32480	no	_
184-4	32481-32490	increased	_
184-5	32491-32499	thalamic	_
184-6	32500-32512	connectivity	_
184-7	32513-32516	was	_
184-8	32517-32525	observed	_
184-9	32526-32529	for	_
184-10	32530-32533	the	_
184-11	32534-32542	ketamine	_
184-12	32543-32552	dependent	_
184-13	32553-32561	subjects	_
184-14	32562-32564	in	_
184-15	32565-32575	comparison	_
184-16	32576-32580	with	_
184-17	32581-32584	the	_
184-18	32585-32592	control	_
184-19	32593-32601	subjects	_
184-20	32601-32602	.	_

#Text=Further understanding of the pathophysiological mechanisms of the thalamus in addiction, specifically ketamine addiction, may facilitate the evaluation of much needed novel pharmacological agents for improved therapy of this complex disease.
185-1	32603-32610	Further	_
185-2	32611-32624	understanding	_
185-3	32625-32627	of	_
185-4	32628-32631	the	_
185-5	32632-32650	pathophysiological	_
185-6	32651-32661	mechanisms	_
185-7	32662-32664	of	_
185-8	32665-32668	the	_
185-9	32669-32677	thalamus	_
185-10	32678-32680	in	_
185-11	32681-32690	addiction	_
185-12	32690-32691	,	_
185-13	32692-32704	specifically	_
185-14	32705-32713	ketamine	_
185-15	32714-32723	addiction	_
185-16	32723-32724	,	_
185-17	32725-32728	may	_
185-18	32729-32739	facilitate	_
185-19	32740-32743	the	_
185-20	32744-32754	evaluation	_
185-21	32755-32757	of	_
185-22	32758-32762	much	_
185-23	32763-32769	needed	_
185-24	32770-32775	novel	_
185-25	32776-32791	pharmacological	_
185-26	32792-32798	agents	_
185-27	32799-32802	for	_
185-28	32803-32811	improved	_
185-29	32812-32819	therapy	_
185-30	32820-32822	of	_
185-31	32823-32827	this	_
185-32	32828-32835	complex	_
185-33	32836-32843	disease	_
185-34	32843-32844	.	_

#Text=Supporting Information
#Text=References
#Text=Pharmacologic effects of CI-581, a new dissociative anesthetic, in man
#Text=A review of the nonmedical use of ketamine: use, users and consequences
#Text=The nonmedical use of ketamine, part two: A review of problem use and dependence
#Text=Psychiatric morbidity in ketamine users attending counselling and youth outreach services
#Text=Ketamine is associated with lower urinary tract signs and symptoms
#Text=Reduced dorsal prefrontal gray matter after chronic ketamine use
#Text=Frontal white matter abnormalities following chronic ketamine use: a diffusion tensor imaging study
#Text=Alterations in regional homogeneity of resting-state brain activity in ketamine addicts
#Text=Genome-wide association study identifies a susceptibility locus for schizophrenia in Han Chinese at 11p11.2
#Text=Effects of chronic ketamine use on frontal and medial temporal cognition
#Text=Cognitive impairments in poly-drug ketamine users
#Text=Acute and chronic effects of ketamine upon human memory: a review
#Text=Ketamine use: a review
#Text=Thalamocortical integration of instrumental learning and performance and their disintegration in addiction
#Text=Low-frequency BOLD fluctuations demonstrate altered thalamocortical connectivity in schizophrenia
#Text=The role of the thalamus in the flow of information to the cortex
#Text=Relationship of resting brain hyperconnectivity and schizophrenia-like symptoms produced by the NMDA receptor antagonist ketamine in humans
#Text=The neurobiology of psychedelic drugs: implications for the treatment of mood disorders
#Text=Glutamatergic mechanisms in schizophrenia
#Text=The structured clinical interview for DSM-III-R (SCID): I: history, rationale, and description
#Text=Measurement strategies: the visual analogue scale
#Text=Intrinsic functional relations between human cerebral cortex and thalamus
#Text=Neural basis of global resting-state fMRI activity
#Text=Noninvasive functional and structural connectivity mapping of the human thalamocortical system
#Text=Non-invasive mapping of connections between human thalamus and cortex using diffusion imaging
#Text=Thalamocortical dysconnectivity in schizophrenia
#Text=Ketamine decreases resting state functional network connectivity in healthy subjects: implications for antidepressant drug action
#Text=Ketamine decreases resting state functional network connectivity in healthy subjects: implications for antidepressant drug action
#Text=Ketamine-Induced Modulation of the Thalamo-Cortical Network in Healthy Volunteers As a Model for Schizophrenia
#Text=Addiction and the brain: the neurobiology of compulsion and its persistence
#Text=Resting state functional connectivity in addiction: Lessons learned and a road ahead
#Text=Cocaine administration decreases functional connectivity in human primary visual and motor cortex as detected by functional MRI
#Text=Reduced interhemispheric resting state functional connectivity in cocaine addiction
#Text=Mesocorticolimbic circuits are impaired in chronic cocaine users as demonstrated by resting-state functional connectivity
#Text=The place of the thalamus in frontal cortical-basal ganglia circuits
#Text=Addiction related alteration in resting-state brain connectivity
#Text=Abnormal brain default-mode network functional connectivity in drug addicts
#Text=Dysfunctional connectivity patterns in chronic heroin users: an fMRI study
#Text=Error-related functional connectivity of the thalamus in cocaine dependence
#Text=Cocaine acute “binge” administration results in altered thalamocortical interactions in mice
#Text=Neurobiology of craving, conditioned reward and relapse
186-1	32845-32855	Supporting	_
186-2	32856-32867	Information	_
186-3	32868-32878	References	_
186-4	32879-32892	Pharmacologic	_
186-5	32893-32900	effects	_
186-6	32901-32903	of	_
186-7	32904-32906	CI	_
186-8	32906-32907	-	_
186-9	32907-32910	581	_
186-10	32910-32911	,	_
186-11	32912-32913	a	_
186-12	32914-32917	new	_
186-13	32918-32930	dissociative	_
186-14	32931-32941	anesthetic	_
186-15	32941-32942	,	_
186-16	32943-32945	in	_
186-17	32946-32949	man	_
186-18	32950-32951	A	_
186-19	32952-32958	review	_
186-20	32959-32961	of	_
186-21	32962-32965	the	_
186-22	32966-32976	nonmedical	_
186-23	32977-32980	use	_
186-24	32981-32983	of	_
186-25	32984-32992	ketamine	_
186-26	32992-32993	:	_
186-27	32994-32997	use	_
186-28	32997-32998	,	_
186-29	32999-33004	users	_
186-30	33005-33008	and	_
186-31	33009-33021	consequences	_
186-32	33022-33025	The	_
186-33	33026-33036	nonmedical	_
186-34	33037-33040	use	_
186-35	33041-33043	of	_
186-36	33044-33052	ketamine	_
186-37	33052-33053	,	_
186-38	33054-33058	part	_
186-39	33059-33062	two	_
186-40	33062-33063	:	_
186-41	33064-33065	A	_
186-42	33066-33072	review	_
186-43	33073-33075	of	_
186-44	33076-33083	problem	_
186-45	33084-33087	use	_
186-46	33088-33091	and	_
186-47	33092-33102	dependence	_
186-48	33103-33114	Psychiatric	_
186-49	33115-33124	morbidity	_
186-50	33125-33127	in	_
186-51	33128-33136	ketamine	_
186-52	33137-33142	users	_
186-53	33143-33152	attending	_
186-54	33153-33164	counselling	_
186-55	33165-33168	and	_
186-56	33169-33174	youth	_
186-57	33175-33183	outreach	_
186-58	33184-33192	services	_
186-59	33193-33201	Ketamine	_
186-60	33202-33204	is	_
186-61	33205-33215	associated	_
186-62	33216-33220	with	_
186-63	33221-33226	lower	_
186-64	33227-33234	urinary	_
186-65	33235-33240	tract	_
186-66	33241-33246	signs	_
186-67	33247-33250	and	_
186-68	33251-33259	symptoms	_
186-69	33260-33267	Reduced	_
186-70	33268-33274	dorsal	_
186-71	33275-33285	prefrontal	_
186-72	33286-33290	gray	_
186-73	33291-33297	matter	_
186-74	33298-33303	after	_
186-75	33304-33311	chronic	_
186-76	33312-33320	ketamine	_
186-77	33321-33324	use	_
186-78	33325-33332	Frontal	_
186-79	33333-33338	white	_
186-80	33339-33345	matter	_
186-81	33346-33359	abnormalities	_
186-82	33360-33369	following	_
186-83	33370-33377	chronic	_
186-84	33378-33386	ketamine	_
186-85	33387-33390	use	_
186-86	33390-33391	:	_
186-87	33392-33393	a	_
186-88	33394-33403	diffusion	_
186-89	33404-33410	tensor	_
186-90	33411-33418	imaging	_
186-91	33419-33424	study	_
186-92	33425-33436	Alterations	_
186-93	33437-33439	in	_
186-94	33440-33448	regional	_
186-95	33449-33460	homogeneity	_
186-96	33461-33463	of	_
186-97	33464-33477	resting-state	_
186-98	33478-33483	brain	_
186-99	33484-33492	activity	_
186-100	33493-33495	in	_
186-101	33496-33504	ketamine	_
186-102	33505-33512	addicts	_
186-103	33513-33524	Genome-wide	_
186-104	33525-33536	association	_
186-105	33537-33542	study	_
186-106	33543-33553	identifies	_
186-107	33554-33555	a	_
186-108	33556-33570	susceptibility	_
186-109	33571-33576	locus	_
186-110	33577-33580	for	_
186-111	33581-33594	schizophrenia	_
186-112	33595-33597	in	_
186-113	33598-33601	Han	_
186-114	33602-33609	Chinese	_
186-115	33610-33612	at	_
186-116	33613-33620	11p11.2	_
186-117	33621-33628	Effects	_
186-118	33629-33631	of	_
186-119	33632-33639	chronic	_
186-120	33640-33648	ketamine	_
186-121	33649-33652	use	_
186-122	33653-33655	on	_
186-123	33656-33663	frontal	_
186-124	33664-33667	and	_
186-125	33668-33674	medial	_
186-126	33675-33683	temporal	_
186-127	33684-33693	cognition	_
186-128	33694-33703	Cognitive	_
186-129	33704-33715	impairments	_
186-130	33716-33718	in	_
186-131	33719-33728	poly-drug	_
186-132	33729-33737	ketamine	_
186-133	33738-33743	users	_
186-134	33744-33749	Acute	_
186-135	33750-33753	and	_
186-136	33754-33761	chronic	_
186-137	33762-33769	effects	_
186-138	33770-33772	of	_
186-139	33773-33781	ketamine	_
186-140	33782-33786	upon	_
186-141	33787-33792	human	_
186-142	33793-33799	memory	_
186-143	33799-33800	:	_
186-144	33801-33802	a	_
186-145	33803-33809	review	_
186-146	33810-33818	Ketamine	_
186-147	33819-33822	use	_
186-148	33822-33823	:	_
186-149	33824-33825	a	_
186-150	33826-33832	review	_
186-151	33833-33848	Thalamocortical	_
186-152	33849-33860	integration	_
186-153	33861-33863	of	_
186-154	33864-33876	instrumental	_
186-155	33877-33885	learning	_
186-156	33886-33889	and	_
186-157	33890-33901	performance	_
186-158	33902-33905	and	_
186-159	33906-33911	their	_
186-160	33912-33926	disintegration	_
186-161	33927-33929	in	_
186-162	33930-33939	addiction	_
186-163	33940-33953	Low-frequency	_
186-164	33954-33958	BOLD	_
186-165	33959-33971	fluctuations	_
186-166	33972-33983	demonstrate	_
186-167	33984-33991	altered	_
186-168	33992-34007	thalamocortical	_
186-169	34008-34020	connectivity	_
186-170	34021-34023	in	_
186-171	34024-34037	schizophrenia	_
186-172	34038-34041	The	_
186-173	34042-34046	role	_
186-174	34047-34049	of	_
186-175	34050-34053	the	_
186-176	34054-34062	thalamus	_
186-177	34063-34065	in	_
186-178	34066-34069	the	_
186-179	34070-34074	flow	_
186-180	34075-34077	of	_
186-181	34078-34089	information	_
186-182	34090-34092	to	_
186-183	34093-34096	the	_
186-184	34097-34103	cortex	_
186-185	34104-34116	Relationship	_
186-186	34117-34119	of	_
186-187	34120-34127	resting	_
186-188	34128-34133	brain	_
186-189	34134-34151	hyperconnectivity	_
186-190	34152-34155	and	_
186-191	34156-34174	schizophrenia-like	_
186-192	34175-34183	symptoms	_
186-193	34184-34192	produced	_
186-194	34193-34195	by	_
186-195	34196-34199	the	_
186-196	34200-34204	NMDA	_
186-197	34205-34213	receptor	_
186-198	34214-34224	antagonist	_
186-199	34225-34233	ketamine	_
186-200	34234-34236	in	_
186-201	34237-34243	humans	_
186-202	34244-34247	The	_
186-203	34248-34260	neurobiology	_
186-204	34261-34263	of	_
186-205	34264-34275	psychedelic	_
186-206	34276-34281	drugs	_
186-207	34281-34282	:	_
186-208	34283-34295	implications	_
186-209	34296-34299	for	_
186-210	34300-34303	the	_
186-211	34304-34313	treatment	_
186-212	34314-34316	of	_
186-213	34317-34321	mood	_
186-214	34322-34331	disorders	_
186-215	34332-34345	Glutamatergic	_
186-216	34346-34356	mechanisms	_
186-217	34357-34359	in	_
186-218	34360-34373	schizophrenia	_
186-219	34374-34377	The	_
186-220	34378-34388	structured	_
186-221	34389-34397	clinical	_
186-222	34398-34407	interview	_
186-223	34408-34411	for	_
186-224	34412-34421	DSM-III-R	_
186-225	34422-34423	(	_
186-226	34423-34427	SCID	_
186-227	34427-34428	)	_
186-228	34428-34429	:	_
186-229	34430-34431	I	_
186-230	34431-34432	:	_
186-231	34433-34440	history	_
186-232	34440-34441	,	_
186-233	34442-34451	rationale	_
186-234	34451-34452	,	_
186-235	34453-34456	and	_
186-236	34457-34468	description	_
186-237	34469-34480	Measurement	_
186-238	34481-34491	strategies	_
186-239	34491-34492	:	_
186-240	34493-34496	the	_
186-241	34497-34503	visual	_
186-242	34504-34512	analogue	_
186-243	34513-34518	scale	_
186-244	34519-34528	Intrinsic	_
186-245	34529-34539	functional	_
186-246	34540-34549	relations	_
186-247	34550-34557	between	_
186-248	34558-34563	human	_
186-249	34564-34572	cerebral	_
186-250	34573-34579	cortex	_
186-251	34580-34583	and	_
186-252	34584-34592	thalamus	_
186-253	34593-34599	Neural	_
186-254	34600-34605	basis	_
186-255	34606-34608	of	_
186-256	34609-34615	global	_
186-257	34616-34629	resting-state	_
186-258	34630-34634	fMRI	_
186-259	34635-34643	activity	_
186-260	34644-34655	Noninvasive	_
186-261	34656-34666	functional	_
186-262	34667-34670	and	_
186-263	34671-34681	structural	_
186-264	34682-34694	connectivity	_
186-265	34695-34702	mapping	_
186-266	34703-34705	of	_
186-267	34706-34709	the	_
186-268	34710-34715	human	_
186-269	34716-34731	thalamocortical	_
186-270	34732-34738	system	_
186-271	34739-34751	Non-invasive	_
186-272	34752-34759	mapping	_
186-273	34760-34762	of	_
186-274	34763-34774	connections	_
186-275	34775-34782	between	_
186-276	34783-34788	human	_
186-277	34789-34797	thalamus	_
186-278	34798-34801	and	_
186-279	34802-34808	cortex	_
186-280	34809-34814	using	_
186-281	34815-34824	diffusion	_
186-282	34825-34832	imaging	_
186-283	34833-34848	Thalamocortical	_
186-284	34849-34864	dysconnectivity	_
186-285	34865-34867	in	_
186-286	34868-34881	schizophrenia	_
186-287	34882-34890	Ketamine	_
186-288	34891-34900	decreases	_
186-289	34901-34908	resting	_
186-290	34909-34914	state	_
186-291	34915-34925	functional	_
186-292	34926-34933	network	_
186-293	34934-34946	connectivity	_
186-294	34947-34949	in	_
186-295	34950-34957	healthy	_
186-296	34958-34966	subjects	_
186-297	34966-34967	:	_
186-298	34968-34980	implications	_
186-299	34981-34984	for	_
186-300	34985-34999	antidepressant	_
186-301	35000-35004	drug	_
186-302	35005-35011	action	_
186-303	35012-35020	Ketamine	_
186-304	35021-35030	decreases	_
186-305	35031-35038	resting	_
186-306	35039-35044	state	_
186-307	35045-35055	functional	_
186-308	35056-35063	network	_
186-309	35064-35076	connectivity	_
186-310	35077-35079	in	_
186-311	35080-35087	healthy	_
186-312	35088-35096	subjects	_
186-313	35096-35097	:	_
186-314	35098-35110	implications	_
186-315	35111-35114	for	_
186-316	35115-35129	antidepressant	_
186-317	35130-35134	drug	_
186-318	35135-35141	action	_
186-319	35142-35158	Ketamine-Induced	_
186-320	35159-35169	Modulation	_
186-321	35170-35172	of	_
186-322	35173-35176	the	_
186-323	35177-35193	Thalamo-Cortical	_
186-324	35194-35201	Network	_
186-325	35202-35204	in	_
186-326	35205-35212	Healthy	_
186-327	35213-35223	Volunteers	_
186-328	35224-35226	As	_
186-329	35227-35228	a	_
186-330	35229-35234	Model	_
186-331	35235-35238	for	_
186-332	35239-35252	Schizophrenia	_
186-333	35253-35262	Addiction	_
186-334	35263-35266	and	_
186-335	35267-35270	the	_
186-336	35271-35276	brain	_
186-337	35276-35277	:	_
186-338	35278-35281	the	_
186-339	35282-35294	neurobiology	_
186-340	35295-35297	of	_
186-341	35298-35308	compulsion	_
186-342	35309-35312	and	_
186-343	35313-35316	its	_
186-344	35317-35328	persistence	_
186-345	35329-35336	Resting	_
186-346	35337-35342	state	_
186-347	35343-35353	functional	_
186-348	35354-35366	connectivity	_
186-349	35367-35369	in	_
186-350	35370-35379	addiction	_
186-351	35379-35380	:	_
186-352	35381-35388	Lessons	_
186-353	35389-35396	learned	_
186-354	35397-35400	and	_
186-355	35401-35402	a	_
186-356	35403-35407	road	_
186-357	35408-35413	ahead	_
186-358	35414-35421	Cocaine	_
186-359	35422-35436	administration	_
186-360	35437-35446	decreases	_
186-361	35447-35457	functional	_
186-362	35458-35470	connectivity	_
186-363	35471-35473	in	_
186-364	35474-35479	human	_
186-365	35480-35487	primary	_
186-366	35488-35494	visual	_
186-367	35495-35498	and	_
186-368	35499-35504	motor	_
186-369	35505-35511	cortex	_
186-370	35512-35514	as	_
186-371	35515-35523	detected	_
186-372	35524-35526	by	_
186-373	35527-35537	functional	_
186-374	35538-35541	MRI	_
186-375	35542-35549	Reduced	_
186-376	35550-35566	interhemispheric	_
186-377	35567-35574	resting	_
186-378	35575-35580	state	_
186-379	35581-35591	functional	_
186-380	35592-35604	connectivity	_
186-381	35605-35607	in	_
186-382	35608-35615	cocaine	_
186-383	35616-35625	addiction	_
186-384	35626-35643	Mesocorticolimbic	_
186-385	35644-35652	circuits	_
186-386	35653-35656	are	_
186-387	35657-35665	impaired	_
186-388	35666-35668	in	_
186-389	35669-35676	chronic	_
186-390	35677-35684	cocaine	_
186-391	35685-35690	users	_
186-392	35691-35693	as	_
186-393	35694-35706	demonstrated	_
186-394	35707-35709	by	_
186-395	35710-35723	resting-state	_
186-396	35724-35734	functional	_
186-397	35735-35747	connectivity	_
186-398	35748-35751	The	_
186-399	35752-35757	place	_
186-400	35758-35760	of	_
186-401	35761-35764	the	_
186-402	35765-35773	thalamus	_
186-403	35774-35776	in	_
186-404	35777-35784	frontal	_
186-405	35785-35799	cortical-basal	_
186-406	35800-35807	ganglia	_
186-407	35808-35816	circuits	_
186-408	35817-35826	Addiction	_
186-409	35827-35834	related	_
186-410	35835-35845	alteration	_
186-411	35846-35848	in	_
186-412	35849-35862	resting-state	_
186-413	35863-35868	brain	_
186-414	35869-35881	connectivity	_
186-415	35882-35890	Abnormal	_
186-416	35891-35896	brain	_
186-417	35897-35909	default-mode	_
186-418	35910-35917	network	_
186-419	35918-35928	functional	_
186-420	35929-35941	connectivity	_
186-421	35942-35944	in	_
186-422	35945-35949	drug	_
186-423	35950-35957	addicts	_
186-424	35958-35971	Dysfunctional	_
186-425	35972-35984	connectivity	_
186-426	35985-35993	patterns	_
186-427	35994-35996	in	_
186-428	35997-36004	chronic	_
186-429	36005-36011	heroin	_
186-430	36012-36017	users	_
186-431	36017-36018	:	_
186-432	36019-36021	an	_
186-433	36022-36026	fMRI	_
186-434	36027-36032	study	_
186-435	36033-36046	Error-related	_
186-436	36047-36057	functional	_
186-437	36058-36070	connectivity	_
186-438	36071-36073	of	_
186-439	36074-36077	the	_
186-440	36078-36086	thalamus	_
186-441	36087-36089	in	_
186-442	36090-36097	cocaine	_
186-443	36098-36108	dependence	_
186-444	36109-36116	Cocaine	_
186-445	36117-36122	acute	_
186-446	36123-36124	“	_
186-447	36124-36129	binge	_
186-448	36129-36130	”	_
186-449	36131-36145	administration	_
186-450	36146-36153	results	_
186-451	36154-36156	in	_
186-452	36157-36164	altered	_
186-453	36165-36180	thalamocortical	_
186-454	36181-36193	interactions	_
186-455	36194-36196	in	_
186-456	36197-36201	mice	_
186-457	36202-36214	Neurobiology	_
186-458	36215-36217	of	_
186-459	36218-36225	craving	_
186-460	36225-36226	,	_
186-461	36227-36238	conditioned	_
186-462	36239-36245	reward	_
186-463	36246-36249	and	_
186-464	36250-36257	relapse	_
